WO2022241229A1 - Stabilized s2 beta-coronavirus antigens - Google Patents
Stabilized s2 beta-coronavirus antigens Download PDFInfo
- Publication number
- WO2022241229A1 WO2022241229A1 PCT/US2022/029216 US2022029216W WO2022241229A1 WO 2022241229 A1 WO2022241229 A1 WO 2022241229A1 US 2022029216 W US2022029216 W US 2022029216W WO 2022241229 A1 WO2022241229 A1 WO 2022241229A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- engineered
- seq
- cov
- mers
- Prior art date
Links
- 241000008904 Betacoronavirus Species 0.000 title claims abstract description 30
- 239000000427 antigen Substances 0.000 title description 55
- 102000036639 antigens Human genes 0.000 title description 55
- 108091007433 antigens Proteins 0.000 title description 55
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 176
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 155
- 238000000034 method Methods 0.000 claims abstract description 58
- 239000000203 mixture Substances 0.000 claims abstract description 39
- 235000018102 proteins Nutrition 0.000 claims description 137
- 208000001528 Coronaviridae Infections Diseases 0.000 claims description 89
- 238000006467 substitution reaction Methods 0.000 claims description 81
- 150000007523 nucleic acids Chemical class 0.000 claims description 44
- 102000039446 nucleic acids Human genes 0.000 claims description 40
- 108020004707 nucleic acids Proteins 0.000 claims description 40
- 102100031673 Corneodesmosin Human genes 0.000 claims description 35
- 101710139375 Corneodesmosin Proteins 0.000 claims description 35
- 108020004414 DNA Proteins 0.000 claims description 29
- 239000008194 pharmaceutical composition Substances 0.000 claims description 18
- 125000003729 nucleotide group Chemical group 0.000 claims description 16
- 239000013638 trimer Substances 0.000 claims description 15
- 239000002773 nucleotide Substances 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 238000005829 trimerization reaction Methods 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 9
- 239000013604 expression vector Substances 0.000 claims description 8
- 238000011049 filling Methods 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 101710198474 Spike protein Proteins 0.000 claims description 6
- 230000009881 electrostatic interaction Effects 0.000 claims description 6
- 108020004999 messenger RNA Proteins 0.000 claims description 6
- 229940096437 Protein S Drugs 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 230000028993 immune response Effects 0.000 claims description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 4
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 4
- 101710189104 Fibritin Proteins 0.000 claims description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 2
- 235000018417 cysteine Nutrition 0.000 claims description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 208000025370 Middle East respiratory syndrome Diseases 0.000 abstract description 111
- 229960005486 vaccine Drugs 0.000 abstract description 24
- 238000012216 screening Methods 0.000 abstract description 5
- 230000027455 binding Effects 0.000 description 107
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 description 74
- 210000004027 cell Anatomy 0.000 description 66
- 241000711573 Coronaviridae Species 0.000 description 54
- 241000699670 Mus sp. Species 0.000 description 43
- 230000014509 gene expression Effects 0.000 description 42
- 150000002632 lipids Chemical class 0.000 description 33
- 150000001413 amino acids Chemical class 0.000 description 32
- 235000000346 sugar Nutrition 0.000 description 27
- 235000001014 amino acid Nutrition 0.000 description 26
- 108090000765 processed proteins & peptides Proteins 0.000 description 26
- 239000000523 sample Substances 0.000 description 26
- 241001678559 COVID-19 virus Species 0.000 description 25
- 238000001514 detection method Methods 0.000 description 24
- 230000003472 neutralizing effect Effects 0.000 description 24
- 239000013598 vector Substances 0.000 description 24
- 229920001184 polypeptide Polymers 0.000 description 23
- 102000004196 processed proteins & peptides Human genes 0.000 description 23
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 22
- 239000012634 fragment Substances 0.000 description 22
- 235000002639 sodium chloride Nutrition 0.000 description 22
- 238000004458 analytical method Methods 0.000 description 21
- 238000013461 design Methods 0.000 description 21
- 230000003612 virological effect Effects 0.000 description 21
- 101000629318 Severe acute respiratory syndrome coronavirus 2 Spike glycoprotein Proteins 0.000 description 20
- 102000025171 antigen binding proteins Human genes 0.000 description 20
- 108091000831 antigen binding proteins Proteins 0.000 description 20
- 238000006386 neutralization reaction Methods 0.000 description 20
- 239000003446 ligand Substances 0.000 description 19
- 229920001223 polyethylene glycol Polymers 0.000 description 19
- 241000701161 unidentified adenovirus Species 0.000 description 19
- 238000003556 assay Methods 0.000 description 18
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 17
- -1 azido, thio Chemical group 0.000 description 17
- 210000001519 tissue Anatomy 0.000 description 17
- 239000002245 particle Substances 0.000 description 15
- 238000002965 ELISA Methods 0.000 description 14
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 14
- 230000004048 modification Effects 0.000 description 14
- 238000012986 modification Methods 0.000 description 14
- 239000002953 phosphate buffered saline Substances 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 13
- 238000012575 bio-layer interferometry Methods 0.000 description 13
- 230000015572 biosynthetic process Effects 0.000 description 13
- 238000011161 development Methods 0.000 description 13
- 230000001965 increasing effect Effects 0.000 description 13
- 239000002105 nanoparticle Substances 0.000 description 13
- 230000004044 response Effects 0.000 description 13
- 238000001542 size-exclusion chromatography Methods 0.000 description 13
- 239000011780 sodium chloride Substances 0.000 description 13
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 12
- 102100038195 Exonuclease mut-7 homolog Human genes 0.000 description 12
- 101000958030 Homo sapiens Exonuclease mut-7 homolog Proteins 0.000 description 12
- 239000000872 buffer Substances 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- 230000035772 mutation Effects 0.000 description 12
- 229920000642 polymer Polymers 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 241000315672 SARS coronavirus Species 0.000 description 11
- 230000005875 antibody response Effects 0.000 description 11
- 239000003623 enhancer Substances 0.000 description 11
- 230000002209 hydrophobic effect Effects 0.000 description 11
- 239000012528 membrane Substances 0.000 description 11
- 239000002777 nucleoside Substances 0.000 description 11
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 10
- 125000000217 alkyl group Chemical group 0.000 description 10
- 125000002091 cationic group Chemical group 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 230000004927 fusion Effects 0.000 description 10
- 230000010076 replication Effects 0.000 description 10
- 238000005406 washing Methods 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 239000000499 gel Substances 0.000 description 9
- 238000011534 incubation Methods 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 9
- 231100000518 lethal Toxicity 0.000 description 9
- 230000001665 lethal effect Effects 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 238000002439 negative-stain electron microscopy Methods 0.000 description 9
- 102000040430 polynucleotide Human genes 0.000 description 9
- 108091033319 polynucleotide Proteins 0.000 description 9
- 239000002157 polynucleotide Substances 0.000 description 9
- 108091026890 Coding region Proteins 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 241000700605 Viruses Species 0.000 description 8
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 238000001415 gene therapy Methods 0.000 description 8
- 239000011159 matrix material Substances 0.000 description 8
- 125000003835 nucleoside group Chemical group 0.000 description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 8
- 238000003127 radioimmunoassay Methods 0.000 description 8
- 150000003839 salts Chemical class 0.000 description 8
- 230000000087 stabilizing effect Effects 0.000 description 8
- 150000003431 steroids Chemical class 0.000 description 8
- 238000013518 transcription Methods 0.000 description 8
- 230000035897 transcription Effects 0.000 description 8
- 208000025721 COVID-19 Diseases 0.000 description 7
- 241000282412 Homo Species 0.000 description 7
- 244000309467 Human Coronavirus Species 0.000 description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 description 7
- 101000629313 Severe acute respiratory syndrome coronavirus Spike glycoprotein Proteins 0.000 description 7
- 238000007792 addition Methods 0.000 description 7
- 238000013459 approach Methods 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 238000012217 deletion Methods 0.000 description 7
- 230000037430 deletion Effects 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 7
- 230000002068 genetic effect Effects 0.000 description 7
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 210000004072 lung Anatomy 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 239000007790 solid phase Substances 0.000 description 7
- 230000009870 specific binding Effects 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 125000001424 substituent group Chemical group 0.000 description 7
- 230000007704 transition Effects 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 102000053602 DNA Human genes 0.000 description 6
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 241001112090 Pseudovirus Species 0.000 description 6
- 125000003342 alkenyl group Chemical group 0.000 description 6
- 230000003321 amplification Effects 0.000 description 6
- 229960002685 biotin Drugs 0.000 description 6
- 235000020958 biotin Nutrition 0.000 description 6
- 239000011616 biotin Substances 0.000 description 6
- 229940098773 bovine serum albumin Drugs 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 238000002649 immunization Methods 0.000 description 6
- 230000002163 immunogen Effects 0.000 description 6
- 230000005847 immunogenicity Effects 0.000 description 6
- 238000003199 nucleic acid amplification method Methods 0.000 description 6
- 150000003904 phospholipids Chemical class 0.000 description 6
- 238000003752 polymerase chain reaction Methods 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 5
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 5
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- 108091005804 Peptidases Proteins 0.000 description 5
- 239000004365 Protease Substances 0.000 description 5
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 5
- 239000007983 Tris buffer Substances 0.000 description 5
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 5
- 125000003118 aryl group Chemical group 0.000 description 5
- 210000003719 b-lymphocyte Anatomy 0.000 description 5
- 238000004422 calculation algorithm Methods 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 238000000684 flow cytometry Methods 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 230000000977 initiatory effect Effects 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 150000003833 nucleoside derivatives Chemical class 0.000 description 5
- 230000008488 polyadenylation Effects 0.000 description 5
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 4
- PEHVGBZKEYRQSX-UHFFFAOYSA-N 7-deaza-adenine Chemical compound NC1=NC=NC2=C1C=CN2 PEHVGBZKEYRQSX-UHFFFAOYSA-N 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- 230000004543 DNA replication Effects 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 4
- 241000712431 Influenza A virus Species 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- 239000000020 Nitrocellulose Substances 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 210000000628 antibody-producing cell Anatomy 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 238000004590 computer program Methods 0.000 description 4
- 238000005520 cutting process Methods 0.000 description 4
- 229940104302 cytosine Drugs 0.000 description 4
- 238000002022 differential scanning fluorescence spectroscopy Methods 0.000 description 4
- 238000010494 dissociation reaction Methods 0.000 description 4
- 230000005593 dissociations Effects 0.000 description 4
- 230000001747 exhibiting effect Effects 0.000 description 4
- 210000002443 helper t lymphocyte Anatomy 0.000 description 4
- 238000003364 immunohistochemistry Methods 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 229920001220 nitrocellulos Polymers 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 4
- 229940035893 uracil Drugs 0.000 description 4
- 229930024421 Adenine Natural products 0.000 description 3
- 108091028732 Concatemer Proteins 0.000 description 3
- 241000494545 Cordyline virus 2 Species 0.000 description 3
- 241000701022 Cytomegalovirus Species 0.000 description 3
- 241000702421 Dependoparvovirus Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- 102000003992 Peroxidases Human genes 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- 208000037847 SARS-CoV-2-infection Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 108010090804 Streptavidin Proteins 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 108020005202 Viral DNA Proteins 0.000 description 3
- 229960000643 adenine Drugs 0.000 description 3
- 125000000304 alkynyl group Chemical group 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000012472 biological sample Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical group C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 3
- 230000009137 competitive binding Effects 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 230000005574 cross-species transmission Effects 0.000 description 3
- 238000013480 data collection Methods 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 238000006471 dimerization reaction Methods 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000001493 electron microscopy Methods 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 230000008520 organization Effects 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 108040007629 peroxidase activity proteins Proteins 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000002864 sequence alignment Methods 0.000 description 3
- 238000013207 serial dilution Methods 0.000 description 3
- 230000000405 serological effect Effects 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 229940113082 thymine Drugs 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 241001430294 unidentified retrovirus Species 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 230000007502 viral entry Effects 0.000 description 3
- 230000029812 viral genome replication Effects 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- 238000009736 wetting Methods 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- MIJDSYMOBYNHOT-UHFFFAOYSA-N 2-(ethylamino)ethanol Chemical compound CCNCCO MIJDSYMOBYNHOT-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- FZWGECJQACGGTI-UHFFFAOYSA-N 2-amino-7-methyl-1,7-dihydro-6H-purin-6-one Chemical compound NC1=NC(O)=C2N(C)C=NC2=N1 FZWGECJQACGGTI-UHFFFAOYSA-N 0.000 description 2
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- OVONXEQGWXGFJD-UHFFFAOYSA-N 4-sulfanylidene-1h-pyrimidin-2-one Chemical compound SC=1C=CNC(=O)N=1 OVONXEQGWXGFJD-UHFFFAOYSA-N 0.000 description 2
- RYVNIFSIEDRLSJ-UHFFFAOYSA-N 5-(hydroxymethyl)cytosine Chemical compound NC=1NC(=O)N=CC=1CO RYVNIFSIEDRLSJ-UHFFFAOYSA-N 0.000 description 2
- HCGHYQLFMPXSDU-UHFFFAOYSA-N 7-methyladenine Chemical compound C1=NC(N)=C2N(C)C=NC2=N1 HCGHYQLFMPXSDU-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
- MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 239000013607 AAV vector Substances 0.000 description 2
- 206010001258 Adenoviral infections Diseases 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 102100035765 Angiotensin-converting enzyme 2 Human genes 0.000 description 2
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 108090000565 Capsid Proteins Proteins 0.000 description 2
- 102100023321 Ceruloplasmin Human genes 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 102000002265 Human Growth Hormone Human genes 0.000 description 2
- 241001135569 Human adenovirus 5 Species 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- 241000713666 Lentivirus Species 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 102000043131 MHC class II family Human genes 0.000 description 2
- 108091054438 MHC class II family Proteins 0.000 description 2
- 108010059343 MM Form Creatine Kinase Proteins 0.000 description 2
- 102000003792 Metallothionein Human genes 0.000 description 2
- 108090000157 Metallothionein Proteins 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 108010069196 Neural Cell Adhesion Molecules Proteins 0.000 description 2
- 102100023616 Neural cell adhesion molecule L1-like protein Human genes 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 108010071690 Prealbumin Proteins 0.000 description 2
- 102000007584 Prealbumin Human genes 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 102000002067 Protein Subunits Human genes 0.000 description 2
- 108010001267 Protein Subunits Proteins 0.000 description 2
- 230000006819 RNA synthesis Effects 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 108091028664 Ribonucleotide Proteins 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 102000054727 Serum Amyloid A Human genes 0.000 description 2
- 108700028909 Serum Amyloid A Proteins 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 108700026226 TATA Box Proteins 0.000 description 2
- 101000980463 Treponema pallidum (strain Nichols) Chaperonin GroEL Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 108010059722 Viral Fusion Proteins Proteins 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 230000033289 adaptive immune response Effects 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 230000003190 augmentative effect Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 239000003593 chromogenic compound Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000012875 competitive assay Methods 0.000 description 2
- 239000005547 deoxyribonucleotide Substances 0.000 description 2
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 2
- 125000002228 disulfide group Chemical group 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000013401 experimental design Methods 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 108010017007 glucose-regulated proteins Proteins 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 125000001475 halogen functional group Chemical group 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 125000001165 hydrophobic group Chemical group 0.000 description 2
- 150000004679 hydroxides Chemical class 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000003100 immobilizing effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 238000001361 intraarterial administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 2
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 238000011031 large-scale manufacturing process Methods 0.000 description 2
- 231100000636 lethal dose Toxicity 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 239000006179 pH buffering agent Substances 0.000 description 2
- 230000007918 pathogenicity Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 2
- 229960004919 procaine Drugs 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 239000002336 ribonucleotide Substances 0.000 description 2
- 125000002652 ribonucleotide group Chemical group 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 229940125575 vaccine candidate Drugs 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 1
- LUAHEUHBAZYUOI-KVXMBEGHSA-N (2s,3r,4r,5r)-4-[(2r,3r,4r,5s,6r)-5-[(2r,3r,4r,5s,6r)-3,4-dihydroxy-6-(hydroxymethyl)-5-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexane-1,2,3,5,6-pentol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O[C@@H]([C@H](O)[C@@H](O)CO)[C@H](O)CO)O[C@H](CO)[C@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@@H](CO)O1 LUAHEUHBAZYUOI-KVXMBEGHSA-N 0.000 description 1
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- QGVQZRDQPDLHHV-DPAQBDIFSA-N (3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthrene-3-thiol Chemical compound C1C=C2C[C@@H](S)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 QGVQZRDQPDLHHV-DPAQBDIFSA-N 0.000 description 1
- HBZBAMXERPYTFS-SECBINFHSA-N (4S)-2-(6,7-dihydro-5H-pyrrolo[3,2-f][1,3]benzothiazol-2-yl)-4,5-dihydro-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)[C@H]1CSC(=N1)c1nc2cc3CCNc3cc2s1 HBZBAMXERPYTFS-SECBINFHSA-N 0.000 description 1
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- FYADHXFMURLYQI-UHFFFAOYSA-N 1,2,4-triazine Chemical class C1=CN=NC=N1 FYADHXFMURLYQI-UHFFFAOYSA-N 0.000 description 1
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 description 1
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 1
- UVBYMVOUBXYSFV-XUTVFYLZSA-N 1-methylpseudouridine Chemical compound O=C1NC(=O)N(C)C=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 UVBYMVOUBXYSFV-XUTVFYLZSA-N 0.000 description 1
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
- TZMSYXZUNZXBOL-UHFFFAOYSA-N 10H-phenoxazine Chemical compound C1=CC=C2NC3=CC=CC=C3OC2=C1 TZMSYXZUNZXBOL-UHFFFAOYSA-N 0.000 description 1
- UHUHBFMZVCOEOV-UHFFFAOYSA-N 1h-imidazo[4,5-c]pyridin-4-amine Chemical compound NC1=NC=CC2=C1N=CN2 UHUHBFMZVCOEOV-UHFFFAOYSA-N 0.000 description 1
- VGONTNSXDCQUGY-RRKCRQDMSA-N 2'-deoxyinosine Chemical group C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC2=O)=C2N=C1 VGONTNSXDCQUGY-RRKCRQDMSA-N 0.000 description 1
- QSHACTSJHMKXTE-UHFFFAOYSA-N 2-(2-aminopropyl)-7h-purin-6-amine Chemical compound CC(N)CC1=NC(N)=C2NC=NC2=N1 QSHACTSJHMKXTE-UHFFFAOYSA-N 0.000 description 1
- JRYMOPZHXMVHTA-DAGMQNCNSA-N 2-amino-7-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1h-pyrrolo[2,3-d]pyrimidin-4-one Chemical compound C1=CC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O JRYMOPZHXMVHTA-DAGMQNCNSA-N 0.000 description 1
- WKMPTBDYDNUJLF-UHFFFAOYSA-N 2-fluoroadenine Chemical compound NC1=NC(F)=NC2=C1N=CN2 WKMPTBDYDNUJLF-UHFFFAOYSA-N 0.000 description 1
- 108700022172 2019-nCoV Vaccine mRNA-1273 Proteins 0.000 description 1
- 108020005345 3' Untranslated Regions Proteins 0.000 description 1
- 108020003589 5' Untranslated Regions Proteins 0.000 description 1
- AGFIRQJZCNVMCW-UAKXSSHOSA-N 5-bromouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 AGFIRQJZCNVMCW-UAKXSSHOSA-N 0.000 description 1
- ZLAQATDNGLKIEV-UHFFFAOYSA-N 5-methyl-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound CC1=CNC(=S)NC1=O ZLAQATDNGLKIEV-UHFFFAOYSA-N 0.000 description 1
- UJBCLAXPPIDQEE-UHFFFAOYSA-N 5-prop-1-ynyl-1h-pyrimidine-2,4-dione Chemical compound CC#CC1=CNC(=O)NC1=O UJBCLAXPPIDQEE-UHFFFAOYSA-N 0.000 description 1
- KXBCLNRMQPRVTP-UHFFFAOYSA-N 6-amino-1,5-dihydroimidazo[4,5-c]pyridin-4-one Chemical compound O=C1NC(N)=CC2=C1N=CN2 KXBCLNRMQPRVTP-UHFFFAOYSA-N 0.000 description 1
- DCPSTSVLRXOYGS-UHFFFAOYSA-N 6-amino-1h-pyrimidine-2-thione Chemical compound NC1=CC=NC(S)=N1 DCPSTSVLRXOYGS-UHFFFAOYSA-N 0.000 description 1
- QNNARSZPGNJZIX-UHFFFAOYSA-N 6-amino-5-prop-1-ynyl-1h-pyrimidin-2-one Chemical compound CC#CC1=CNC(=O)N=C1N QNNARSZPGNJZIX-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- NJBMMMJOXRZENQ-UHFFFAOYSA-N 6H-pyrrolo[2,3-f]quinoline Chemical compound c1cc2ccc3[nH]cccc3c2n1 NJBMMMJOXRZENQ-UHFFFAOYSA-N 0.000 description 1
- LOSIULRWFAEMFL-UHFFFAOYSA-N 7-deazaguanine Chemical compound O=C1NC(N)=NC2=C1CC=N2 LOSIULRWFAEMFL-UHFFFAOYSA-N 0.000 description 1
- HRYKDUPGBWLLHO-UHFFFAOYSA-N 8-azaadenine Chemical compound NC1=NC=NC2=NNN=C12 HRYKDUPGBWLLHO-UHFFFAOYSA-N 0.000 description 1
- LPXQRXLUHJKZIE-UHFFFAOYSA-N 8-azaguanine Chemical compound NC1=NC(O)=C2NN=NC2=N1 LPXQRXLUHJKZIE-UHFFFAOYSA-N 0.000 description 1
- 229960005508 8-azaguanine Drugs 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000288673 Chiroptera Species 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- 108010061994 Coronavirus Spike Glycoprotein Proteins 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- HEBKCHPVOIAQTA-QWWZWVQMSA-N D-arabinitol Chemical compound OC[C@@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-QWWZWVQMSA-N 0.000 description 1
- OXQKEKGBFMQTML-UHFFFAOYSA-N D-glycero-D-gluco-heptitol Natural products OCC(O)C(O)C(O)C(O)C(O)CO OXQKEKGBFMQTML-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-ZXXMMSQZSA-N D-iditol Chemical compound OC[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-ZXXMMSQZSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- UNXHWFMMPAWVPI-QWWZWVQMSA-N D-threitol Chemical compound OC[C@@H](O)[C@H](O)CO UNXHWFMMPAWVPI-QWWZWVQMSA-N 0.000 description 1
- 102000016559 DNA Primase Human genes 0.000 description 1
- 108010092681 DNA Primase Proteins 0.000 description 1
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 1
- 108700041152 Endoplasmic Reticulum Chaperone BiP Proteins 0.000 description 1
- 102100021451 Endoplasmic reticulum chaperone BiP Human genes 0.000 description 1
- 102100039328 Endoplasmin Human genes 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- 241000233756 Fabriciana elisa Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 241000713813 Gibbon ape leukemia virus Species 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010062347 HLA-DQ Antigens Proteins 0.000 description 1
- 108010067802 HLA-DR alpha-Chains Proteins 0.000 description 1
- 101150112743 HSPA5 gene Proteins 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 description 1
- 101001000998 Homo sapiens Protein phosphatase 1 regulatory subunit 12C Proteins 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 241000598171 Human adenovirus sp. Species 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 241000711467 Human coronavirus 229E Species 0.000 description 1
- 241001109669 Human coronavirus HKU1 Species 0.000 description 1
- 241000482741 Human coronavirus NL63 Species 0.000 description 1
- 241001428935 Human coronavirus OC43 Species 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 108700002232 Immediate-Early Genes Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical class O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
- YINZYTTZHLPWBO-UHFFFAOYSA-N Kifunensine Natural products COC1C(O)C(O)C(O)C2NC(=O)C(=O)N12 YINZYTTZHLPWBO-UHFFFAOYSA-N 0.000 description 1
- SKCKOFZKJLZSFA-UHFFFAOYSA-N L-Gulomethylit Natural products CC(O)C(O)C(O)C(O)CO SKCKOFZKJLZSFA-UHFFFAOYSA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 238000006845 Michael addition reaction Methods 0.000 description 1
- 229940026207 Moderna COVID-19 vaccine Drugs 0.000 description 1
- 240000002769 Morchella esculenta Species 0.000 description 1
- 235000002779 Morchella esculenta Nutrition 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- JQGGAELIYHNDQS-UHFFFAOYSA-N Nic 12 Natural products CC(C=CC(=O)C)c1ccc2C3C4OC4C5(O)CC=CC(=O)C5(C)C3CCc2c1 JQGGAELIYHNDQS-UHFFFAOYSA-N 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical group CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 108700005081 Overlapping Genes Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 241000701945 Parvoviridae Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108091093037 Peptide nucleic acid Proteins 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 229940026233 Pfizer-BioNTech COVID-19 vaccine Drugs 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 102100035620 Protein phosphatase 1 regulatory subunit 12C Human genes 0.000 description 1
- 102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 description 1
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 1
- 206010037394 Pulmonary haemorrhage Diseases 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 102000009572 RNA Polymerase II Human genes 0.000 description 1
- 108010009460 RNA Polymerase II Proteins 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 101000868151 Rattus norvegicus Somatotropin Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000009661 Repressor Proteins Human genes 0.000 description 1
- 108010034634 Repressor Proteins Proteins 0.000 description 1
- JVWLUVNSQYXYBE-UHFFFAOYSA-N Ribitol Natural products OCC(C)C(O)C(O)CO JVWLUVNSQYXYBE-UHFFFAOYSA-N 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 108091006367 SARS-CoV-2 Spike Subunit S2 Proteins 0.000 description 1
- WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 1
- 101100111629 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) KAR2 gene Proteins 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical class [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 101710195626 Transcriptional activator protein Proteins 0.000 description 1
- 101800001690 Transmembrane protein gp41 Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 102000013394 Troponin I Human genes 0.000 description 1
- 108010065729 Troponin I Proteins 0.000 description 1
- 206010053614 Type III immune complex mediated reaction Diseases 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000010530 Virus Neutralization Effects 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000000367 ab initio method Methods 0.000 description 1
- XVIYCJDWYLJQBG-UHFFFAOYSA-N acetic acid;adamantane Chemical compound CC(O)=O.C1C(C2)CC3CC1CC2C3 XVIYCJDWYLJQBG-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 210000000776 antibody secreting cell Anatomy 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 238000007622 bioinformatic analysis Methods 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000005101 cell tropism Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 239000008395 clarifying agent Substances 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000008876 conformational transition Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 125000001651 cyanato group Chemical group [*]OC#N 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000007402 cytotoxic response Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 150000001982 diacylglycerols Chemical class 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 125000005265 dialkylamine group Chemical group 0.000 description 1
- 150000001985 dialkylglycerols Chemical class 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- PGUYAANYCROBRT-UHFFFAOYSA-N dihydroxy-selanyl-selanylidene-lambda5-phosphane Chemical compound OP(O)([SeH])=[Se] PGUYAANYCROBRT-UHFFFAOYSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- AFABGHUZZDYHJO-UHFFFAOYSA-N dimethyl butane Natural products CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 1
- MWRBNPKJOOWZPW-CLFAGFIQSA-N dioleoyl phosphatidylethanolamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-CLFAGFIQSA-N 0.000 description 1
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000008393 encapsulating agent Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- XJRPTMORGOIMMI-UHFFFAOYSA-N ethyl 2-amino-4-(trifluoromethyl)-1,3-thiazole-5-carboxylate Chemical compound CCOC(=O)C=1SC(N)=NC=1C(F)(F)F XJRPTMORGOIMMI-UHFFFAOYSA-N 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000013230 female C57BL/6J mice Methods 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- SKCKOFZKJLZSFA-FSIIMWSLSA-N fucitol Chemical compound C[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO SKCKOFZKJLZSFA-FSIIMWSLSA-N 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- FBPFZTCFMRRESA-GUCUJZIJSA-N galactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-GUCUJZIJSA-N 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 231100000734 genotoxic potential Toxicity 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 125000003827 glycol group Chemical group 0.000 description 1
- 101150028578 grp78 gene Proteins 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 244000144980 herd Species 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- 239000012145 high-salt buffer Substances 0.000 description 1
- 210000001624 hip Anatomy 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 102000045598 human DPP4 Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000016178 immune complex formation Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000013115 immunohistochemical detection Methods 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000009878 intermolecular interaction Effects 0.000 description 1
- 230000008863 intramolecular interaction Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 239000000905 isomalt Substances 0.000 description 1
- 235000010439 isomalt Nutrition 0.000 description 1
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- OIURYJWYVIAOCW-VFUOTHLCSA-N kifunensine Chemical compound OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H]2NC(=O)C(=O)N12 OIURYJWYVIAOCW-VFUOTHLCSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000007477 logistic regression Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 238000013178 mathematical model Methods 0.000 description 1
- 238000010297 mechanical methods and process Methods 0.000 description 1
- 238000005399 mechanical ventilation Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000034217 membrane fusion Effects 0.000 description 1
- 210000001806 memory b lymphocyte Anatomy 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 230000020654 modulation by virus of host translation Effects 0.000 description 1
- 239000002991 molded plastic Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 238000011201 multiple comparisons test Methods 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 238000007481 next generation sequencing Methods 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 244000309711 non-enveloped viruses Species 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- ONTNXMBMXUNDBF-UHFFFAOYSA-N pentatriacontane-17,18,19-triol Chemical compound CCCCCCCCCCCCCCCCC(O)C(O)C(O)CCCCCCCCCCCCCCCC ONTNXMBMXUNDBF-UHFFFAOYSA-N 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 238000009522 phase III clinical trial Methods 0.000 description 1
- 229950000688 phenothiazine Drugs 0.000 description 1
- 150000002991 phenoxazines Chemical class 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-N phosphoramidic acid Chemical compound NP(O)(O)=O PTMHPRAIXMAOOB-UHFFFAOYSA-N 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001566 pro-viral effect Effects 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000005451 protein repair Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- RXTQGIIIYVEHBN-UHFFFAOYSA-N pyrimido[4,5-b]indol-2-one Chemical compound C1=CC=CC2=NC3=NC(=O)N=CC3=C21 RXTQGIIIYVEHBN-UHFFFAOYSA-N 0.000 description 1
- SRBUGYKMBLUTIS-UHFFFAOYSA-N pyrrolo[2,3-d]pyrimidin-2-one Chemical compound O=C1N=CC2=CC=NC2=N1 SRBUGYKMBLUTIS-UHFFFAOYSA-N 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000037425 regulation of transcription Effects 0.000 description 1
- 101150066583 rep gene Proteins 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- HEBKCHPVOIAQTA-ZXFHETKHSA-N ribitol Chemical compound OC[C@H](O)[C@H](O)[C@H](O)CO HEBKCHPVOIAQTA-ZXFHETKHSA-N 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- JRPHGDYSKGJTKZ-UHFFFAOYSA-K selenophosphate Chemical compound [O-]P([O-])([O-])=[Se] JRPHGDYSKGJTKZ-UHFFFAOYSA-K 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000013605 shuttle vector Substances 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000008137 solubility enhancer Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000003335 steric effect Effects 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 125000005309 thioalkoxy group Chemical group 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-O triethylammonium ion Chemical compound CC[NH+](CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-O 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 150000004043 trisaccharides Chemical class 0.000 description 1
- PBYZMCDFOULPGH-UHFFFAOYSA-N tungstate Chemical compound [O-][W]([O-])(=O)=O PBYZMCDFOULPGH-UHFFFAOYSA-N 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000007501 viral attachment Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 238000001429 visible spectrum Methods 0.000 description 1
- OXQKEKGBFMQTML-KVTDHHQDSA-N volemitol Chemical compound OC[C@@H](O)[C@@H](O)C(O)[C@H](O)[C@H](O)CO OXQKEKGBFMQTML-KVTDHHQDSA-N 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1002—Coronaviridae
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1002—Coronaviridae
- C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Definitions
- the present disclosure relates generally to the fields of medicine, virology, immunology, and protein engineering. More particular, the disclosure relates to engineered beta-coronavirus S2 domain-only proteins and the use thereof in drug design and vaccine formulation.
- Coronaviruses are a genetically diverse group of enveloped viruses containing a large appx. 30 kb, positive-sense, single- stranded RNA genome (Li, 2016).
- HCoVs human Co Vs
- CoVs exhibit adaptation to alternative host species, and spillover of three novel beta genus CoVs (b-CoVs) — Middle East respiratory syndrome (MERS)-CoV, severe acute respiratory syndrome (SARS)-CoV, and SARS-CoV-2 — from bats directly or indirectly into humans within the past two decades underscores the serious and persistent threat to public health that coronaviruses hold.
- SARS-CoV-2 has led to >100 million cases worldwide and left in its path detrimental socioeconomic consequences.
- global development of vaccines and therapeutics against SARS-CoV-2 has proceeded at an
- VOC virus-associated virus-2
- SARS-CoV-2 “variants of concern” distinguished by one to many unique or recurring changes in S, recently emerged in multiple regions of the world, including western Europe, South Africa, and North America. These variants have spread at disproportionately fast rates relative to predecessor variants in certain geographic regions, consistent with augmented replication capacity, greater transmissibility, and/or immune evasion.
- SARS-CoV-2 trained on conserved S2 epitopes and stimulated by SARS-CoV-2 infection may account for the skewed neutralizing antibody response to the SARS-CoV-2 S2 subunit in young individuals.
- SARS-CoV-2 a majority of the anti- SARS-CoV-2 IgG repertoire targets the S2 subdomain, reiterating the potential for cross reactivity directed at conserved epitopes on HCoVs (Nguyen-Contant et al., 2020).
- the S2 subunit serves as an attractive target for development of broad-spectrum vaccines and therapeutic antibodies for current and future novel HCoVs.
- Coronaviruses are genetically diverse positive-strand RNA viruses that generally dwell in animal reservoirs but can cause pandemics after spillover into the human population.
- Vaccine development for SARS-CoV-2 has progressed at unprecedented speed resulting in several vaccine candidates with up to 95% efficacy against COVID-19.
- current CoV vaccines primarily target immunodominant epitopes in the S 1 subunit, which are generally not well conserved across CoV subgenera and are sensitive to escape mutations, thus threatening vaccine efficacy.
- structure-guided protein engineering was used to remove the SI subunit from the MERS-CoV spike (S) glycoprotein and develop stabilized stem (SS) antigens.
- Vaccination with MERS SS elicited cross-reactive b-CoV antibody responses and protected mice against lethal MERS-CoV challenge.
- High-throughput microfluidic discovery of antibody secreting cells from MERS SS-immunized mice led to discovery of a panel of cross-reactive monoclonal antibodies.
- Antibody IgG22 bound with high affinity to both MERS-CoV and SARS-CoV-2 S proteins, and electron microscopy localized the epitope to a conserved coiled-coil region in the S2 subunit.
- engineered proteins comprising an engineered beta-coronavirus S2 domain that comprises a sequence at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, or at least 95% identical to: (a) positions 762-1291 of SEQ ID NO: 1 (i.e., the S2 domain of MERS-CoV spike protein); (b) positions 687-1208 of SEQ ID NO: 2 (i.e., the S2 domain of SARS-CoV-2 spike protein); (c) positions 668-1190 of SEQ ID NO: 3 (i.e., the S2 domain of SARS -CoV spike protein) or (d) position 683-1205 of SEQ ID NO: 4; wherein the engineered protein comprises the following substitutions relative to the sequence of SEQ ID NO: 1: S975M, T803C, K933C, V958S, V983I, S1091E, L1094Q, N1132Y, V1060P,
- engineered proteins comprising an engineered beta-coronavirus S2 domain that comprises a sequence at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, or at least 95%identical to: (a) positions 762-1291 of SEQ ID NO: 1; (b) positions 687-1208 of SEQ ID NO: 2; (c) positions 668-1190 of SEQ ID NO: 3; or (d) position 683-1205 of SEQ ID NO: 4; wherein the engineered protein does not comprise a beta-coronavirus SI domain, and wherein the engineered protein comprises at least one substitution relative to the sequence of SEQ ID NO: 1, 2, or 3, said at least one substitution being at a position corresponding to: V958, V983, A918, V1139, L1094, S1091, N1132, K816, H1020, H1146, V1150, S845, T803, K933, S858, G953, S975, L923, L1033, P93
- the engineered proteins comprise at least one engineered disulfide bond comprising paired cysteine substitutions at positions corresponding to: T803C and K933C; S858C and G953C; and/or Q769C and S858C relative to SEQ ID NO: 1.
- the engineered proteins further comprise at least one additional engineered disulfide bond.
- the engineered proteins comprise at least one cavity filling substitution at a position corresponding to: S975, P937, M939, L923, and/or L1033 relative to SEQ ID NO: 1. In some aspects, the engineered proteins comprise at least one cavity filling substitution selected from: S975M, P937F, M939K, L923W, and L1033F relative to SEQ ID NO: 1.
- the engineered proteins comprise at least one substitution that provides an electrostatic interaction substitution at a position corresponding to: S845, L923, L1033, A1049, S787, Q1003, L840, and/or A1093 relative to SEQ ID NO: 1.
- the engineered proteins comprise at least one electrostatic interaction substitution selected from S845E, L923K, L1033E, A1049S, S787D, Q1003K, L840E, and A1093R relative to SEQ ID NO: 1.
- the engineered proteins comprise V1060P and L1061P substitutions relative to SEQ ID NO: 1.
- the engineered proteins comprise a combination of at least one engineered disulfide bond, at least one cavity filling substitution, at least one proline substitution, and at least one electrostatic interaction substitution.
- the engineered proteins comprise the following substitutions relative to SEQ ID NO: 1: V983I/, V958S, L1094Q, S1091E, N1132Y, V1060P, and L1061P. In some aspects, the engineered proteins comprise the following substitutions relative to SEQ ID NO: 1: V983I, A918P, V1139F, V958S, L1094Q, S1091E, N1132Y, V1060P, and L1061P.
- the engineered proteins comprise the following substitutions relative to SEQ ID NO: 1: V983I, A918P, V1139F, V958S, L1094Q, S1091E, N1132Y, K816R, H1020Q, H1146Y, V1150T, V1060P, and L1061P. In some aspects, the engineered proteins comprise the following substitutions relative to SEQ ID NO: 1: S975M, T803C, K933C, V958S, V983I, S1091E, L1094Q, N1132Y, V1060P, and L1061P.
- the engineered proteins comprise the following substitutions relative to SEQ ID NO: 1: S975M, T803C, K933C, V958S, V983I, S1091E, L1094Q, N1132Y, V1060P, L1061P, V898C, V1022C, A838C, and S0189C.
- the engineered proteins are fused or conjugated to a dimerization domain. In some aspects, the engineered proteins are fused to a dimerization domain. In some aspects, the trimerization domain is positioned C-terminally relative to S protein ectodomain. In some aspects, the trimerization domain comprises a T4 fibritin trimerization domain.
- the engineered proteins are fused or conjugated to a transmembrane domain. In some aspects, the engineered proteins are fused to a transmembrane domain. In some aspects, the transmembrane domain comprises a beta- coronavirus spike protein transmembrane domain. In some aspects, the transmembrane domain comprises a homologous beta-coronavirus spike protein transmembrane domain.
- engineered beta-coronavirus S2 trimers comprising at least one subunit according to any one of the present embodiments.
- the S2 trimers are stabilized in a prefusion conformation relative to a S2 trimer of wildtype S protein subunits.
- the S2 trimers comprise at least one engineered disulfide bond between subunits.
- 5 disulfide bond between subunits is selected from: T803C and K933C; S858C and G953C; and/or Q769C and S858C relative to SEQ ID NO: 1.
- compositions comprising a pharmaceutically acceptable carrier; and an engineered protein or an engineered trimer of any one of the present embodiments.
- the compositions further comprise an adjuvant.
- nucleic acid molecules comprising a nucleotide sequence that encodes an amino acid sequence of an engineered protein of any one of the present embodiments.
- the nucleic acid comprises a DNA expression vector.
- the nucleic acid comprises a mRNA.
- kits for preventing coronavirus infection or a disease associate with coronavirus infection in a subject comprising administering to the subject an effective amount of the pharmaceutical composition or a nucleic acid molecule according to any one of the present embodiments.
- the methods elicit a beta-coronavirus cross-reactive immune response.
- the methods elicit the production of pan-coronavirus antibodies in the subject.
- composition comprising an engineered protein of any one of the present embodiments bound to an antibody.
- FIG. 1 Exemplary substitutions for MERS spike stem stabilization.
- One protomer of the S2 subunits is shown as a ribbon diagram with the other two protomers shown in a transparent molecular surface.
- the regions that refold during the pre-to-postfusion transition are colored cyan with the rest of the S2 in wheat.
- Each inset corresponds to the location of exemplary substitutions in the MERS SS.V1 construct.
- FIGS. 2A-H Characterization of MERS stem stabilized spike variants.
- FIG. 2A SDS-PAGE of MERS-CoV S2-2P and single-substitution spike variants on mutll backbone. Molecular weight standards are indicated at the left in kDa.
- FIGS. 2B-D Size- exclusion chromatography traces of purified spike variants, grouped by type (FIG. 2B, cavity and aromatic pi; FIG. 2C, disulfide; FIG. 2D polar and salt bridge). A vertical dotted line indicates the peak retention volume for S2-2P.
- FIG. 2E SEC traces for reversed and combinational-substitution spike variants. Mut5, mut6 and mut7 have six, five and four residues of mutll reversed to the wild-type, respectively.
- S975M and T803C/K933C are additional mutations combined with mut5, mut6 and mut7.
- FIG. 2F SEC traces for combinatorial disulfide-substituted spike variants. Additional one or two disulfide substitutions are introduced on MERS SS.V1 backbone.
- FIG. 2G Differential scanning fluorimetry analysis of spike variant thermostability. The vertical dotted line indicates the apparent melting temperature for S2-2P.
- FIG. 2H SEC traces of MERS SS.V1 and MERS SS.V2 purified from a 1 L culture of FreeStyle 293F cells.
- FIGS. 3A-F Immunogenicity of MERS SS immunogens in mice.
- SAS Sigma Adjuvant System
- Mice were immunized at weeks 0 and 3 and bled two weeks post-boost for serological analyses including ELISAs to assess binding to (FIG. 3B) MERS-CoV, (FIG.
- FIG. 3C HCoV-HKUl
- FIG. 3D SARS-CoV
- FIG. 3E SARS-CoV-2 S-2P-specific binding IgG
- FIG. 3F MERS-CoV pseudovirus neutralization assay.
- Each circle represents an individual mouse. Dotted lines represent upper and lower limits of detection where applicable.
- FIGS. 3B-F Min to max box plots, with the box from 25-75% and the median value denoted by the line.
- FIGGS. 3B-E Experimental groups were compared by two-way ANOVA with multiple
- FIGS. 4A-H Efficacy of SS.V1 against lethal MERS-CoV challenge in mice.
- Two weeks post-boost mice were bled for analysis of (FIG. 4B) MERS-CoV S-2P-specific IgG and (FIG. 4C) pseudovirus neutralizing antibodies.
- FIG. 4C pseudovirus neutralizing antibodies.
- mice were challenged with a lethal dose of mouse-adapted MERS-CoV (MA35c5).
- mice were monitored for weight loss.
- FIGGS. 4B-C, E-H Each circle represents an individual mouse. Min to max box plots, with the box from 25-75% and the median value denoted by the line. Dotted lines represent lower limits of detection where applicable. Experimental groups were compared by one-way ANOVA with Kruskal-Wallis post-test. (FIG.
- FIGS. 5A-F MERS stem-targeted mAbs neutralize authentic MERS- CoV. Binding of Fab22 to (FIG. 5A) MERS-CoV S, (FIG. 5B) SARS-CoV S, and (FIG. 5C) SARS-CoV-2 S assessed by surface plasmon resonance. Binding data are shown as black lines and the best fit to a 1:1 binding model is shown as gray lines. (FIG. 5D) IgG22 and IgG72 demonstrated concentration-dependent neutralization of MERS-CoV infectivity. Other SS.V1 elicited mAbs shown lacked detectable neutralizing activity against MERS-CoV.
- mAbs IgG20, IgG22 and IgG72 were tested in duplicate, and remaining mAbs were tested once. Neutralizing mAh G4 was included as a positive control and tested in triplicate.
- FIG. 5E Neither IgG22 or IgG72 exhibited detectable neutralization of SARS-CoV-2.
- mAh S309 which neutralizes SARS-CoV-2, was included as a positive control.
- IgG22 and IgG72 were tested once, and S309 was tested in duplicate.
- FIG. 5F Representative 2D class averages and cryo-EM density map of Fab22 bound to MERS S-2P. The local resolution is depicted by
- FIGS. 6A-D Stem-targeted mAb 22 binds to helical stalk region of SARS- CoV-2 spike.
- FIG. 6A Representative 2D class averages and 3D reconstructions of Fab22 bound SARS-CoV-2 S.
- FIG. 6B Side view of cryo-EM density of Fab22 bound to SARS- CoV-2 S. The local resolution is depicted by a spectrum as a scale bar.
- Fab22 binds to the base of the spike.
- FIG. 6C Model of full-length wildtype SARS-CoV-2 spike (PDB: 6XR8) docked into EM map of Fab22 bound SARS-CoV-2 S.
- Sequence alignments of the helical stalk region of four b-CoVs show high sequence similarity.
- the sequences for SARS-CoV and SARS-CoV-2 are SEQ ID NO: 7.
- the sequence for MERS-CoV is SEQ ID NO: 8.
- the sequence for HKU1 is SEQ ID NO: 9.
- FIG. 6D Binding of Fab22 to three spike variants captured by RBD-directed IgG is assessed by BLI. Binding data are shown as black lines and the best fit to a 1:1 binding model is shown as gray lines.
- FIGS. 7A-C Characterization of MERS stem stabilized spike variants.
- FIGS. 7A and B DSF analysis for spike variant thermostability.
- FIG. 7A For reversed spike variants (the first and the second iterations), mut5, mut6 and mut7 have six, five and four residues of mutll reverted to the wild-type, respectively.
- S975M and T803C/K933C are additional mutations combined with mut5, mut6 and mut7.
- the dotted line indicates the melting curve for S2-2P.
- FIG. 7B DSF analysis for reversed spike variants (the third iterations). The variants having the same Tm are indicated by a dot line, dash line, dash- single dotted line or dash-double dotted line for clarity.
- FIG. 7A For reversed spike variants (the first and the second iterations), mut5, mut6 and mut7 have six, five and four residues of mutll reverted to the wild-type, respectively.
- S975M and T803C/K933C are
- FIGS. 8A-B MERS S-2P and MERS SS.V1 exhibit nanomolar binding affinity to mAb G4. Binding of (FIG. 8A) MERS S-2P or (FIG. 8B) MERS SS.V1 to mAb G4 assessed by biolayer interferometry (BLI). AHC sensor tips were used to capture mAh G4 and then dipped into a well containing MERS S-2P or MERS SS in BLI buffer. The end point binding responses were plotted against concentrations of the spikes, and the best fit by steady state analysis is shown as a nonlinear line.
- BLI buffer biolayer interferometry
- FIGS. 9A-C MERS SS.V1 elicited mAbs exhibit a spectrum of the binding specificities to betacorona virus spikes. Binding of MERS SS.V1 elicited mAbs to MERS-CoV S, SARS-CoV S, HCoV-HKUl S assessed by biolayer interferometry (BLI). RSV-F containing a consensus trimerization motif (foldon) is also included as a negative control. Binding data are shown as solid lines, and the best fit to a 1:1 binding model is shown as dash lines. A vertical dotted line indicates the end of the binding event. The selected mAbs are grouped by their binding kinetics: (FIG.
- FIG. 9A bi-specificity, faster on rates to MERS-S than SARS-S
- FIG. 9B bi-specificity, faster on rates to SARS-S than MERS-S
- FIG. 9C only binding to MERS-S or only binding to foldon.
- FIGS. 10A-B Two third of MERS SS.V1 elicited mAbs bind to the regions other than G4 binding loop.
- FIG. 10A Illustration of the scheme of experimental design for G4 competition assay by BLI. AHC biosensors were used to capture selected Ah and then dipped into G4 Fab pre-saturated MERS-S or apo MERS-S. Binding data are shown as solid lines and the best fit to a 1:1 binding model is shown as dash lines. A vertical dotted line indicates the end of the binding event when the responses are used for end-point binding analysis.
- FIG. 10A Illustration of the scheme of experimental design for G4 competition assay by BLI. AHC biosensors were used to capture selected Ah and then dipped into G4 Fab pre-saturated MERS-S or apo MERS-S. Binding data are shown as solid lines and the best fit to a 1:1 binding model is shown as dash lines. A vertical dotted line indicates the end of the binding event when the responses are used for
- End-point binding responses of mAbs to G4 Fab pre-saturated MERS-S versus MERS-S are calculated and shown as percentage. Ah G4 is also included as a control (white bar). Non-G4 competing mAbs having higher responses to G4 Fab pre saturated MERS-S than MERS-S are depicted as gray bars. G4 competing mAbs having higher responses to MERS-S than G4 Fab pre-saturated MERS-S are depicted as black bars.
- FIGS. 11A-C Fab22 and Fab72 bind to a helical stalk region of the spikes.
- FIG. 11 A Representative 2D class averages of Fab22 complexed with MERS-CoV S by negative stain electron microscopy (nsEM).
- FIG. 11B Representative 2D class averages of Fab72 complexed with MERS-CoV S by nsEM.
- FIG. 11C Representative 2D class averages of Fab22 complexed with HexaPro, a prefusion stabilized SARS-CoV-2 S, by nsEM.
- FIGS. 12A-C Cryo-EM structure validation. FSC curves and viewing distribution plots for (FIG. 12A) MERS-CoV S-Fab 22 structure, (FIGS. 12B-C) SARS- CoV-2 S-Fab 22 structures with (FIG. 12B) 1-RBD up and (FIG. 12C) 3-RBD down generated in cry oS PARC v2.15.
- Vaccine development for SARS-CoV-2 has progressed at unprecedented speed resulting in several vaccine candidates with up to 95% efficacy against COVID-19.
- current CoV vaccines primarily target immunodominant epitopes in the S 1 subunit, which are generally not well conserved across CoV subgenera.
- Structure-guided protein engineering was used to remove the SI subunit from the MERS-CoV spike (S) glycoprotein and develop stabilized stem (SS) antigens.
- Vaccination with MERS SS elicited cross-reactive b-CoV antibody responses and protected mice against lethal MERS-CoV challenge.
- MERS-CoV stabilized stem constructs MERS SS.V1 and MERS SS.V2, both of which lack the SI subunit (FIG. 1). Both antigens are immunogenic in mice, inducing broadly cross-reactive antibodies to MERS-CoV, HCoV HKU1, SARS-CoV, and SARS-CoV-2 S, and confer protection in a lethal murine MERS- CoV challenge model.
- Two monoclonal antibodies, IgG22 and IgG72 isolated using microfluidic single B-cell screening technology from MERS SS. VI -immunized mice, neutralized authentic MERS-CoV.
- All CoV spikes are composed of an SI subunit, a major determinant for host cell tropism, and an S2 subunit, which contains the machinery that drives viral-host fusion
- the SI subunit which directly interacts with the host receptor, is composed of an N-terminal domain (NTD), a receptor-binding domain (RBD) and subdomains (SDs).
- NTD N-terminal domain
- RBD receptor-binding domain
- SDs subdomains
- SARS-CoV-2 transient hinging of the RBD into an ‘up’ conformation allows for host-cell receptor engagement.
- a helix-loop region spanning from the fusion peptide (FP) to heptad repeat 1 (HR1) constitutes a metastable structure that transitions to a long stable a-helix in the postfusion conformation during viral entry.
- the FP, HR1, central helix (CH) and connector domain (CD) comprise the globular head of the S2 subunit.
- the helical stalk region, connecting the globular head to the viral membrane is elongated and highly flexible (Ke et al., 2020; Turonova et al., 2020).
- the stalk region can be further divided into a hip, knee, and ankle, wherein the knee functions as a hinge, providing a considerable range in flexibility and movement for the spikes on the viral surface.
- the S2 subunit of CoV S analogous to HA2 of influenza vims HA and gp41 of HIV-1 Env, functions as a fusogen by bringing viral and host cell membranes together, thus enabling viral entry.
- the S2 subunit transitions from a metastable prefusion to a highly stable 250 post- fusion conformation (Li, 2016).
- HA stem hemagglutinin stem region (functionally analogous to the CoV S2 subunit) to elicit broad protection in animals.
- two independent research groups rationally engineered the HA stem by introducing disulfide bridges, increasing surface hydrophilicity, stabilizing the hydrophobic core, optimizing the protease cleavage site, and/or displaying the HA stem on nanoparticles (Impagliazzo et al., 2015; Yassine et al., 2015).
- the HA stem trimers stabilized in the prefusion conformation induced neutralizing antibodies targeting stems of various group 1 HA subtypes and protected animals from heterotypic IAV challenge.
- a similar strategy based on structure-guided vaccine design was successfully applied to more distantly related group 2 IAV (Boyoglu-Barnum et al., 2020; Corbett et al., 2019).
- the Cys803-Cys933 pair was introduced to cross-link regions of mobility and immobility during the pre- to post-fusion transition in a manner similar to the Cysl55-Cys290 substitution in RSV F (DS-Cavl) (McLellan et al., 2013).
- a covalent linkage was made across the S2' protease cleavage site, via the formation of a Cys838-Cysl089 bridge, akin to the Cys93(HA2)- Cys310(HAl) substitution in the HA stem (Impagliazzo et al., 2015).
- Cys898 and Cysl022 substitutions were placed in the fusion peptide and HR1 to prevent the helix-loop region from transitioning to a single, elongated helix. Both Cys898 and Cysl022 substitutions were at regions that move substantially, and a similar approach was employed to increase the trimer fraction of HA stem (Cys68-Cys76) and to keep PIV3 F in a prefusion conformation (Cysl62-Cysl68) (Impagliazzo et al., 2015; Stewart-Jones et al., 2018).
- Disulfide engineering has also been used to restrict local flexibility of secondary structures in SARS-CoV-2 S (Hsieh et al., 2020) or to trap the RBDs in a closed configuration (Henderson et al., 2020; McCallum et al., 2020; Xiong et al., 2020).
- MERS SS V2 elicited 10-fold higher neutralizing antibodies against MERS CoV than SS VI in a single prime-boost immunization regimen.
- Each disulfide substitution significantly improved
- thermostability of the MERS SS antigens consistent with disulfide designs in other class I viral fusion proteins.
- N1132Y substitution seems to pack against Pro937, Vall206, and Proll31 and possibly forms H bonds with Gln800 and Asnl029.
- Other modifications intended to enhance polar interactions for instance, V958S, S1091E and L1094Q substitutions — were considered as beneficial additions to the best construct.
- Alternative strategies such as stabilizing proline substitutions, reducing hydrophobicity at the S1-S2 interface, and nanoparticle display, are viable options to further improve our MERS SS.V2 antigens in efforts to induce cross-neutralizing antibodies.
- MERS SS -immunization stimulated the production of antibodies that were cross-reactive to multiple CoV S proteins.
- This disclosure is the first to show protection against lethal CoV challenge with a stem-only immunogen — protection that comes without elicitation of potent neutralizing antibody responses.
- Previous studies suggest that in vivo activity of influenza virus stem-specific antibodies rely on Fc-mediated functions (DiLillo et al., 2014, 2016). In fact, only a handful of S2-specific neutralizing antibodies against MERS- CoV have been defined (Wang et al., 2015; Widjaja et al., 2019).
- This disclosure also describes a conserved epitope near the base of S, distinct from the G4-binding site.
- this disclosure provides rationally engineered CoV S stems as stabilized immunogens to elicit antibodies cross-reactive with all three epidemic b-HCoVs and to provide complete protection in animals against a lethal MERS-CoV challenge.
- a stabilized stem construct the production of antibodies was elicited which enabled the identification of a novel site of vulnerability in the S2 subunit, which will inform development of next-generation CoV vaccines and fortify CoV pandemic preparedness.
- essentially free in terms of a specified component, is used herein to mean that none of the specified component has been purposefully formulated into a composition and/or is present only as a contaminant or in trace amounts.
- the total amount of the specified component resulting from any unintended contamination of a composition is therefore well below 0.05%, preferably below 0.01%.
- Most preferred is a composition in which no amount of the specified component can be detected with standard analytical methods.
- antibody refers to an intact immunoglobulin of any isotype, or a fragment thereof that can compete with the intact antibody for specific binding to the target antigen, and includes, for instance, chimeric, humanized, fully human, and bispecific antibodies.
- An “antibody” is a species of an antigen binding protein.
- An intact antibody will generally comprise at least two full-length heavy chains and two full-length light chains, but in some instances can include fewer chains such as antibodies naturally occurring in camelids which can comprise only heavy chains.
- Antibodies can be derived solely from a single source, or can be “chimeric,” that is, different portions of the antibody can be derived from two different antibodies as described further below.
- antigen binding proteins, antibodies, or binding fragments can be produced in hybridomas, by recombinant DNA techniques, or by enzymatic or chemical cleavage of intact antibodies.
- antibody includes, in addition to antibodies comprising two full-length heavy chains and two full-length light chains, derivatives, variants, fragments, and muteins thereof, examples of which are described below.
- antibodies include monoclonal antibodies, bispecific antibodies, minibodies, domain antibodies, synthetic
- antibody mimetics sometimes referred to herein as “antibody mimetics”
- chimeric antibodies humanized antibodies
- human antibodies sometimes referred to herein as “antibody conjugates”
- fragments thereof respectively.
- the term also encompasses peptibodies.
- Naturally occurring antibody structural units typically comprise a tetramer.
- Each such tetramer typically is composed of two identical pairs of polypeptide chains, each pair having one full-length “light” (in certain embodiments, about 25 kDa) and one full- length “heavy” chain (in certain embodiments, about 50-70 kDa).
- the amino-terminal portion of each chain typically includes a variable region of about 100 to 110 or more amino acids that typically is responsible for antigen recognition.
- the carboxy-terminal portion of each chain typically defines a constant region that can be responsible for effector function.
- Human light chains are typically classified as kappa and lambda light chains.
- Heavy chains are typically classified as mu, delta, gamma, alpha, or epsilon, and define the antibody's isotype as IgM, IgD, IgG, IgA, and IgE, respectively.
- IgG has several subclasses, including, but not limited to, IgGl, IgG2, IgG3, and IgG4.
- IgM has subclasses including, but not limited to, IgMl and IgM2.
- IgA is similarly subdivided into subclasses including, but not limited to, IgAl and IgA2.
- variable and constant regions are joined by a “J” region of about 12 or more amino acids, with the heavy chain also including a “D” region of about 10 more amino acids.
- J Fundamental Immunology
- the variable regions of each light/heavy chain pair typically form the antigen binding site.
- variable region refers to a portion of the light and/or heavy chains of an antibody, typically including approximately the amino-terminal 120 to 130 amino acids in the heavy chain and about 100 to 110 amino terminal amino acids in the light chain.
- variable regions of different antibodies differ extensively in amino acid sequence even among antibodies of the same species.
- the variable region of an antibody typically determines specificity of a particular antibody for its target.
- variable regions typically exhibit the same general structure of relatively conserved framework regions (FR) joined by three hyper variable regions, also called complementarity determining regions or CDRs.
- FR relatively conserved framework regions
- CDRs complementarity determining regions
- both light and heavy chain variable regions typically comprise the domains FR1, CDR1, FR2, CDR2, FR3, CDR3 and FR4.
- the assignment of amino acids to each domain is typically in accordance with the definitions of Rabat Sequences of Proteins of Immunological Interest (National Institutes of Health, Bethesda, Md. (1987 and 1991)), Chothia & Lesk, J. Mol. Biol., 196:901-917 (1987) or Chothia et al, Nature, 342:878-883 (1989).
- an antibody heavy chain binds to an antigen in the absence of an antibody light chain.
- an antibody light chain binds to an antigen in the absence of an antibody heavy chain.
- an antibody binding region binds to an antigen in the absence of an antibody light chain.
- an antibody binding region binds to an antigen in the absence of an antibody heavy chain.
- an individual variable region specifically binds to an antigen in the absence of other variable regions.
- definitive delineation of a CDR and identification of residues comprising the binding site of an antibody is accomplished by solving the structure of the antibody and/or solving the structure of the antibody-ligand complex. In certain embodiments, that can be accomplished by any of a variety of techniques known to those skilled in the art, such as X-ray crystallography. In certain embodiments, various methods of analysis can be employed to identify or approximate the CDR regions. Examples of such methods include, but are not limited to, the Rabat definition, the Chothia definition, the AbM definition and the contact definition.
- the Rabat definition is a standard for numbering the residues in an antibody and is typically used to identify CDR regions. See, e.g., Johnson & Wu, Nucleic Acids Res., 28: 214-8 (2000).
- the Chothia definition is similar to the Rabat definition, but the Chothia definition takes into account positions of certain structural loop regions. See, e.g., Chothia et al, J. Mol. Biol., 196: 901-17 (1986); Chothia et al, Nature, 342: 877-83 (1989).
- the AbM definition uses an integrated suite of computer programs produced by Oxford Molecular Group that model antibody structure.
- the CDR regions in the heavy chain are typically referred to as HI, H2, and H3 and are numbered sequentially in the direction from the amino terminus to the carboxy terminus.
- the CDR regions in the light chain are typically referred to as LI, L2, and L3 and are numbered sequentially in the direction from the amino terminus to the carboxy term in us.
- the term “light chain” includes a full-length light chain and fragments thereof having sufficient variable region sequence to confer binding specificity.
- a full-length light chain includes a variable region domain, VL, and a constant region domain, CL.
- the variable region domain of the light chain is at the amino-terminus of the polypeptide.
- Light chains include kappa chains and lambda chains.
- the term “heavy chain” includes a full-length heavy chain and fragments thereof having sufficient variable region sequence to confer binding specificity.
- a full-length heavy chain includes a variable region domain, VH, and three constant region domains, CHI, CH2, and CH3.
- the VH domain is at the amino-terminus of the polypeptide, and the CH domains are at the carboxyl-terminus, with the CH3 being closest to the carboxy- terminus of the polypeptide.
- Heavy chains can be of any isotype, including IgG (including IgGl, IgG2, IgG3 and IgG4 subtypes), IgA (including IgAl and IgA2 subtypes), IgM and IgE.
- a bispecific or bifunctional antibody typically is an artificial hybrid antibody having two different heavy/light chain pairs and two different binding sites.
- Bispecific antibodies can be produced by a variety of methods including, but not limited to, fusion of hybridomas or linking of Fab' fragments. See, e.g., Songsivilai et al., Clin. Exp. Immunol., 79: 315-321 (1990); Kostelny et al, J. Immunol., 148:1547-1553 (1992).
- an antigen refers to a substance capable of inducing adaptive immune responses.
- an antigen is a substance which serves as a target for the receptors of an adaptive immune response.
- an antigen is a molecule that binds to antigen- specific receptors but cannot induce an immune response in the body by itself. Antigens are
- antigens 21 usually proteins and polysaccharides, less frequently also lipids.
- antigens also include immunogens and haptens.
- An “Fc” region comprises two heavy chain fragments comprising the CHI and CH2 domains of an antibody.
- the two heavy chain fragments are held together by two or more disulfide bonds and by hydrophobic interactions of the CH3 domains.
- the “Fv region” comprises the variable regions from both the heavy and light chains but lacks the constant regions.
- An antibody that “specifically binds to” or is “specific for” a particular polypeptide or an epitope on a particular polypeptide is one that binds to that particular polypeptide or epitope on a particular polypeptide without substantially binding to any other polypeptide or polypeptide epitope.
- the Coronavirus S protein specific antibodies of the present invention are specific to Coronavirus S protein.
- the antibody that binds to Coronavirus S protein has a dissociation constant (Kd) of £100 nM, £100 nM, £ nM, £0.1 nM, £0.01 nM, or £0.001 nM (e.g., 10 -8 M or less, e.g., from 10 _8 M to 10 -13 M, e.g., from 10 -9 M to 10 -13 M).
- Kd dissociation constant
- antigen binding proteins e.g., atnibody or antigen-binding fragment thereof
- competition when used in the context of antigen binding proteins (e.g., atnibody or antigen-binding fragment thereof) that compete for the same epitope means competition between antigen binding proteins as determined by an assay in which the antigen binding protein (e.g., antibody or antigen-binding fragment thereof) being tested prevents or inhibits (e.g., reduces) specific binding of a reference antigen binding protein (e.g., a ligand, or a reference antibody) to a common antigen (e.g., Coronavirus S protein or a fragment thereof).
- a reference antigen binding protein e.g., a ligand, or a reference antibody
- RIA solid phase direct or indirect radioimmunoassay
- EIA solid phase direct or indirect enzyme immunoassay
- sandwich competition assay see, e.g., Stahli et al., 1983, Methods in Enzymology 9:242- 253
- solid phase direct biotin-avidin EIA see, e.g., Kirkland et al., 1986, J. Immunol.
- solid phase direct labeled assay solid phase direct labeled sandwich assay (see, e.g., Harlow and Lane, 1988, Antibodies, A Laboratory Manual, Cold Spring Harbor Press); solid phase direct label RIA using 1-125 label (see, e.g., Morel et al, 1988, Molec. Immunol. 25:7-15); solid phase direct biotin-avidin EIA (see, e.g., Cheung, et al, 1990, Virology 176:546-552); and direct labeled RIA (Moldenhauer et al, 1990,
- Such an assay involves the use of purified antigen bound to a solid surface or cells bearing either of these, an unlabelled test antigen binding protein and a labeled reference antigen binding protein. Competitive inhibition is measured by determining the amount of label bound to the solid surface or cells in the presence of the test antigen binding protein. Usually the test antigen binding protein is present in excess.
- Antigen binding proteins identified by competition assay include antigen binding proteins binding to the same epitope as the reference antigen binding proteins and antigen binding proteins binding to an adjacent epitope sufficiently proximal to the epitope bound by the reference antigen binding protein for steric hindrance to occur.
- a competing antigen binding protein when present in excess, it will inhibit (e.g., reduce) specific binding of a reference antigen binding protein to a common antigen by at least 40-45%, 45-50%, 50-55%, 55-60%, 60-65%, 65- 70%, 70-75 % or 75% or more. In some instances, binding is inhibited by at least 80-85%, 85- 90%, 90-95%, 95-97%, or 97% or more.
- epitope refers to the specific group of atoms or amino acids on an antigen to which an antibody binds.
- the epitope can be either linear epitope or a conformational epitope.
- a linear epitope is formed by a continuous sequence of amino acids from the antigen and interacts with an antibody based on their primary structure.
- a conformational epitope is composed of discontinuous sections of the antigen’s amino acid sequence and interacts with the antibody based on the 3D structure of the antigen.
- an epitope is approximately five or six amino acid in length. Two antibodies may bind the same epitope within an antigen if they exhibit competitive binding for the antigen.
- the term “host cell” means a cell that has been transformed, or is capable of being transformed, with a nucleic acid sequence and thereby expresses a gene of interest.
- the term includes the progeny of the parent cell, whether or not the progeny is identical in morphology or in genetic make-up to the original parent cell, so long as the gene of interest is present.
- identity refers to a relationship between the sequences of two or more polypeptide molecules or two or more nucleic acid molecules, as determined by aligning and comparing the sequences. “Percent identity” means the percent of identical
- the sequences being compared are typically aligned in a way that gives the largest match between the sequences.
- One example of a computer program that can be used to determine percent identity is the GCG program package, which includes GAP (Devereux et al, 1984, Nucl. Acid Res. 12:387; Genetics Computer Group, University of Wisconsin, Madison, Wis.).
- GAP is used to align the two polypeptides or polynucleotides for which the percent sequence identity is to be determined.
- the sequences are aligned for optimal matching of their respective amino acid or nucleotide (the “matched span”, as determined by the algorithm).
- a gap opening penalty (which is calculated as 3x the average diagonal, wherein the “average diagonal” is the average of the diagonal of the comparison matrix being used; the “diagonal” is the score or number assigned to each perfect amino acid match by the particular comparison matrix) and a gap extension penalty (which is usually 1/10 times the gap opening penalty), as well as a comparison matrix such as PAM 250 or BLOSUM 62 are used in conjunction with the algorithm.
- a standard comparison matrix (see, Dayhoff et al, 1978, Atlas of Protein Sequence and Structure 5:345-352 for the PAM 250 comparison matrix; Henikoff et al, 1992, Proc. Natl. Acad. Sci. U.S.A. 89:10915-10919 for the BLOSUM 62 comparison matrix) is also used by the algorithm.
- Certain alignment schemes for aligning two amino acid sequences may result in matching of only a short region of the two sequences, and this small aligned region may have very high sequence identity even though there is no significant relationship between the two full-length sequences. Accordingly, the selected alignment method (GAP program) can be adjusted if so desired to result in an alignment that spans at least 50 or other number of contiguous amino acids of the target polypeptide.
- link refers to the association via intramolecular interaction, e.g., covalent bonds, metallic bonds, and/or ionic bonding, or inter-molecular interaction, e.g., hydrogen bond or noncovalent bonds.
- operably linked refers to an arrangement of elements wherein the components so described are configured so as to perform their usual function.
- a given signal peptide that is operably linked to a polypeptide directs the secretion of the polypeptide from a cell.
- a promoter that is operably linked to a coding sequence will direct the expression of the coding sequence.
- the promoter or other control elements need not be contiguous with the coding sequence, so long as they function to direct the expression thereof. For example, intervening untranslated yet transcribed sequences can be present between the promoter sequence and the coding sequence and the promoter sequence can still be considered “operably linked” to the coding sequence.
- polynucleotide or “nucleic acid” includes both single-stranded and double-stranded nucleotide polymers.
- the nucleotides comprising the polynucleotide can be ribonucleotides or deoxyribonucleotides or a modified form of either type of nucleotide.
- Said modifications include base modifications such as bromouridine and inosine derivatives, ribose modifications such as 2',3'-dideoxyribose, and intemucleotide linkage modifications such as phosphorothioate, phosphorodithioate, phosphoroselenoate, phosphorodiselenoate, phosphoroanilothioate, phoshoraniladate and phosphoroamidate.
- polypeptide or “protein” means a macromolecule having the amino acid sequence of a native protein, that is, a protein produced by a naturally-occurring
- non-recombinant cell or it is produced by a genetically-engineered or recombinant cell, and comprise molecules having the amino acid sequence of the native protein, or molecules having deletions from, additions to, and/or substitutions of one or more amino acids of the native sequence.
- the term also includes amino acid polymers in which one or more amino acids are chemical analogs of a corresponding naturally occurring amino acid and polymers.
- polypeptide and protein specifically encompass Coronavirus S protein binding proteins, antibodies, or sequences that have deletions from, additions to, and/or substitutions of one or more amino acid of antigen-binding protein.
- polypeptide fragment refers to a polypeptide that has an amino-terminal deletion, a carboxyl-terminal deletion, and/or an internal deletion as compared with the full-length native protein. Such fragments can also contain modified amino acids as compared with the native protein. In certain embodiments, fragments are about five to 500 amino acids long. For example, fragments can be at least 5, 6, 8, 10, 14, 20, 50, 70, 100, 110, 150, 200, 250, 300, 350, 400, or 450 amino acids long.
- Useful polypeptide fragments include immunologically functional fragments of antibodies, including binding domains.
- useful fragments include but are not limited to a CDR region, a variable domain of a heavy and/or light chain, a portion of an antibody chain or just its variable region including two CDRs, and the like.
- compositions and formulations suitable for pharmaceutical delivery of the fusion proteins herein disclosed are conventional. Remington’s Pharmaceutical Sciences, by E. W. Martin, Mack Publishing Co., Easton, PA, 15th Edition (1975), describes compositions and formulations suitable for pharmaceutical delivery of the fusion proteins herein disclosed. In general, the nature of the carrier will depend on the particular mode of administration being employed. For instance, parenteral formulations usually comprise injectable fluids that include pharmaceutically and physiologically acceptable fluids such as water, physiological saline, balanced salt solutions, aqueous dextrose, glycerol or the like as a vehicle.
- injectable fluids that include pharmaceutically and physiologically acceptable fluids such as water, physiological saline, balanced salt solutions, aqueous dextrose, glycerol or the like as a vehicle.
- non-toxic solid carriers can include, for example, pharmaceutical grades of mannitol, lactose, starch or magnesium stearate.
- pharmaceutical compositions to be administered can contain minor amounts of non-toxic auxiliary substances, such as wetting or emulsifying agents, preservatives, and pH buffering agents and the like, for example sodium acetate or sorbitan monolaurate.
- the term “subject” refers to a human or any non-human animal (e.g., mouse, rat, rabbit, dog, cat, cattle, swine, sheep, horse or primate).
- a human includes pre- and post-natal forms.
- a subject is a human being.
- a subject can be a patient, which refers to a human presenting to a medical provider for diagnosis or treatment of a disease.
- the term “subject” is used herein interchangeably with “individual” or “patient.”
- a subject can be afflicted with or is susceptible to a disease or disorder but may or may not display symptoms of the disease or disorder.
- terapéuticaally effective amount or “effective dosage” as used herein refers to the dosage or concentration of a drug effective to treat a disease or condition.
- a drug effective to treat a disease or condition.
- monoclonal antibodies or antigen-binding fragments thereof disclosed herein to treat viral infection.
- Treating” or “treatment” of a condition as used herein includes preventing or alleviating a condition, slowing the onset or rate of development of a condition, reducing the risk of developing a condition, preventing or delaying the development of symptoms associated with a condition, reducing or ending symptoms associated with a condition, generating a complete or partial regression of a condition, curing a condition, or some combination thereof.
- a “vector” refers to a nucleic acid molecule as introduced into a host cell, thereby producing a transformed host cell.
- a vector may include nucleic acid sequences that permit it to replicate in the host cell, such as an origin of replication.
- a vector may also include one or more therapeutic genes and/or selectable marker genes and other genetic elements known in the art.
- a vector can transduce, transform or infect a cell, thereby causing the cell to express nucleic acids and/or proteins other than those native to the cell.
- a vector optionally includes materials to aid in achieving entry of the nucleic acid into the cell, such as a viral particle, liposome, protein coating or the like.
- compositions comprising an engineered, stabilized beta-coronavirus S2 domain-only protein, a nucleic acid molecule encoding an engineered, stabilized beta-coronavirus S2 domain-only protein, and viral vector comprising an engineered, stabilized beta-coronavirus S2 domain-only protein and/or encoding the engineered, stabilized beta-coronavirus S2 domain-only protein in its genomic
- compositions can be used for stimulating an immune response, such as part of a vaccine formulation.
- nucleic acid molecule encoding an engineered, stabilized beta-coronavirus S2 domain-only protein
- the nucleic acid molecule may comprise or consist of deoxyribonucleotides and/or ribonucleotides, or analogs thereof, covalently linked together.
- a nucleic acid molecule as described herein generally contains phosphodiester bonds, although in some cases, nucleic acid analogs are included that may have at least one different linkage, e.g., phosphoramidate, phosphorothioate, phosphorodithioate, or O-methylphophoroamidite linkages, and peptide nucleic acid backbones and linkages.
- a nucleic acid molecule may comprise modified nucleotides, such as methylated nucleotides and nucleotide analogs. If present, modifications to the nucleotide structure may be imparted before or after assembly of the polymer.
- the sequence of nucleotides may be interrupted by non-nucleotide components.
- a polynucleotide may be further modified after polymerization, such as by conjugation with a labeling component. The term also includes both double- and single- stranded molecules.
- polynucleotide encompasses both the double- stranded form and each of two complementary single-stranded forms known or predicted to make up the double- stranded form.
- a nucleic acid molecule is composed of a specific sequence of four nucleotide bases: adenine (A), cytosine (C), guanine (G), thymine (T), and uracil (U) for thymine when the polynucleotide is RNA.
- A adenine
- C cytosine
- G guanine
- T thymine
- U uracil
- nucleic acid sequence is the alphabetical representation of a nucleic acid molecule.
- nucleic acid sequence also implicitly encompasses conservatively modified variants thereof (e.g., degenerate codon substitutions) and complementary sequences as well as the sequence explicitly indicated.
- degenerate codon substitutions may be achieved by generating sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and/or deoxyinosine residues.
- the nucleic acids of the present disclosure comprise one or more modified nucleosides comprising a modified sugar moiety.
- modified nucleosides comprising a modified sugar moiety.
- Such compounds comprising one or more sugar-modified nucleosides may have desirable properties, such as
- modified sugar moieties are substituted sugar moieties.
- modified sugar moieties are sugar surrogates. Such sugar surrogates may comprise one or more substitutions corresponding to those of substituted sugar moieties.
- modified sugar moieties are substituted sugar moieties comprising one or more non-bridging sugar substituent, including but not limited to substituents at the 2' and/or 5' positions.
- sugar substituents suitable for the 2'- position include, but are not limited to: 2'-F, 2'-OCH 3 ("OMe” or "O-methyl"), and 2'- 0(CH 2 ) 2 0CH 3 (“MOE").
- sugar substituents at the 5'-position include, but are not limited to: 5'-methyl (R or S); 5'- vinyl, and 5'-methoxy.
- substituted sugars comprise more than one non-bridging sugar substituent, for example, T-F-5'-methyl sugar moieties (see, e.g., PCT International Application WO 2008/101157, for additional 5',2'-bis substituted sugar moieties and nucleosides).
- Nucleosides comprising 2'-substituted sugar moieties are referred to as 2'- substituted nucleosides.
- These 2'-substituent groups can be further substituted with one or more substituent groups independently selected from hydroxyl, amino, alkoxy, carboxy, benzyl, phenyl, nitro (N0 2 ), thiol, thioalkoxy (S-alkyl), halogen, alkyl, aryl, alkenyl and alkynyl.
- each R m and R n is, independently, H, an amino protecting group or substituted or unsubstituted Ci-Cio alkyl.
- a 2'-substituted nucleoside comprises a sugar moiety comprising a 2'-substituent group selected from F, O--CH3, and OCH2CH2OCH3.
- nucleosides of the present disclosure comprise one or more unmodified nucleobases. In certain embodiments, nucleosides of the present disclosure comprise one or more modified nucleobases.
- modified nucleobases are selected from: universal bases, hydrophobic bases, promiscuous bases, size-expanded bases, and fluorinated bases as defined herein.
- nucleobases include tricyclic pyrimidines such as phenoxazine cytidine([5,4-b][l,4]benzoxazin-2(3H)-one), phenothiazine cytidine (lH-pyrimido[5,4- b][l,4]benzothiazin-2(3H)-one), G-clamps such as a substituted phenoxazine cytidine (e.g.
- nucleobases may also include those in which the purine or
- nucleobases include those disclosed in U.S. Patent 3,687,808, those disclosed in The Concise Encyclopedia Of Polymer Science And Engineering, Kroschwitz, J. I., Ed., John Wiley & Sons, 1990, 858-859; those disclosed by Englisch et al, 1991; and those disclosed by Sanghvi, Y. S., 1993.
- Additional modifications may also be made at other positions on the oligonucleotide, particularly the 3' position of the sugar on the 3' terminal nucleotide and the 5' position of 5' terminal nucleotide.
- one additional modification of the ligand conjugated oligonucleotides of the present disclosure involves chemically linking to the oligonucleotide one or more additional non-ligand moieties or conjugates which enhance the activity, cellular distribution or cellular uptake of the oligonucleotide.
- Such moieties include but are not limited to lipid moieties such as a cholesterol moiety (Letsinger et al, 1989), cholic acid (Manoharan et al, 1994), a thioether, e.g., hexyl-5-tritylthiol (Manoharan et al., 1992; Manoharan et al., 1993), a thiocholesterol (Oberhauser et al., 1992), an aliphatic chain, e.g., dodecandiol or undecyl residues (Saison-Behmoaras et al., 1991; Kabanov et al., 1990; Svinarchuk et al, 1993), a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethylammonium l,2-di-0-hexadecyl-rac-glycero-3-H-phosphon
- a nucleic acid molecule encoding an engineered Coronavirus S protein is a modified RNA, such as, for example, a modified mRNA.
- Modified (m)RNA contemplates certain chemical modifications that confer increased stability and low immunogenicity to mRNAs, thereby facilitating expression of therapeutically important proteins. For instance, N1 -methyl-pseudouridine (NIhiY) outperforms several other nucleoside modifications and their combinations in terms of translation capacity.
- the (m)RNA such as, for example, a modified mRNA.
- the 31 molecules used herein may have the uracils replaced with psuedouracils such as 1 -methyl-3 '- pseudouridylyl bases. In some embodiments, some of the uracils are replaced, but in other embodiments, all of the uracils have been replaced.
- the (m)RNA may comprise a 5’ cap, a 5’ UTR element, an optionally codon optimized open reading frame, a 3’ UTR element, and a poly(A) sequence and/or a polyadenylation signal.
- the nucleic acid molecule may be delivered as a naked nucleic acid molecule or in a delivery vehicle, such as a lipid nanoparticle.
- a lipid nanoparticle may comprise one or more nucleic acids present in a weight ratio to the lipid nanoparticles from about 5:1 to about 1:100.
- the weight ratio of nucleic acid to lipid nanoparticles is from about 5:1, 2.5:1, 1:1, 1:5, 1:10, 1:15, 1:20, 1:25, 1:30, 1:35, 1:40, 1:45, 1:50, 1:60, 1:70, 1:80, 1:90, or 1:100, or any value derivable therein.
- the lipid nanoparticles used herein may contain one, two, three, four, five, six, seven, eight, nine, or ten lipids.
- These lipids may include triglycerides, phospholipids, steroids or sterols, a PEGylated lipids, or a group with a ionizable group such as an alkyl amine and one or more hydrophobic groups such as C6 or greater alkyl groups.
- the lipid nanoparticles are mixed with one or more steroid or a steroid derivative.
- the steroid or steroid derivative comprises any steroid or steroid derivative.
- the term “steroid” is a class of compounds with a four ring 17 carbon cyclic structure which can further comprises one or more substitutions including alkyl groups, alkoxy groups, hydroxy groups, oxo groups, acyl groups, or a double bond between two or more carbon atoms.
- the lipid nanoparticles are mixed with one or more PEGylated lipids (or PEG lipid).
- the present disclosure comprises using any lipid to which a PEG group has been attached.
- the PEG lipid is a diglyceride which also comprises a PEG chain attached to the glycerol group.
- the PEG lipid is a compound which contains one or more C6-C24 long chain alkyl or alkenyl group or a C6-C24 fatty acid group attached to a linker group with a PEG chain.
- a PEG lipid includes a PEG modified phosphatidylethanolamine and phosphatidic acid, a PEG ceramide conjugated, PEG
- the PEG modification is measured by the molecular weight of PEG component of the lipid. In some embodiments, the PEG modification has a molecular weight from about 100 to about 15,000. In some embodiments, the molecular weight is from about 200 to about 500, from about 400 to about 5,000, from about 500 to about 3,000, or from about 1,200 to about 3,000. The molecular weight of the PEG modification is from about 100, 200, 400,
- lipids that may be used in the present disclosure are taught by U.S. Patent 5,820,873, WO 2010/141069, or U.S. Patent 8,450,298, which is incorporated herein by reference.
- the lipid nanoparticles are mixed with one or more phospholipids.
- the phospholipid is a structure which contains one or two long chain C6-C24 alkyl or alkenyl groups, a glycerol or a sphingosine, one or two phosphate groups, and, optionally, a small organic molecule.
- the small organic molecule is an amino acid, a sugar, or an amino substituted alkoxy group, such as choline or ethanolamine.
- the phospholipid is a phosphatidylcholine.
- the phospholipid is distearoylphosphatidylcholine or dioleoylphosphatidylethanolamine.
- other zwitterionic lipids are used, where zwitterionic lipid defines lipid and lipid-like molecules with both a positive charge and a negative charge.
- lipid nanoparticle containing compounds containing lipophilic and cationic components, wherein the cationic component is ionizable are provided.
- the cationic ionizable lipids contain one or more groups which is protonated at physiological pH but may deprotonated and has no charge at a pH above 8, 9, 10, 11, or 12.
- the ionizable cationic group may contain one or more protonatable amines which are able to form a cationic group at physiological pH.
- the cationic ionizable lipid compound may also further comprise one or more lipid components such as two or more fatty acids with C6-C24 alkyl or alkenyl carbon groups.
- 33 groups may be attached through an ester linkage or may be further added through a Michael addition to a sulfur atom.
- these compounds may be a dendrimer, a dendron, a polymer, or a combination thereof.
- composition containing compounds containing lipophilic and cationic components, wherein the cationic component is ionizable are provided.
- ionizable cationic lipids refer to lipid and lipid- like molecules with nitrogen atoms that can acquire charge (pKa). These lipids may be known in the literature as cationic lipids. These molecules with amino groups typically have between 2 and 6 hydrophobic chains, often alkyl or alkenyl such as C6-C24 alkyl or alkenyl groups, but may have at least 1 or more that 6 tails.
- the amount of the lipid nanoparticle with the nucleic acid molecule encapsulated in the pharmaceutical composition is from about 0.1% w/w to about 50% w/w, from about 0.25% w/w to about 25% w/w, from about 0.5% w/w to about 20% w/w, from about 1% w/w to about 15% w/w, from about 2% w/w to about 10% w/w, from about 2% w/w to about 5% w/w, or from about 6% w/w to about 10% w/w.
- the amount of the lipid nanoparticle with the nucleic acid molecule encapsulated in the pharmaceutical composition is from about 0.1% w/w, 0.25% w/w, 0.5% w/w, 1% w/w, 2.5% w/w, 5% w/w, 7.5% w/w, 10% w/w, 15% w/w, 20% w/w, 25% w/w, 30% w/w, 35% w/w, 40% w/w, 45% w/w, 50% w/w, 55% w/w, 60% w/w, 65% w/w, 70% w/w, 75% w/w, 80% w/w, 85% w/w, 90% w/w, to about 95% w/w, or any range derivable therein.
- the present disclosure comprises one or more sugars formulated into pharmaceutical compositions.
- the sugars used herein are saccharides. These saccharides may be used to act as a lyoprotectant that protects the pharmaceutical composition from destabilization during the drying process.
- These water- soluble excipients include carbohydrates or saccharides such as disaccharides such as sucrose, trehalose, or lactose, a trisaccharide such as fructose, glucose, galactose comprising raffinose, polysaccharides such as starches or cellulose, or a sugar alcohol such as xylitol, sorbitol, or mannitol.
- these excipients are solid at room temperature.
- sugar alcohols include erythritol, threitol, arabitol, xylitol, ribitol, mannitol, sorbitol, galactitol, fucitol, iditol, inositol, volemitol, isomalt, maltitol, lactitol, maltotritol, maltotetraitol, or a polyglycitol.
- the amount of the sugar in the pharmaceutical composition is from about 25% w/w to about 98% w/w, 40% w/w to about 95% w/w, 50% w/w to about 90% w/w, 50% w/w to about 70% w/w, or from about 80% w/w to about 90% w/w.
- the amount of the sugar in the pharmaceutical composition is from about 10% w/w, 15% w/w, 20% w/w, 25% w/w, 30% w/w, 35% w/w, 40% w/w, 45% w/w, 50% w/w, 52.5% w/w, 55% w/w, 57.5% w/w, 60% w/w, 62.5% w/w, 65% w/w, 67.5 % w/w, 70% w/w, 75% w/w, 80% w/w, 82.5% w/w, 85% w/w, 87.5% w/w, 90% w/w, to about 95% w/w, or any range derivable therein.
- the pharmaceutically acceptable polymer is a copolymer.
- the pharmaceutically acceptable polymer may further comprise one, two, three, four, five, or six subunits of discrete different types of polymer subunits. These polymer subunits may include polyoxypropylene, polyoxyethylene, or a similar subunit.
- the pharmaceutically acceptable polymer may comprise at least one hydrophobic subunit and at least one hydrophilic subunit.
- the copolymer may have hydrophilic subunits on each side of a hydrophobic unit.
- the copolymer may have a hydrophilic subunit that is polyoxyethylene and a hydrophobic subunit that is polyoxypropylene.
- expression cassettes are employed to express an engineered, stabilized beta-coronavirus S2 domain-only protein, either for subsequent purification and delivery to a cell/subject, or for use directly in a viral-based delivery approach.
- expression vectors which contain one or more nucleic acids encoding an engineered, stabilized beta-coronavirus S2 domain-only protein.
- Expression requires that appropriate signals be provided in the vectors and include various regulatory elements such as enhancers/promoters from both viral and mammalian sources that drive expression of the an engineered, stabilized beta-coronavirus S2 domain-only protein in cells.
- expression cassette is meant to include any type of genetic construct containing a nucleic acid coding for a gene product in which part or all of the nucleic acid encoding sequence is capable of being transcribed and translated, /. ⁇ ? ., is under the control of a promoter.
- a “promoter” refers to a DNA sequence recognized by the synthetic machinery of the cell, or introduced synthetic machinery, required to initiate the specific transcription of a gene.
- under transcriptional control means that the promoter is in the correct location and orientation in relation to the nucleic acid to control RNA polymerase initiation and expression of the gene.
- an “expression vector” is meant to include expression cassettes comprised in a genetic construct that is capable of replication, and thus including one or more of origins of replication, transcription termination signals, poly-A regions, selectable markers, and multipurpose cloning sites.
- promoter will be used here to refer to a group of transcriptional control modules that are clustered around the initiation site for RNA polymerase II. Much of the thinking about how promoters are organized derives from analyses of several viral promoters, including those for the HSV thymidine kinase (tk) and SV40 early transcription units. These studies, augmented by more recent work, have shown that promoters are composed of discrete functional modules, each consisting of approximately 7-20 bp of DNA, and containing one or more recognition sites for transcriptional activator or repressor proteins.
- At least one module in each promoter functions to position the start site for RNA synthesis.
- the best known example of this is the TATA box, but in some promoters lacking a TATA box, such as the promoter for the mammalian terminal deoxynucleotidyl transferase gene and the promoter for the SV40 late genes, a discrete element overlying the start site itself helps to fix the place of initiation.
- Additional promoter elements regulate the frequency of transcriptional initiation. Typically, these are located in the region 30-110 bp upstream of the start site, although a number of promoters have recently been shown to contain functional elements downstream of the start site as well. The spacing between promoter elements frequently is flexible, so that promoter function is preserved when elements are inverted or moved relative to one another. In the tk promoter, the spacing between promoter elements can be increased to 50 bp apart before activity begins to decline. Depending on the promoter, it appears that individual elements can function either co-operatively or independently to activate transcription.
- viral promotes such as the human cytomegalovirus (CMV) immediate early gene promoter, the SV40 early promoter, the Rous sarcoma vims long terminal repeat, rat insulin promoter and glyceraldehyde-3 -phosphate dehydrogenase can be used to obtain high-level expression of the coding sequence of interest.
- CMV human cytomegalovirus
- SV40 early promoter the Rous sarcoma vims long terminal repeat
- rat insulin promoter and glyceraldehyde-3 -phosphate dehydrogenase
- Enhancers are genetic elements that increase transcription from a promoter located at a distant position on the same molecule of DNA. Enhancers are organized much like promoters. That is, they are composed of many individual elements, each of which binds to one or more transcriptional proteins. The basic distinction between enhancers and promoters is operational. An enhancer region as a whole must be able to stimulate transcription at a distance; this need not be true of a promoter region or its component elements. On the other hand, a promoter must have one or more elements that direct initiation of RNA synthesis at a particular site and in a particular orientation, whereas enhancers lack these specificities. Promoters and enhancers are often overlapping and contiguous, often seeming to have a very similar modular organization.
- promoters/enhancers and inducible promoters/enhancers that could be used in combination with the nucleic acid encoding a gene of interest in an expression construct. Additionally, any promoter/enhancer combination (as per the Eukaryotic Promoter Data Base EPDB) could also be used to drive expression of the gene. Eukaryotic cells can support cytoplasmic transcription from certain bacterial promoters if the appropriate bacterial polymerase is provided, either as part of the delivery complex or as an additional genetic expression construct.
- the promoter and/or enhancer may be, for example, immunoglobulin light chain, immunoglobulin heavy chain, T-cell receptor, HLA DQ a and/or DQ b, b-interferon, interleukin-2, interleukin-2 receptor, MHC class II 5, MHC class II HLA-Dra, b-Actin, muscle creatine kinase (MCK), prealbumin (transthyretin), elastase I, metallothionein (MTII), collagenase, albumin, a-fetoprotein, t-globin, b-globin, c-fos, c-HA-ra.v, insulin, neural cell adhesion molecule (NCAM), oci-antitrypain, H2B (TH2B) histone, mouse and/or type I collagen, glucose-regulated proteins (GRP94 and GRP78), rat growth hormone, human serum amyloid A (SAA), troponin I (TN I
- a cDNA insert is employed, one will typically desire to include a polyadenylation signal to effect proper polyadenylation of the gene transcript.
- Any polyadenylation sequence may be employed such as human growth hormone and SV40 polyadenylation signals.
- a terminator is also contemplated as an element of the expression cassette. These elements can serve to enhance message levels and to minimize read through from the cassette into other sequences.
- the expression construct comprises a virus or engineered constmct derived from a viral genome.
- Adenovirus expression vector is meant to include those constructs containing adenovirus sequences sufficient to (a) support packaging of the constmct and (b) to express engineered, stabilized beta-coronavirus S2 domain-only protein that has been cloned therein. In this context, expression does not require that the gene product be synthesized.
- the expression vector comprises a genetically engineered form of adenovirus.
- Knowledge of the genetic organization of adenovirus, a 36 kB, linear, double-stranded DNA vims, allows substitution of large pieces of adenoviral DNA with foreign sequences up to 7 kB.
- retrovirus the adenoviral infection of host cells does not result in chromosomal integration because adenoviral DNA can replicate in an episomal manner without potential genotoxicity.
- adenoviruses are structurally stable, and no genome rearrangement has been detected after extensive amplification. Adenovims can infect
- adenoviral infection appears to be linked only to mild disease such as acute respiratory disease in humans.
- Adenovirus is particularly suitable for use as a gene transfer vector because of its mid-sized genome, ease of manipulation, high titer, wide target cell range and high infectivity. Both ends of the viral genome contain 100-200 base pair inverted repeats (ITRs), which are cis elements necessary for viral DNA replication and packaging.
- ITRs inverted repeats
- the early (E) and late (L) regions of the genome contain different transcription units that are divided by the onset of viral DNA replication.
- the El region (E1A and E1B) encodes proteins responsible for the regulation of transcription of the viral genome and a few cellular genes.
- the expression of the E2 region results in the synthesis of the proteins for viral DNA replication. These proteins are involved in DNA replication, late gene expression and host cell shut-off.
- the products of the late genes are expressed only after significant processing of a single primary transcript issued by the major late promoter (MLP).
- MLP major late promoter
- the MLP (located at 16.8 m.u.) is particularly efficient during the late phase of infection, and all the mRNAs issued from this promoter possess a 5’- tripartite leader (TPL) sequence which makes them preferred mRNAs for translation.
- TPL tripartite leader
- recombinant adenovirus is generated from homologous recombination between shuttle vector and provirus vector. Due to the possible recombination between two proviral vectors, wild-type adenovirus may be generated from this process. Therefore, it is critical to isolate a single clone of vims from an individual plaque and examine its genomic structure.
- adenovirus generation and propagation of the current adenovirus vectors, which are replication deficient, depend on a unique helper cell line, designated 293, which was transformed from human embryonic kidney cells by Ad5 DNA fragments and constitutively expresses El proteins. Since the E3 region is dispensable from the adenovirus genome, the current adenovirus vectors, with the help of 293 cells, carry foreign DNA in either the El, the D3 or both regions. In nature, adenovirus can package approximately 105% of the wild-type genome, providing capacity for about 2 extra kb of DNA.
- the maximum capacity of the current adenovirus vector is under 7.5 kb, or about 15% of the total length of the vector. More than 80% of the adenovirus viral genome remains in the vector backbone and is the source of vector-borne cytotoxicity. Also, the replication deficiency of the El-deleted virus is incomplete.
- Helper cell lines may be derived from human cells such as human embryonic kidney cells, muscle cells, hematopoietic cells or other human embryonic mesenchymal or epithelial cells.
- the helper cells may be derived from the cells of other mammalian species that are permissive for human adenovirus. Such cells include, e.g., Vero cells or other monkey embryonic mesenchymal or epithelial cells.
- the preferred helper cell line is 293.
- the adenoviruses of the disclosure are replication defective, or at least conditionally replication defective.
- the adenovirus may be of any of the 42 different known serotypes or subgroups A-F.
- Adenovirus type 5 of subgroup C is one exemplary starting material that may be used to obtain the conditional replication-defective adenovirus vector for use in the present disclosure.
- viral vectors may be employed as expression constructs in the present disclosure.
- Vectors derived from viruses such as vaccinia vims, adeno-associated virus (AAV) and herpesviruses may be employed. They offer several attractive features for various mammalian cells.
- the vector is an AAV vector.
- AAV is a small virus that infects humans and some other primate species. AAV is not currently known to cause disease. The vims causes a very mild immune response, lending further support to its apparent lack of pathogenicity.
- AAV vectors integrate into the host cell genome, which can be important for certain applications, but can also have unwanted consequences. Gene therapy vectors using AAV can infect both dividing and quiescent cells and persist in an extrachromosomal state without integrating into the genome of the host cell, although in the native vims some integration of virally carried genes into the host genome does occur. These features make AAV a very attractive candidate for creating viral vectors for gene therapy, and for the creation of isogenic human disease models.
- AAV belongs to the genus Dependoparvovirus , which in turn belongs to the family Parvoviridae.
- the virus is a small (20 nm) replication-defective, nonenveloped virus.
- Wild-type AAV has attracted considerable interest from gene therapy researchers due to a number of features. Chief amongst these is the vims's apparent lack of pathogenicity. It can also infect non-dividing cells and has the ability to stably integrate into
- the desired gene together with a promoter to drive transcription of the gene is inserted between the inverted terminal repeats (ITR) that aid in concatemer formation in the nucleus after the single-stranded vector DNA is converted by host cell DNA polymerase complexes into double-stranded DNA.
- ITR inverted terminal repeats
- AAV-based gene therapy vectors form episomal concatemers in the host cell nucleus. In non-dividing cells, these concatemers remain intact for the life of the host cell. In dividing cells, AAV DNA is lost through cell division, since the episomal DNA is not replicated along with the host cell DNA. Random integration of AAV DNA into the host genome is detectable but occurs at very low frequency.
- AAVs also present very low immunogenicity, seemingly restricted to generation of neutralizing antibodies, while they induce no clearly defined cytotoxic response. This feature, along with the ability to infect quiescent cells present their dominance over adenoviruses as vectors for human gene therapy.
- the AAV genome is built of single- stranded deoxyribonucleic acid (ssDNA), either positive- or negative-sensed, which is about 4.7 kilobase long.
- the genome comprises inverted terminal repeats (ITRs) at both ends of the DNA strand, and two open reading frames (ORFs): rep and cap.
- ITRs inverted terminal repeats
- ORFs open reading frames
- the former is composed of four overlapping genes encoding Rep proteins required for the AAV life cycle, and the latter contains overlapping nucleotide sequences of capsid proteins: VP1, VP2 and VP3, which interact together to form a capsid of an icosahedral symmetry.
- the Inverted Terminal Repeat (ITR) sequences comprise 145 bases each. They were named so because of their symmetry, which was shown to be required for efficient multiplication of the AAV genome. The feature of these sequences that gives them this property is their ability to form a hairpin, which contributes to so-called self-priming that allows primase-independent synthesis of the second DNA strand.
- the ITRs were also shown to be required for both integration of the AAV DNA into the host cell genome (19th chromosome in humans) and rescue from it, as well as for efficient encapsidation of the AAV
- ITRs seem to be the only sequences required in cis next to the therapeutic gene: structural (cap) and packaging (rep) proteins can be delivered in trans. With this assumption many methods were established for efficient production of recombinant AAV (rAAV) vectors containing a reporter or therapeutic gene. However, it was also published that the ITRs are not the only elements required in cis for the effective replication and encapsidation. A few research groups have identified a sequence designated cis-acting Rep-dependent element (CARE) inside the coding sequence of the rep gene. CARE was shown to augment the replication and encapsidation when present in cis.
- CARE Rep-dependent element
- the present disclosure provides pharmaceutical compositions that contain one or more salts.
- the salts may be an inorganic potassium or sodium salt such as potassium chloride, sodium chloride, potassium phosphate dibasic, potassium phosphate monobasic, sodium phosphate dibasic, or sodium phosphate monobasic.
- the pharmaceutical composition may comprise one or more phosphate salts such to generate a phosphate buffer solution.
- the phosphate buffer solution may be comprise each of the phosphates to buffer a solution to a pH from about 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, or 8.0, or any range derivable therein.
- the present disclosure comprises one or more excipients formulated into pharmaceutical compositions.
- excipient refers to pharmaceutically acceptable carriers that are relatively inert substances used to facilitate administration or delivery of an API into a subject or used to facilitate processing of an API into drug formulations that can be used pharmaceutically for delivery to the site of action in a subject.
- these compounds may be used as diluents in order to obtain a dosage that can be readily measured or administered to a patient.
- excipients include polymers, stabilizing agents, surfactants, surface modifiers, solubility enhancers, buffers, encapsulating agents, antioxidants, preservatives, nonionic wetting or clarifying agents, viscosity increasing agents, and absorption-enhancing agents.
- the term “pharmaceutically acceptable” means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more
- carrier refers to a diluent, excipient, or vehicle with which the therapeutic is administered.
- Such pharmaceutical carriers can be sterile liquids, such as water and can preferably include an adjuvant. Water is a particular carrier when the pharmaceutical composition is administered by injections, such an intramuscular injection. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions.
- Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like.
- compositions can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents.
- These compositions can take the form of solutions, suspensions, emulsion, tablets, pills, capsules, powders, sustained-release formulations and the like.
- Oral formulations can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc. Examples of suitable pharmaceutical agents are described in “Remington's Pharmaceutical Sciences.”
- Such compositions will contain a prophylactically or therapeutically effective amount of the antibody or fragment thereof, preferably in purified form, together with a suitable amount of carrier so as to provide the form for proper administration to the patient.
- the formulation should suit the mode of administration, which can be oral, intravenous, intraarterial, intrabuccal, intranasal, nebulized, bronchial inhalation, or delivered by mechanical ventilation.
- Engineered proteins or nucleic acids encoding engineered proteins of the present disclosure, as described herein, can be formulated for parenteral administration, e.g., formulated for injection via the intradermal, intravenous, intramuscular, subcutaneous, intra- tumoral or even intraperitoneal routes.
- the formulation could alternatively be administered by a topical route directly to the mucosa, for example by nasal drops, inhalation, or by nebulizer.
- Pharmaceutically acceptable salts include the acid salts and those which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like.
- Salts formed with the free carboxyl groups may also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine, procaine, and the like.
- inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine, procaine, and the like.
- compositions of the disclosure are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water-free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent.
- a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent.
- the composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline.
- an ampoule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration ⁇
- compositions of the disclosure can be formulated as neutral or salt forms.
- Pharmaceutically acceptable salts include those formed with anions such as those derived from hydrochloric, phosphoric, acetic, oxalic, tartaric acids, etc. , and those formed with cations such as those derived from sodium, potassium, ammonium, calcium, ferric hydroxides, isopropylamine, triethylamine, 2-ethylamino ethanol, histidine, procaine, etc.
- Dosage can be by a single dose schedule or a multiple dose schedule. Multiple doses may be used in a primary immunization schedule and/or in a booster immunization schedule. In a multiple dose schedule the various doses may be given by the same or different routes. Multiple doses will typically be administered at least 1 week apart (e.g., about 2 weeks, about 3 weeks, about 4 weeks, about 6 weeks, about 8 weeks, about 10 weeks, about 12 weeks, about 16 weeks, etc.).
- compositions disclosed herein may be used to treat both children and adults.
- a human subject may be less than 1 year old, 1-5 years old, 5-16 years old, 16-55 years old, 55-65 years old, or at least 65 years old.
- Preferred routes of administration include, but are not limited to, intramuscular, intraperitoneal, intradermal, subcutaneous, intravenous, intraarterial, and intraoccular injection. Particularly preferred routes of administration include intramuscular, intradermal and subcutaneous injection.
- the present disclosure concerns immunodetection methods for binding, purifying, removing, quantifying and otherwise generally detecting Coronavirus S protein. While such methods can be applied in a traditional
- antibodies according to the present disclosure can be used to assess the amount or integrity (/. ⁇ ? ., long term stability) of antigens.
- the methods may be used to screen various antibodies for appropriate/desired reactivity profiles.
- Some immunodetection methods include enzyme linked immunosorbent assay (ELISA), radioimmunoassay (RIA), immunoradiometric assay, fluoroimmunoassay, chemiluminescent assay, bioluminescent assay, and Western blot to mention a few.
- ELISA enzyme linked immunosorbent assay
- RIA radioimmunoassay
- immunoradiometric assay fluoroimmunoassay
- fluoroimmunoassay fluoroimmunoassay
- chemiluminescent assay chemiluminescent assay
- bioluminescent assay bioluminescent assay
- Western blot to mention a few.
- a competitive assay for the detection and quantitation of Coronavirus S protein also is provided.
- the steps of various useful immunodetection methods have been described in the scientific literature, such as, e.g., Doolittle and Ben-Zeev (1999), Gulbis and Gal
- These methods include methods for detecting or purifying Coronavirus S protein or Coronavirus S protein from a sample.
- the antibody will preferably be linked to a solid support, such as in the form of a column matrix, and the sample suspected of containing the Coronavirus S protein will be applied to the immobilized antibody. The unwanted components will be washed from the column, leaving the Coronavirus S protein-expressing cells immunocomplexed to the immobilized antibody, which is then collected by removing the organism or antigen from the column.
- the immunobinding methods also include methods for detecting and quantifying the amount of Coronavirus S protein or related components in a sample and the detection and quantification of any immune complexes formed during the binding process.
- a sample suspected of containing Coronavirus S protein and contact the sample with an antibody that binds Coronavirus S protein or components thereof, followed by detecting and quantifying the amount of immune complexes formed under the specific conditions.
- the biological sample analyzed may be any sample that is suspected of containing Coronavirus S protein, such as a tissue section or specimen, a homogenized tissue extract, a biological fluid (e.g., a nasal swab), including blood and serum, or a secretion, such as feces or urine.
- the antibody employed in the detection may itself be linked to a detectable label, wherein one would then simply detect this label, thereby allowing the amount of the primary immune complexes in the composition to be determined.
- the first antibody that becomes bound within the primary immune complexes may be detected by means of a second binding ligand that has binding affinity for the antibody.
- the second binding ligand may be linked to a detectable label.
- the second binding ligand is itself often an antibody, which may thus be termed a “secondary” antibody.
- the primary immune complexes are contacted with the labeled, secondary binding ligand, or antibody, under effective conditions and for a period of time sufficient to allow the formation of secondary immune complexes.
- the secondary immune complexes are then generally washed to remove any non-specifically bound labeled secondary antibodies or ligands, and the remaining label in the secondary immune complexes is then detected.
- Further methods include the detection of primary immune complexes by a two-step approach.
- a second binding ligand such as an antibody that has binding affinity for the antibody, is used to form secondary immune complexes, as described above.
- the secondary immune complexes are contacted with a third binding ligand or antibody that has binding affinity for the second antibody, again under effective conditions and for a period of time sufficient to allow the formation of immune complexes (tertiary immune complexes).
- the third ligand or antibody is linked to a detectable label, allowing detection of the tertiary immune complexes thus formed. This system may provide for signal amplification if this is desired.
- One method of immunodetection uses two different antibodies.
- a first biotinylated antibody is used to detect the target antigen, and a second antibody is then used to detect the biotin attached to the complexed biotin.
- the sample to be tested is first incubated in a solution containing the first step antibody. If the target antigen is present, some of the antibody binds to the antigen to form a biotinylated antibody/antigen complex.
- the antibody/antigen complex is then amplified by incubation in successive solutions of streptavidin (or avidin), biotinylated DNA, and/or complementary biotinylated DNA, with each step adding additional biotin sites to the antibody/antigen complex.
- the amplification steps are repeated until a suitable level of amplification is achieved, at which point the sample is incubated in a solution containing the second step antibody against biotin.
- This second step antibody is labeled, as for example with an enzyme that can be used to detect the presence of the antibody/antigen complex by histoenzymology using a chromogen substrate.
- a conjugate can be produced which is macroscopically visible.
- Another known method of immunodetection takes advantage of the immuno-PCR (Polymerase Chain Reaction) methodology.
- the PCR method is similar to the Cantor method up to the incubation with biotinylated DNA, however, instead of using multiple rounds of strep tavidin and biotinylated DNA incubation, the DNA/biotin/streptavidin/antibody complex is washed out with a low pH or high salt buffer that releases the antibody. The resulting wash solution is then used to carry out a PCR reaction with suitable primers with appropriate controls.
- the enormous amplification capability and specificity of PCR can be utilized to detect a single antigen molecule.
- Immunoassays in their most simple and direct sense, are binding assays. Certain preferred immunoassays are the various types of enzyme linked
- ELISAs immunosorbent assays
- RIA radioimmunoassays
- the antibodies of the disclosure are immobilized onto a selected surface exhibiting protein affinity, such as a well in a polystyrene microtiter plate. Then, a test composition suspected of containing the Coronavirus S protein is added to the wells. After binding and washing to remove non- specifically bound immune complexes, the bound antigen may be detected. Detection may be achieved by the addition of another anti-Coronavirus S protein antibody that is linked to a detectable label.
- ELISA is a simple “sandwich ELISA.” Detection may also be achieved by the addition of a second anti-Coronavirus S protein antibody, followed by the addition of a third antibody that has binding affinity for the second antibody, with the third antibody being linked to a detectable label.
- the samples suspected of containing the Coronavirus S protein are immobilized onto the well surface and then contacted with the anti- Coronavirus S protein antibodies of the disclosure. After binding and washing to remove non-specifically bound immune complexes, the bound anti- Coronavirus S protein antibodies are detected. Where the initial anti-Coronavirus S protein antibodies are linked to a detectable label, the immune complexes may be detected directly. Again, the immune complexes may be detected using a second antibody that has binding affinity for the first anti-Coronavirus S protein antibody, with the second antibody being linked to a detectable label.
- ELISAs have certain features in common, such as coating, incubating and binding, washing to remove non-specifically bound species, and detecting the bound immune complexes. These are described below.
- antisera include bovine serum albumin (BSA), casein or solutions of milk powder.
- BSA bovine serum albumin
- the coating allows for blocking of nonspecific adsorption sites on the immobilizing surface and thus reduces the background caused by nonspecific binding of antisera onto the surface.
- Under conditions effective to allow immune complex (antigen/antibody) formation means that the conditions preferably include diluting the antigens and/or antibodies with solutions such as BSA, bovine gamma globulin (BGG) or phosphate buffered saline (PBS)/Tween. These added agents also tend to assist in the reduction of nonspecific background.
- the “suitable” conditions also mean that the incubation is at a temperature or for a period of time sufficient to allow effective binding. Incubation steps are typically from about 1 to 2 to 4 hours or so, at temperatures preferably on the order of 25 °C to 27°C, or may be overnight at about 4°C or so.
- the contacted surface is washed so as to remove non-complexed material.
- a preferred washing procedure includes washing with a solution such as PBS/Tween, or borate buffer. Following the formation of specific immune complexes between the test sample and the originally bound material, and subsequent washing, the occurrence of even minute amounts of immune complexes may be determined.
- the second or third antibody will have an associated label to allow detection.
- this will be an enzyme that will generate color development upon incubating with an appropriate chromogenic substrate.
- a urease glucose oxidase, alkaline phosphatase or hydrogen peroxidase-conjugated antibody
- the amount of label is quantified, e.g., by incubation with a chromogenic substrate such as urea, or bromocresol purple, or 2,2'-azino-di-(3-ethyl- benzthiazoline-6-sulfonic acid (ABTS), or 3 ⁇ 4(3 ⁇ 4, in the case of peroxidase as the enzyme label. Quantification is then achieved by measuring the degree of color generated, e.g., using a visible spectra spectrophotometer.
- a chromogenic substrate such as urea, or bromocresol purple, or 2,2'-azino-di-(3-ethyl- benzthiazoline-6-sulfonic acid (ABTS), or 3 ⁇ 4(3 ⁇ 4, in the case of peroxidase as the enzyme label.
- Quantification is then achieved by measuring the degree of color generated, e.g., using a visible spectra spectrophotometer.
- the Western blot is an analytical technique used to detect specific proteins in a given sample of tissue homogenate or extract. It uses gel electrophoresis to separate native or denatured proteins by the length of the polypeptide (denaturing conditions) or by the 3-D structure of the protein (native/ non denaturing conditions). The proteins are then transferred to a membrane (typically nitrocellulose or PVDF), where they are probed (detected) using antibodies specific to the target protein.
- a membrane typically nitrocellulose or PVDF
- Samples may be taken from whole tissue or from cell culture. In most cases, solid tissues are first broken down mechanically using a blender (for larger sample volumes), using a homogenizer (smaller volumes), or by sonication. Cells may also be broken open by one of the above mechanical methods. Assorted detergents, salts, and buffers may be employed to encourage lysis of cells and to solubilize proteins. Protease and phosphatase inhibitors are often added to prevent the digestion of the sample by its own enzymes. Tissue preparation is often done at cold temperatures to avoid protein denaturing.
- the proteins of the sample are separated using gel electrophoresis. Separation of proteins may be by isoelectric point (pi), molecular weight, electric charge, or a combination of these factors. The nature of the separation depends on the treatment of the sample and the nature of the gel. This is a very useful way to determine a protein. It is also possible to use a two-dimensional (2-D) gel which spreads the proteins from a single sample out in two dimensions. Proteins are separated according to isoelectric point (pH at which they
- the proteins are moved from within the gel onto a membrane made of nitrocellulose or polyvinylidene difluoride (PVDF).
- PVDF polyvinylidene difluoride
- the membrane is placed on top of the gel, and a stack of filter papers placed on top of that. The entire stack is placed in a buffer solution which moves up the paper by capillary action, bringing the proteins with it.
- Another method for transferring the proteins is called electroblotting and uses an electric current to pull proteins from the gel into the PVDF or nitrocellulose membrane.
- the proteins move from within the gel onto the membrane while maintaining the organization they had within the gel. As a result of this blotting process, the proteins are exposed on a thin surface layer for detection (see below).
- the antibodies of the present disclosure may also be used in conjunction with both fresh-frozen and/or formalin-fixed, paraffin-embedded tissue blocks prepared for study by immunohistochemistry (IHC).
- IHC immunohistochemistry
- the method of preparing tissue blocks from these particulate specimens has been successfully used in previous IHC studies of various prognostic factors, and is well known to those of skill in the art (Brown et al, 1990; Abbondanzo et al, 1990; Allred el al. , 1990).
- frozen- sections may be prepared by rehydrating 50 ng of frozen “pulverized” tissue at room temperature in phosphate buffered saline (PBS) in small plastic capsules; pelleting the particles by centrifugation; resuspending them in a viscous embedding medium (OCT); inverting the capsule and/or pelleting again by centrifugation; snap-freezing in -70°C isopentane; cutting the plastic capsule and/or removing the frozen
- PBS phosphate buffered saline
- OCT viscous embedding medium
- Permanent- sections may be prepared by a similar method involving rehydration of the 50 mg sample in a plastic microfuge tube; pelleting; resuspending in 10% formalin for 4 hours fixation; washing/pelleting; resuspending in warm 2.5% agar; pelleting; cooling in ice water to harden the agar; removing the tissue/agar block from the tube; infiltrating and/or embedding the block in paraffin; and/or cutting up to 50 serial permanent sections. Again, whole tissue samples may be substituted.
- the present disclosure concerns immunodetection kits for use with the immunodetection methods described above.
- the antibodies may be used to detect Coronavirus S protein, the antibodies may be included in the kit.
- the immunodetection kits will thus comprise, in suitable container means, a first antibody that binds to an Coronavirus S protein, and optionally an immunodetection reagent.
- the antibody may be pre-bound to a solid support, such as a column matrix and/or well of a microtitre plate.
- the immunodetection reagents of the kit may take any one of a variety of forms, including those detectable labels that are associated with or linked to the given antibody. Detectable labels that are associated with or attached to a secondary binding ligand are also contemplated. Exemplary secondary ligands are those secondary antibodies that have binding affinity for the first antibody.
- suitable immunodetection reagents for use in the present kits include the two-component reagent that comprises a secondary antibody that has binding affinity for the first antibody, along with a third antibody that has binding affinity for the second antibody, the third antibody being linked to a detectable label.
- a number of exemplary labels are known in the art and all such labels may be employed in connection with the present disclosure.
- kits may further comprise a suitably aliquoted composition of Coronavirus S protein, whether labeled or unlabeled, as may be used to prepare a standard curve for a detection assay.
- kits may contain antibody-label conjugates either in fully
- kits 52 conjugated form, in the form of intermediates, or as separate moieties to be conjugated by the user of the kit.
- the components of the kits may be packaged either in aqueous media or in lyophilized form.
- the container means of the kits will generally include at least one vial, test tube, flask, bottle, syringe or other container means, into which the antibody may be placed, or preferably, suitably aliquoted.
- the kits of the present disclosure will also typically include a means for containing the antibody, antigen, and any other reagent containers in close confinement for commercial sale.
- Such containers may include injection or blow- molded plastic containers into which the desired vials are retained.
- the antibodies of the present disclosure may also be used in flow cytometry or FACS.
- Flow cytometry is a laser- or impedance-based technology employed in many detection assays, including cell counting, cell sorting, biomarker detection and protein engineering. The technology suspends cells in a stream of fluid and passing them through an electronic detection apparatus, which allows simultaneous multiparametric analysis of the physical and chemical characteristics of up to thousands of particles per second.
- Flow cytometry is routinely used in the diagnosis disorders, especially blood cancers, but has many other applications in basic research, clinical practice and clinical trials.
- Fluorescence-activated cell sorting is a specialized type of cytometry. It provides a method for sorting a heterogenous mixture of biological cells into two or more containers, one cell at a time, based on the specific light scattering and fluorescent characteristics of each cell.
- the technology involves a cell suspension entrained in the center of a narrow, rapidly flowing stream of liquid. The flow is arranged so that there is a large separation between cells relative to their diameter. A vibrating mechanism causes the stream of cells to break into individual droplets. Just before the stream breaks into droplets, the flow passes through a fluorescence measuring station where the fluorescence of each cell is measured. An electrical charging ring is placed just at the point where the stream breaks into droplets.
- a charge is placed on the ring based immediately prior to fluorescence intensity being measured, and the opposite charge is trapped on the droplet as it breaks form the stream.
- the charged droplets then fall through an electrostatic deflection system that diverts droplets into containers based upon their charge.
- the antibodies of the present disclosure are labeled with fluorophores and then allowed to bind to the cells of interest, which are analyzed in a flow cytometer or sorted by a FACS machine.
- the base construct used for the S2 subunit of MERS-CoV S-2P variant contained residues 762-1291 of MERS-CoV S (GenBank ID: AFY13307) with proline substituted at residues 1060 and 1061, the foldon dimerization motif of T4 fibritin, an HRV3C protease recognition site, an octa- histidine tag, and a tandem Twin-Strep-tag, cloned into the mammalian expression plasmid paH. All mutations in subsequent designs were introduced into this base construct.
- the initial design was conducted via the PROSS server (Goldenzweig et ah, 2016), and a total of 11 substitutions were picked (yielding the ‘mutll’ construct) from 53 computational designs based on the biochemical property of the residues and steric effect on the prefusion-stabilized MERS S-2P structure (PDB ID: 5W9I).
- additional substitutions that were aimed at favoring the stability of the prefusion structure were introduced into the mutll backbone. Pairs of core-facing residues less than 5 A apart were replaced with aromatic sidechains or pairs of aromatic and positively charged sidechains to favor pi-pi or pi-cation interactions, respectively.
- MERS SS variants Protein expression and purification for MERS SS variants. Plasmids encoding MERS SS variants were transiently transfected into FreeStyle293F cells (Thermo Fisher) using polyethyleneimine, with 5 mM kifunensine being added 3h post-transfection. Cultures were grown for 6 days, and culture supernatant was separated via centrifugation and passage through a 0.22 pm filter. Protein was purified from supernatants using StrepTactin resin (IB A).
- IB A StrepTactin resin
- MERS SS variants were further purified by size-exclusion chromatography (SEC) using a Superose 6 10/300 column (GE Healthcare) in a buffer composed of 2 mM Tris pH 8.0, 200 mM NaCl and 0.02% NaN3.
- SEC size-exclusion chromatography
- GE Healthcare Superose 6 10/300 column
- a buffer composed of 2 mM Tris pH 8.0, 200 mM NaCl and 0.02% NaN3.
- single-substitution and combinatorial variants were purified from 40 mL cultures.
- the SS.V1 and SS.V2 variants were further tested in large-scale expression and purification from 1 L cultures.
- the protein purity, monodispersity and expression level were determined by SDS- PAGE and SEC.
- MERS SS variants were prepared at a concentration of 1.5 pM with a final concentration 5X SYPRO Orange Protein Gel Stain (ThermoFisher) in a white, opaque 96-wellplate.
- mice were carried out in compliance with all pertinent US National Institutes of Health regulations and approval from the Animal Care and Use Committee (ACUC) of the Vaccine Research Center, University of North Carolina at Chapel Hill, or Abcellera Biologies.
- ACUC Animal Care and Use Committee
- mice were used for immunogenicity studies.
- mice were inoculated intramuscularly with protein
- mice Female C57BL/6J mice aged 4- to 8-weeks (Jackson Laboratory) were used. Mice were immunized intramuscularly with 10 pg MERS SS.V1 + SAS at weeks 0, 3, and 9. At week 13, mice were euthanized and spleens, thymuses, and lymph nodes were harvested for single B cell technology for mAh isolation. Sample size for animal experiments was determined on the basis of criteria set by institutional ACUC. Experiments were neither randomized nor blinded.
- Serum IgG measurement HCoV S-2P-specific IgG in immunized mouse sera were quantified via enzyme-linked immunosorbent assay (ELISA). Briefly, Nunc MaxiSorp 96-well plates (ThermoFisher) were coated with either MERS S2P, SARS S-2P, SARS-CoV-2 S-2P, or HKU1 S-2P at 1 pg/mL in IX PBS 400 at 4°C for 16h. Sera dilutions were prepared in blocking buffer, which consisted of PBS-Tween 20 + 5% non-fat dairy milk, and diluted serially at 1:100, four- fold, 8x.
- blocking buffer which consisted of PBS-Tween 20 + 5% non-fat dairy milk
- Sigmoidal curves taking averages of triplicates at each dilution, were generated from RLU readings; 50% neutralization (ID50) titers were calculated considering uninfected cells as 100% neutralization and cells transduced with only vims as 0% neutralization, by fitting RLU readings to a log(agonist) vs. normalized-response (variable slope) nonlinear regression model in Prism v8 (GraphPad).
- BSA bovine serum albumin His-tag and T4 foldon trimerization domain were used as negative controls. Beads were flowed into microfluidic screening devices and incubated with single antibody- secreting cells, and monoclonal antibody binding to cognate antigens was detected via a fluorescently labeled anti-human IgG secondary antibody. Positive hits were identified using machine vision and recovered using automated robotics- based protocols.
- IgGs and Fab Expression and purification of IgGs and Fab. Twenty monoclonal antibodies discovered by single B cell technology were selected for characterization based on their binding specifies to HKU1-S, MERS-S and SARS-l-S (monospecific, bi-specific or tri specific), diversity of heavy and light chain CDR3s, and high frequency rates in the B cell repertoire (independently isolated by the probes more than 2 times). The individual VH sequence of selected IgGs was cloned into a mammalian expression plasmid pVRC8400 containing HRV 3C cleavage site in the hinge, and human IgGl Fc domain. VL sequences were also cloned into pVRC8400 with human CL.
- Paired VH and VL in a 1 : 1 ratio were co transfected transiently into FreeStyle293F cells as previously described.
- the supernatant was harvested six days post-transfection and IgGs were purified with Protein A agarose (ThermoFisher).
- IgGs were eluted with 100 mM glycine, pH 3 into 1/lOth volume 1 M Tris- HC1 pH 8.0. IgGs were then buffer exchanged into PBS pH 7.4.
- Fab fragments were generated by digesting the IgGs with HRV 3C protease at 4 °C.
- Fc was removed by passing digests over a fresh Protein A agarose, leaving the Fab in the flowthrough, which was further purified by SEC using a Superdex 200 increase 10/300 column (GE Healthcare) in PBS buffer, pH 7.4.
- the binding affinity of purified IgGs to HKUl-CoV S, MERS-CoV S or SARS-CoV S was characterized by BLI using an Octet RED96e (ForteBio). Briefly, anti-human Fc (AHC) sensors (ForteBio) with captured IgG were dipped into the wells containing 100 nM of CoV spikes in a BLI buffer composed of 10 mM HEPES pH 7.4, 150 mM NaCl, 0.005% v/v Tween 20 and 1 mg/mL BSA. After 600s association step, the dissociation step was carried out in the wells containing only BLI buffer for 600s.
- AHC anti-human Fc
- RSV F-foldon was also included in the experiments as negative control.
- the binding affinity of purified mAh G4 to MERS-CoV S and MERS SS was also characterized by BLI using similar approach.
- AHC sensors with captured mAh G4 were dipped into the wells containing serial dilutions of MERS-CoV S or MERS SS at concentration ranging from 100 to 1.56 nM in a BLI buffer.
- the data were aligned to a baseline prior to association step and fit to a 1:1 binding model to calculate rate and dissociation constants using Octet Data Analysis software vll.l.
- the IgGs exhibiting binding to MERS-CoV S was further examined for the ability to compete with mAh G4, the only S2- targed antibody MERS-S antibody with a defined epitope (Pallesen et al., 2017).
- Four-fold molar excess of G4 Fab was preincubated with 100 nM MERS-S at room temperature for 10 min.
- the IgG being tested was loaded on AHC sensors and then dipped into either 100 nM
- G4 IgG was also included in one set of the experiments as a control. The data were plotted as the difference between the binding level of G4-saturated and apo MERS-S, normalized to the binding level of apo MERS-S to the IgG of interest.
- Fab22 concentrations ranging from 100 to 3.13 nM were used instead.
- the Ni- NTA sensorchip was regenerated between each cycle with 0.35 M EDTA, 50 mM NaOH and followed by 0.5 mM NiC12. Response curves were double-reference subtracted and fit to a 1:1 binding model using Biacore X100 Evaluation Software (GE Healthcare).
- Plaque reduction neutralization test PRNT.
- MERS-CoV HCo V -EMC/2012
- SARS-CoV-2 SARS-CoV-2/human/USA/USA-WAl/2020
- 100 pL of vims-mAb mixture was applied to each of two confluent Vero 81 or Vero E6 cell monolayers, respectively, in 6-well (10-cm 2 ) plates.
- DMEM Dulbecco’s modified Eagle’s medium
- Negative stain EM for spike-Fab complexes Purified MERS-CoV S- 2P or SARS-CoV-2 S-HexaPro were incubated with 2-fold molar excess of Fab22 or Fab72 in 2 mM Tris pH 8.0, 200 mM NaCl and 0.02% NaN3 at room temperature for 30 min. The spike-Fab complexes were diluted to a concentration of 0.06 mg/mL in 2 mM Tris pH 8.0,
- purified SARS-CoV-2 S (HexaPro variant) complexed with 2-fold molar excess of Fab22 was diluted to a concentration of 0.37 mg/mL in 2 mM Tris pH 8.0, 200 mM NaCl, 0.02% NaN3 and applied to plasma-cleaned CF-400 1.2/1.3 grids before being blotted for 3.5 seconds with -4 force in a Vitrobot Mark IV and plunge-frozen into liquid ethane.
- Fab22-MERS S-2P sample 4,330 micrographs were collected from a single grid.
- 2,013 micrographs were collected from a single grid.
- FEI Titan Krios (ThermoFisher) equipped with a K3 direct electron detector (Gatan) was used for imaging. Data were collected at a magnification of 22,500x, corresponding to a calibrated pixel size of 1.07 A/pix. A full description of the data collection parameters can be found in Table 4. Warp was used for motion correction, CTF estimation, and particle picking (Tegunov and Cramer, 2019). The particle stack was then imported into cryoSPARC v2.15.0, which was used to curate the particles via iterative rounds of 2D classification (Punjani et al., 2017). The final reconstructions were then arrived at via ab initio reconstruction, heterogeneous refinement, and subsequently non-uniform homogeneous refinement of final classes. The structure validation can be found in FIGS. 12A-C.
- Example 1 Structure-based vaccine design of MERS-CoV stabilized stem (SS) antigens
- the Protein Repair One-Stop Shop was first used to computationally design stabilizing mutations based on a prefusion-stabilized structure of the MERS-CoV spike ectodomain (PDB ID: 5W9I) (Goldenzweig et ah, 2016; Pallesen et ak, 2017).
- PDB ID: 5W9I prefusion-stabilized structure of the MERS-CoV spike ectodomain
- 11 substitutions were selected and introduced in varying combinations into the S2 subunit of MERS-CoV S.
- the protein expression level of the mutant containing all 11 substitutions (mutll) was substantially higher than MERS S2-2P (base construct) (FIG. 2A).
- T803C/K933C disulfide design
- S975M cavity filling design
- T803C/K933C a combination of both designs
- S975M, T803C/K933C was added on top of mut7.
- T803C/K933C decreased the protein expression relative to mut7, but increased the Tm by 1.7 °C (FIG. 7A).
- S975M substitution not only boosted the protein expression relative to mut7, but also enhanced the thermostability.
- MERS SS.V1 containing 7 substitutions in addition to the original 2P mutations (S975M, T803C/K933C, V958S, V983I, S1091E, L1094Q, N1132Y, V1060P, L1061P).
- MERS SS.V1 As an immunogen, large- scale production in FreeStyle 293 -F cells, thermostability, and epitope integrity were investigated. After two consecutive runs of SEC, MERS SS.V1 exhibited a monodispersed trimeric peak, with a yield of 2.2 mg from 1 L of cell culture (FIG. 2H). The Tm of MERS SS.V1 is 59.9 °C, which is a 6.3 °C increase relative to mutll. mAh G4 is one of very few S2-directed antibodies showing neutralizing activity to MERS-CoV (Wang et ah, 2015).
- MERS SS.V1 The binding kinetics of MERS SS.V1 to G4 IgG were comparable to those of MERS S-2P ectodomain, with apparent affinities of 8.5 nM and 13.2 nM, respectively (FIG. 8). Taken together, these results suggest that MERS SS.V1 retains the integrity of the known neutralization epitope and should be amenable to large-scale production.
- Example 2 MERS SS immunization elicits cross-reactive b-CoV antibodies
- Example 3 - MERS SS protects humanized-DPP4 mice against lethal MERS-CoV challenge
- mice In order to assess the ability of MERS stabilized stems to protect against lethal MERS-CoV challenge, 288/330+/+ mice (Cockrell et ak, 2016) were immunized with 10 pg of MERS SS.V1 or S-2P, adjuvanted with SAS. Mock-immunized mice received PBS. 288/330+/+ mice express human DPP4 and harbor localized lung viral replication and succumb to lethal doses of mouse-adapted (MA) MERS-CoV maM35c4 (Douglas et ak, 2018). Giving three immunogen doses at weeks 0, 3, and 9, the antibody responses were then assessed two weeks post-boost and challenged at week 13 (FIG. 4A).
- MA mouse-adapted MERS-CoV maM35c4
- MERS SS.V1 elicits similar levels of robust ⁇ 10 5 homotypic binding IgG as MERS S-2P (FIG. 4B).
- stem-specific binding antibodies were sub neutralizing as MERS SS.
- mice receiving MERS S-2P 1/5758
- mice immunized with either MERS S-2P or MERS SS.V1 demonstrated no weight loss throughout the course of infection.
- mice in the PBS control group demonstrated severe clinical presentations and succumbed to death one week post-challenge (FIG. 4D).
- IgGs were then expressed recombinantly in vitro and characterized by binding specificities to b-CoV prefusion- stabilized S, namely HCoV-HKUl S-2P, MERS-CoV S-2P, and SARS-CoV S-2P.
- IgG20, IgG23 and IgG62 demonstrated cross-reactive binding to MERS- and SARS-CoV S with higher apparent affinity to the former (FIG. 9A).
- IgG21, IgG22 and IgG72 were also MERS- and SARS-specific, but the association rates of these mAbs to SARS-CoV S were nearly 5-fold higher than to MERS-CoV S (FIG. 9B).
- IgG12, IgG19 and IgG42 only bound to MERS-CoV S (FIG. 9C).
- One third of selected mAbs (IgG20, IgG23 and IgG62) competed with G4 binding to MERS-CoV S (FIG. 10).
- IgG12, IgG19, IgG21, IgG22, IgG42, and IgG72 appeared to bind to regions outside of the G4 epitope.
- Example 5 - IgG22 binds to multiple CoV spikes and neutralizes authentic MERS-CoV
- IgG22 and the clonally related IgG72 are two of the cross-reactive antibodies that exhibited faster association to SARS-CoV S than MERS-CoV S (FIG. 9B).
- surface plasmon resonance experiments were performed where Fab was flowed over spike ectodomain immobilized to a sensor chip.
- the binding affinity of Fab22 to MERS-CoV S was comparable to those of SARS-CoV S and SARS-CoV-2 S, with KD values of 2.9 nM, 7.2 nM, and 6.7 nM, respectively (FIGS. 5A-C).
- Fab22 exhibited distinct binding kinetics to MERS-CoV S, featuring a much slower on-rate and off-rate than SARS-CoV or SARS-CoV-2 S.
- the neutralization activities of selected mAbs were examined against authentic MERS-CoV. IgG22 and IgG72 exhibited
- Example 6 Cryo-EM structure of Fab22 bound to the MERS-CoV spike
- Example 7 CryoEM structure of Fab22 bound to the SARS-CoV-2 spike
- a neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS CoV-2. Science (New York, N.Y.) 369, 650- 655.
- SARS- CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature 586, 567-571.
- Impagliazzo A., Milder, F., Kuipers, H., Wagner, M. v, Zhu, X., Hoffman, R.M.B., van Meersbergen, R., Huizingh, J., Wanningen, P., Verspuij, J., et al. (2015).
- cryoSPARC algorithms for rapid unsupervised cryo-EM structure determination. Nature Methods 14, 290-296.
- MERS protective human monoclonal antibodies targeting different domains and functions of the MERS -coronavirus spike glycoprotein. Emerging Microbes & Infections 8, 516-530.
Abstract
Provided herein are engineered, stabilized beta-coronavirus S2 proteins, such as engineered, stabilized MERS S2 proteins. In some aspects, the engineered S2 proteins exhibit enhanced antigenicity. Methods are also provided for use of the engineered S2 proteins as diagnostics, in screening platforms, and/or in vaccine compositions.
Description
DESCRIPTION
STABILIZED S2 BETA-CORONA VIRUS ANTIGENS
REFERENCE TO RELATED APPLICATIONS
[0001] The present application claims the priority benefit of United States provisional application number 63/188,813, filed May 14, 2021, the entire contents of which are incorporated herein by reference.
REFERENCE TO A SEQUENCE LISTING
[0001] The instant application contains a Sequence Listing, which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on April 22, 2022, is named UTFBP1276WO_ST25.txt and is 68,056 bytes in size.
BACKGROUND
1. Field
[0002] The present disclosure relates generally to the fields of medicine, virology, immunology, and protein engineering. More particular, the disclosure relates to engineered beta-coronavirus S2 domain-only proteins and the use thereof in drug design and vaccine formulation.
2. Description of Related Art
[0003] Coronaviruses (Co Vs) are a genetically diverse group of enveloped viruses containing a large appx. 30 kb, positive-sense, single- stranded RNA genome (Li, 2016). Four endemic (or “seasonal”) human Co Vs (HCoVs) — HCoV-OC43, -HKU1, NL63, and 229E — circulate globally and produce primarily mild upper respiratory illness in otherwise healthy individuals. CoVs exhibit adaptation to alternative host species, and spillover of three novel beta genus CoVs (b-CoVs) — Middle East respiratory syndrome (MERS)-CoV, severe acute respiratory syndrome (SARS)-CoV, and SARS-CoV-2 — from bats directly or indirectly into humans within the past two decades underscores the serious and persistent threat to public health that coronaviruses hold. Most recently, SARS-CoV-2 has led to >100 million cases worldwide and left in its path detrimental socioeconomic consequences. As a result, global development of vaccines and therapeutics against SARS-CoV-2 has proceeded at an
1
unprecedented rate in efforts to slow the ongoing pandemic. Effective vaccines are crucial not only to mitigating overall morbidity and mortality of SARS-CoV-2 infection but may enable populations to achieve herd immunity and temper the emergence and spread of new viral variants. Many of the vaccines in the global portfolio are based on an engineered version of the full-length viral attachment protein, Spike (S), stabilized in its prefusion conformation (Walls et al., 2020; Wrapp et al., 2020). In particular, mRNA-1273 and BNT162b2 showed >94% efficacy against COVID-19 in adult phase III clinical trials (Baden et al., 2020; Polack et al., 2020). However, recent emergence of numerous SARS-CoV-2 variants harboring diverse changes in S substantiate concerns about breadth of this efficacy (Choi et al., 2020; Grubaugh et al., 2021; Kupferschmidt, 2021; Tang et al., 2021).
[0004] Several new SARS-CoV-2 “variants of concern (VOC),” distinguished by one to many unique or recurring changes in S, recently emerged in multiple regions of the world, including western Europe, South Africa, and North America. These variants have spread at disproportionately fast rates relative to predecessor variants in certain geographic regions, consistent with augmented replication capacity, greater transmissibility, and/or immune evasion. Among recurring changes, multiple amino-acid deletions in the NTD (del 69-70, del 144, del 242-244) and the E484K and N501Y substitutions in the RBD have garnered special attention due to enhanced affinity of S for angiotensin converting enzyme 2 (ACE2) and reduced sensitivity to neutralization by convalescent polyclonal sera and anti-RBD therapeutic mAbs (Gu et al., 2020; Starr et al., 2020; Wang et al., 2021; Weisblum et al., 2020; Wu et al., 2021; Zhao et al., 2021). The del 69-70 and N501Y alterations have evolved both together and separately in independent VOC lineages, as has the E484K mutation (Ku et al., 2021). Altogether, these data indicate that selective pressures on the neutralization sensitive epitopes of the SI subunit ultimately result in escape variants.
[0005] Although most neutralizing antibodies target the S 1 subunit, the S2 subunit is more conserved, likely constrained by complex and precisely timed refolding events in S2 that are essential for productive viral entry. Nevertheless, antibodies targeting this region may be neutralizing and protective against infection and pathology in vivo (Chi et al., 2020; Ng et al., 2020; Zhang et al., 2021). Notably, it has been observed that SARS-CoV-2-infected children, and young adolescents that have also recently been infected with an endemic HCoV, develop higher titers of S2 antibodies relative to SARS-CoV-2-infected adults without a recognized antecedent endemic HCoV infection (Ng et al., 2020). Memory B cells
2
trained on conserved S2 epitopes and stimulated by SARS-CoV-2 infection may account for the skewed neutralizing antibody response to the SARS-CoV-2 S2 subunit in young individuals. In individuals not previously infected with SARS-CoV-2, a majority of the anti- SARS-CoV-2 IgG repertoire targets the S2 subdomain, reiterating the potential for cross reactivity directed at conserved epitopes on HCoVs (Nguyen-Contant et al., 2020). Thus, the S2 subunit serves as an attractive target for development of broad-spectrum vaccines and therapeutic antibodies for current and future novel HCoVs.
SUMMARY
[0006] Coronaviruses (CoV) are genetically diverse positive-strand RNA viruses that generally dwell in animal reservoirs but can cause pandemics after spillover into the human population. Vaccine development for SARS-CoV-2 has progressed at unprecedented speed resulting in several vaccine candidates with up to 95% efficacy against COVID-19. However, current CoV vaccines primarily target immunodominant epitopes in the S 1 subunit, which are generally not well conserved across CoV subgenera and are sensitive to escape mutations, thus threatening vaccine efficacy. As disclosed herein, structure-guided protein engineering was used to remove the SI subunit from the MERS-CoV spike (S) glycoprotein and develop stabilized stem (SS) antigens. Vaccination with MERS SS elicited cross-reactive b-CoV antibody responses and protected mice against lethal MERS-CoV challenge. High-throughput microfluidic discovery of antibody secreting cells from MERS SS-immunized mice led to discovery of a panel of cross-reactive monoclonal antibodies. Antibody IgG22 bound with high affinity to both MERS-CoV and SARS-CoV-2 S proteins, and electron microscopy localized the epitope to a conserved coiled-coil region in the S2 subunit.
[0007] In one embodiment, provided herein are engineered proteins comprising an engineered beta-coronavirus S2 domain that comprises a sequence at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, or at least 95% identical to: (a) positions 762-1291 of SEQ ID NO: 1 (i.e., the S2 domain of MERS-CoV spike protein); (b) positions 687-1208 of SEQ ID NO: 2 (i.e., the S2 domain of SARS-CoV-2 spike protein); (c) positions 668-1190 of SEQ ID NO: 3 (i.e., the S2 domain of SARS -CoV spike protein) or (d) position 683-1205 of SEQ ID NO: 4; wherein the engineered protein comprises the following substitutions relative to the sequence of SEQ ID NO: 1: S975M, T803C, K933C, V958S, V983I, S1091E, L1094Q, N1132Y, V1060P, L1061P, V898C, V1022C, A838C, and S0189C, wherein the engineered protein does not comprise a beta-coronavirus SI domain.
3
[0008] In one embodiment, provided herein are engineered proteins comprising an engineered beta-coronavirus S2 domain that comprises a sequence at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, or at least 95%identical to: (a) positions 762-1291 of SEQ ID NO: 1; (b) positions 687-1208 of SEQ ID NO: 2; (c) positions 668-1190 of SEQ ID NO: 3; or (d) position 683-1205 of SEQ ID NO: 4; wherein the engineered protein does not comprise a beta-coronavirus SI domain, and wherein the engineered protein comprises at least one substitution relative to the sequence of SEQ ID NO: 1, 2, or 3, said at least one substitution being at a position corresponding to: V958, V983, A918, V1139, L1094, S1091, N1132, K816, H1020, H1146, V1150, S845, T803, K933, S858, G953, S975, L923, L1033, P937, M939, A1049, L923, L1033, S787, Q1003, L840, Q769, S858, A1093, V1060, L1061, V898, VI 022, S845, A1096, A838, or S 1089 relative to SEQ ID NO: 1.
[0009] In some aspects, the engineered proteins comprise at least one engineered disulfide bond comprising paired cysteine substitutions at positions corresponding to: T803C and K933C; S858C and G953C; and/or Q769C and S858C relative to SEQ ID NO: 1. In some aspects, the engineered proteins further comprise at least one additional engineered disulfide bond.
[0010] In some aspects, the engineered proteins comprise at least one cavity filling substitution at a position corresponding to: S975, P937, M939, L923, and/or L1033 relative to SEQ ID NO: 1. In some aspects, the engineered proteins comprise at least one cavity filling substitution selected from: S975M, P937F, M939K, L923W, and L1033F relative to SEQ ID NO: 1.
[0011] In some aspects, the engineered proteins comprise at least one substitution that provides an electrostatic interaction substitution at a position corresponding to: S845, L923, L1033, A1049, S787, Q1003, L840, and/or A1093 relative to SEQ ID NO: 1. In some aspects, the engineered proteins comprise at least one electrostatic interaction substitution selected from S845E, L923K, L1033E, A1049S, S787D, Q1003K, L840E, and A1093R relative to SEQ ID NO: 1.
[0012] In some aspects, the engineered proteins comprise V1060P and L1061P substitutions relative to SEQ ID NO: 1.
4
[0013] In some aspects, the engineered proteins comprise a combination of at least one engineered disulfide bond, at least one cavity filling substitution, at least one proline substitution, and at least one electrostatic interaction substitution.
[0014] In some aspects, the engineered proteins comprise the following substitutions relative to SEQ ID NO: 1: V983I/, V958S, L1094Q, S1091E, N1132Y, V1060P, and L1061P. In some aspects, the engineered proteins comprise the following substitutions relative to SEQ ID NO: 1: V983I, A918P, V1139F, V958S, L1094Q, S1091E, N1132Y, V1060P, and L1061P. In some aspects, the engineered proteins comprise the following substitutions relative to SEQ ID NO: 1: V983I, A918P, V1139F, V958S, L1094Q, S1091E, N1132Y, K816R, H1020Q, H1146Y, V1150T, V1060P, and L1061P. In some aspects, the engineered proteins comprise the following substitutions relative to SEQ ID NO: 1: S975M, T803C, K933C, V958S, V983I, S1091E, L1094Q, N1132Y, V1060P, and L1061P. IN some aspects, the engineered proteins comprise the following substitutions relative to SEQ ID NO: 1: S975M, T803C, K933C, V958S, V983I, S1091E, L1094Q, N1132Y, V1060P, L1061P, V898C, V1022C, A838C, and S0189C.
[0015] In some aspects, the engineered proteins are fused or conjugated to a dimerization domain. In some aspects, the engineered proteins are fused to a dimerization domain. In some aspects, the trimerization domain is positioned C-terminally relative to S protein ectodomain. In some aspects, the trimerization domain comprises a T4 fibritin trimerization domain.
[0016] In some aspects, the engineered proteins are fused or conjugated to a transmembrane domain. In some aspects, the engineered proteins are fused to a transmembrane domain. In some aspects, the transmembrane domain comprises a beta- coronavirus spike protein transmembrane domain. In some aspects, the transmembrane domain comprises a homologous beta-coronavirus spike protein transmembrane domain.
[0017] In one embodiment, provided herein are engineered beta-coronavirus S2 trimers comprising at least one subunit according to any one of the present embodiments. In some aspects, the S2 trimers are stabilized in a prefusion conformation relative to a S2 trimer of wildtype S protein subunits. In some aspects, the S2 trimers comprise at least one engineered disulfide bond between subunits. In some aspects, the at least one engineered
5
disulfide bond between subunits is selected from: T803C and K933C; S858C and G953C; and/or Q769C and S858C relative to SEQ ID NO: 1.
[0018] In one embodiment, provided herein are pharmaceutical compositions comprising a pharmaceutically acceptable carrier; and an engineered protein or an engineered trimer of any one of the present embodiments. In some aspects, the compositions further comprise an adjuvant.
[0019] In one embodiment, provided herein are nucleic acid molecules comprising a nucleotide sequence that encodes an amino acid sequence of an engineered protein of any one of the present embodiments. In some aspects, the nucleic acid comprises a DNA expression vector. In some aspects, the nucleic acid comprises a mRNA.
[0020] In one embodiment, provided herein are methods of preventing coronavirus infection or a disease associate with coronavirus infection in a subject, comprising administering to the subject an effective amount of the pharmaceutical composition or a nucleic acid molecule according to any one of the present embodiments. In some aspects, the methods elicit a beta-coronavirus cross-reactive immune response. In some aspects, the methods elicit the production of pan-coronavirus antibodies in the subject.
[0021] In one embodiment, provided herein are composition comprising an engineered protein of any one of the present embodiments bound to an antibody.
[0022] Other objects, features and advantages of the present invention will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.
BRIEF DESCRIPTION OF THE DRAWINGS
[0023] The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present invention. The invention may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein.
6
[0024] FIG. 1. Exemplary substitutions for MERS spike stem stabilization. Side view of the trim eric MERS-CoV globular spike ectodomain in a prefusion conformation (PDB ID: 5W9I) with SI subunits omitted. One protomer of the S2 subunits is shown as a ribbon diagram with the other two protomers shown in a transparent molecular surface. The regions that refold during the pre-to-postfusion transition are colored cyan with the rest of the S2 in wheat. Each inset corresponds to the location of exemplary substitutions in the MERS SS.V1 construct.
[0025] FIGS. 2A-H. Characterization of MERS stem stabilized spike variants.
(FIG. 2A) SDS-PAGE of MERS-CoV S2-2P and single-substitution spike variants on mutll backbone. Molecular weight standards are indicated at the left in kDa. (FIGS. 2B-D) Size- exclusion chromatography traces of purified spike variants, grouped by type (FIG. 2B, cavity and aromatic pi; FIG. 2C, disulfide; FIG. 2D polar and salt bridge). A vertical dotted line indicates the peak retention volume for S2-2P. (FIG. 2E) SEC traces for reversed and combinational-substitution spike variants. Mut5, mut6 and mut7 have six, five and four residues of mutll reversed to the wild-type, respectively. S975M and T803C/K933C are additional mutations combined with mut5, mut6 and mut7. (FIG. 2F) SEC traces for combinatorial disulfide-substituted spike variants. Additional one or two disulfide substitutions are introduced on MERS SS.V1 backbone. (FIG. 2G) Differential scanning fluorimetry analysis of spike variant thermostability. The vertical dotted line indicates the apparent melting temperature for S2-2P. (FIG. 2H) SEC traces of MERS SS.V1 and MERS SS.V2 purified from a 1 L culture of FreeStyle 293F cells.
[0026] FIGS. 3A-F. Immunogenicity of MERS SS immunogens in mice. To assess immunogenicity of MERS SS immunogens, (FIG. 3A) BALB/cJ mice (n = 10/group) were inoculated with PBS (gray), 1 pg of MERS S-2P (red), or 0.4, 2, or 10 pg of MERS SS.V1 (blue) or SS.V2 (green) adjuvanted with Sigma Adjuvant System (SAS). Mice were immunized at weeks 0 and 3 and bled two weeks post-boost for serological analyses including ELISAs to assess binding to (FIG. 3B) MERS-CoV, (FIG. 3C) HCoV-HKUl, (FIG. 3D) SARS-CoV and (FIG. 3E) SARS-CoV-2 S-2P-specific binding IgG and (FIG. 3F) MERS-CoV pseudovirus neutralization assay. Each circle represents an individual mouse. Dotted lines represent upper and lower limits of detection where applicable. (FIGS. 3B-F) Min to max box plots, with the box from 25-75% and the median value denoted by the line. (FIGS. 3B-E) Experimental groups were compared by two-way ANOVA with multiple
7
comparisons post-test and (FIG. 3F) one-way ANOVA with groups Kruskal-Wallis multiple comparisons test. * = p-value < 0.05, ** = p-value < 0.01, *** = p-value < 0.001, **** = p- value < 0.0001.
[0027] FIGS. 4A-H. Efficacy of SS.V1 against lethal MERS-CoV challenge in mice. (FIG. 4A) hDPP4 (288/330+/+) mice (n = 20/group) were immunized at weeks 0, 3, and 9 with PBS or 10 pg of MERS-CoV S-2P or SS.V1 adjuvanted with SAS. Two weeks post-boost, mice were bled for analysis of (FIG. 4B) MERS-CoV S-2P-specific IgG and (FIG. 4C) pseudovirus neutralizing antibodies. Four weeks post-boost, mice were challenged with a lethal dose of mouse-adapted MERS-CoV (MA35c5). (FIG. 4D) Following challenge, mice were monitored for weight loss. (FIGS. 4E-H) At days 3 and 5 post-challenge, a subset of mouse lungs (N = 5/timepoint) was harvested for analysis of (FIGS. 4E-F) viral titers and (FIGS. 4G-H) hemorrhage (0 = no hemorrhage, 4 = severe hemorrhage in all lobes). (FIGS. 4B-C, E-H) Each circle represents an individual mouse. Min to max box plots, with the box from 25-75% and the median value denoted by the line. Dotted lines represent lower limits of detection where applicable. Experimental groups were compared by one-way ANOVA with Kruskal-Wallis post-test. (FIG. 4D) For weight loss, the mean of each group is represented by a circle, error bars represent SEM, and experimental groups was compared to the PBS- immunized group on each day post-challenge. * = p-value < 0.05, ** = p-value < 0.01, *** = p-value < 0.001, **** = p-value < 0.0001.
[0028] FIGS. 5A-F. MERS stem-targeted mAbs neutralize authentic MERS- CoV. Binding of Fab22 to (FIG. 5A) MERS-CoV S, (FIG. 5B) SARS-CoV S, and (FIG. 5C) SARS-CoV-2 S assessed by surface plasmon resonance. Binding data are shown as black lines and the best fit to a 1:1 binding model is shown as gray lines. (FIG. 5D) IgG22 and IgG72 demonstrated concentration-dependent neutralization of MERS-CoV infectivity. Other SS.V1 elicited mAbs shown lacked detectable neutralizing activity against MERS-CoV. mAbs IgG20, IgG22 and IgG72 were tested in duplicate, and remaining mAbs were tested once. Neutralizing mAh G4 was included as a positive control and tested in triplicate. (FIG. 5E) Neither IgG22 or IgG72 exhibited detectable neutralization of SARS-CoV-2. mAh S309, which neutralizes SARS-CoV-2, was included as a positive control. IgG22 and IgG72 were tested once, and S309 was tested in duplicate. (FIG. 5F) Representative 2D class averages and cryo-EM density map of Fab22 bound to MERS S-2P. The local resolution is depicted by
8
a spectrum of rainbow color as a scale bar. The side view and top-down view of the smoothened maps indicate three distinct Fab density.
[0029] FIGS. 6A-D. Stem-targeted mAb 22 binds to helical stalk region of SARS- CoV-2 spike. (FIG. 6A) Representative 2D class averages and 3D reconstructions of Fab22 bound SARS-CoV-2 S. (FIG. 6B) Side view of cryo-EM density of Fab22 bound to SARS- CoV-2 S. The local resolution is depicted by a spectrum as a scale bar. Fab22 binds to the base of the spike. (FIG. 6C) Model of full-length wildtype SARS-CoV-2 spike (PDB: 6XR8) docked into EM map of Fab22 bound SARS-CoV-2 S. Sequence alignments of the helical stalk region of four b-CoVs show high sequence similarity. The sequences for SARS-CoV and SARS-CoV-2 are SEQ ID NO: 7. The sequence for MERS-CoV is SEQ ID NO: 8. The sequence for HKU1 is SEQ ID NO: 9. (FIG. 6D) Binding of Fab22 to three spike variants captured by RBD-directed IgG is assessed by BLI. Binding data are shown as black lines and the best fit to a 1:1 binding model is shown as gray lines.
[0030] FIGS. 7A-C. Characterization of MERS stem stabilized spike variants.
(FIGS. 7A and B) DSF analysis for spike variant thermostability. (FIG. 7A) For reversed spike variants (the first and the second iterations), mut5, mut6 and mut7 have six, five and four residues of mutll reverted to the wild-type, respectively. S975M and T803C/K933C are additional mutations combined with mut5, mut6 and mut7. The dotted line indicates the melting curve for S2-2P. (FIG. 7B) DSF analysis for reversed spike variants (the third iterations). The variants having the same Tm are indicated by a dot line, dash line, dash- single dotted line or dash-double dotted line for clarity. (FIG. 7C) SEC traces for reversed spike variants (the third iterations). A vertical dotted line indicates the peak retention volume for S2-2P. (FIGS. 7B-C) Each substitution in mut6,S975M,T803C/K933C backbone was respectively reversed to the wild-type residue.
[0031] FIGS. 8A-B. MERS S-2P and MERS SS.V1 exhibit nanomolar binding affinity to mAb G4. Binding of (FIG. 8A) MERS S-2P or (FIG. 8B) MERS SS.V1 to mAb G4 assessed by biolayer interferometry (BLI). AHC sensor tips were used to capture mAh G4 and then dipped into a well containing MERS S-2P or MERS SS in BLI buffer. The end point binding responses were plotted against concentrations of the spikes, and the best fit by steady state analysis is shown as a nonlinear line.
9
[0032] FIGS. 9A-C. MERS SS.V1 elicited mAbs exhibit a spectrum of the binding specificities to betacorona virus spikes. Binding of MERS SS.V1 elicited mAbs to MERS-CoV S, SARS-CoV S, HCoV-HKUl S assessed by biolayer interferometry (BLI). RSV-F containing a consensus trimerization motif (foldon) is also included as a negative control. Binding data are shown as solid lines, and the best fit to a 1:1 binding model is shown as dash lines. A vertical dotted line indicates the end of the binding event. The selected mAbs are grouped by their binding kinetics: (FIG. 9A) bi- specificity, faster on rates to MERS-S than SARS-S (FIG. 9B) bi-specificity, faster on rates to SARS-S than MERS-S (FIG. 9C) only binding to MERS-S or only binding to foldon.
[0033] FIGS. 10A-B. Two third of MERS SS.V1 elicited mAbs bind to the regions other than G4 binding loop. (FIG. 10A) Illustration of the scheme of experimental design for G4 competition assay by BLI. AHC biosensors were used to capture selected Ah and then dipped into G4 Fab pre-saturated MERS-S or apo MERS-S. Binding data are shown as solid lines and the best fit to a 1:1 binding model is shown as dash lines. A vertical dotted line indicates the end of the binding event when the responses are used for end-point binding analysis. (FIG. 10B) End-point binding responses of mAbs to G4 Fab pre-saturated MERS-S versus MERS-S are calculated and shown as percentage. Ah G4 is also included as a control (white bar). Non-G4 competing mAbs having higher responses to G4 Fab pre saturated MERS-S than MERS-S are depicted as gray bars. G4 competing mAbs having higher responses to MERS-S than G4 Fab pre-saturated MERS-S are depicted as black bars.
[0034] FIGS. 11A-C. Fab22 and Fab72 bind to a helical stalk region of the spikes. (FIG. 11 A) Representative 2D class averages of Fab22 complexed with MERS-CoV S by negative stain electron microscopy (nsEM). (FIG. 11B) Representative 2D class averages of Fab72 complexed with MERS-CoV S by nsEM. (FIG. 11C) Representative 2D class averages of Fab22 complexed with HexaPro, a prefusion stabilized SARS-CoV-2 S, by nsEM.
[0035] FIGS. 12A-C. Cryo-EM structure validation. FSC curves and viewing distribution plots for (FIG. 12A) MERS-CoV S-Fab 22 structure, (FIGS. 12B-C) SARS- CoV-2 S-Fab 22 structures with (FIG. 12B) 1-RBD up and (FIG. 12C) 3-RBD down generated in cry oS PARC v2.15.
10
DETAILED DESCRIPTION
[0036] Vaccine development for SARS-CoV-2 has progressed at unprecedented speed resulting in several vaccine candidates with up to 95% efficacy against COVID-19. However, current CoV vaccines primarily target immunodominant epitopes in the S 1 subunit, which are generally not well conserved across CoV subgenera. Structure-guided protein engineering was used to remove the SI subunit from the MERS-CoV spike (S) glycoprotein and develop stabilized stem (SS) antigens. Vaccination with MERS SS elicited cross-reactive b-CoV antibody responses and protected mice against lethal MERS-CoV challenge. High- throughput microfluidic discovery of antibody secreting cells from MERS SS-immunized mice led to discovery of a panel of cross-reactive monoclonal antibodies. Antibody IgG22 bound with high affinity to both MERS-CoV and SARS-CoV-2 S proteins, and electron microscopy localized the epitope to a conserved coiled-coil region in the S2 subunit. Collectively, these results provide proof of principle for cross-reactive CoV antibodies and inform the future development of next-generation pan-CoV vaccines.
[0037] Provided herein are two MERS-CoV stabilized stem constructs, MERS SS.V1 and MERS SS.V2, both of which lack the SI subunit (FIG. 1). Both antigens are immunogenic in mice, inducing broadly cross-reactive antibodies to MERS-CoV, HCoV HKU1, SARS-CoV, and SARS-CoV-2 S, and confer protection in a lethal murine MERS- CoV challenge model. Two monoclonal antibodies, IgG22 and IgG72, isolated using microfluidic single B-cell screening technology from MERS SS. VI -immunized mice, neutralized authentic MERS-CoV. Single-particle cryo-EM studies revealed that IgG22 binds to an epitope in the S2 stalk of MERS-CoV and SARS-CoV-2 S proteins that undergoes substantial changes during the pre- to -post-fusion conformational transition. These findings establish feasibility of rationally designing stabilized S2 constructs as protective vaccine immunogens against emerging HCoVs, which upon further development, may exhibit efficacy against divergent HCoV species. In addition, stem cross-reactive antibodies may serve as valuable tools for prospective serological surveillance of future CoV spillover into humans.
I. Coronavirus Stabilized Stem S2
[0038] All CoV spikes are composed of an SI subunit, a major determinant for host cell tropism, and an S2 subunit, which contains the machinery that drives viral-host fusion
11
(Li, 2016; Siebert et al., 2003). The SI subunit, which directly interacts with the host receptor, is composed of an N-terminal domain (NTD), a receptor-binding domain (RBD) and subdomains (SDs). For SARS-CoV-2, transient hinging of the RBD into an ‘up’ conformation allows for host-cell receptor engagement. In the S2 subunit, a helix-loop region spanning from the fusion peptide (FP) to heptad repeat 1 (HR1), constitutes a metastable structure that transitions to a long stable a-helix in the postfusion conformation during viral entry. The FP, HR1, central helix (CH) and connector domain (CD) comprise the globular head of the S2 subunit. In contrast, the helical stalk region, connecting the globular head to the viral membrane, is elongated and highly flexible (Ke et al., 2020; Turonova et al., 2020). The stalk region can be further divided into a hip, knee, and ankle, wherein the knee functions as a hinge, providing a considerable range in flexibility and movement for the spikes on the viral surface. As the SI is responsible for interacting directly with the host receptor, the majority of vaccine-induced antibodies and antibodies elicited upon natural infection target this subunit, most notably the RBD (Corbett et al., 2020b, 2020a; Jackson et al., 2020). In addition, a portion of neutralizing monoclonal antibodies (mAbs) isolated from convalescent COVID-19 patients recognize the NTD (Chi et al., 2020; Liu et al., 2020). Amino acid changes are concentrated in the SI subunit among the majority of SARS-CoV-2 variants described thus far. Additionally, recent data suggest that antibodies in convalescent sera that target neutralization-sensitive epitopes in the SI domain induce a selective pressure that yields escape mutations in these epitopes (Andreano et al., 2020).
[0039] The S2 subunit of CoV S, analogous to HA2 of influenza vims HA and gp41 of HIV-1 Env, functions as a fusogen by bringing viral and host cell membranes together, thus enabling viral entry. To complete fusion, the S2 subunit transitions from a metastable prefusion to a highly stable 250 post- fusion conformation (Li, 2016). The introduction of stabilizing mutations into the S2 subunit of MERS-CoV, SARS-CoV and SARS-CoV-2 permitted production of large quantities of prefusion stabilized trim eric full-length S retaining well-folded 3D structures resembling native S on the virion surface (Hsieh et al., 2020; Ke et al., 2020; Kirchdoerfer et al., 2018; Pallesen et al., 2017; Turonova et al., 2020; Wrapp et al., 2020). Importantly, neutralization-sensitive epitopes and host receptor-binding sites in the SI subunit were completely preserved. Collectively, the strategy of stabilizing S through engineered prevention of S2 refolding has been successful for generating vaccine antigens that protect animals in CoV-challenge models and humans from SARS-CoV-2 infection (Baden et al., 2020; Corbett et al., 2020a, 2020b; Polack et al., 2020).
12
[0040] Efforts toward a universal influenza A virus (IAV) vaccine yielded the first proof-of-concept for exploiting antigenic conservation in the hemagglutinin stem (HA stem) region (functionally analogous to the CoV S2 subunit) to elicit broad protection in animals. Specifically, two independent research groups rationally engineered the HA stem by introducing disulfide bridges, increasing surface hydrophilicity, stabilizing the hydrophobic core, optimizing the protease cleavage site, and/or displaying the HA stem on nanoparticles (Impagliazzo et al., 2015; Yassine et al., 2015). The HA stem trimers stabilized in the prefusion conformation induced neutralizing antibodies targeting stems of various group 1 HA subtypes and protected animals from heterotypic IAV challenge. A similar strategy based on structure-guided vaccine design was successfully applied to more distantly related group 2 IAV (Boyoglu-Barnum et al., 2020; Corbett et al., 2019).
[0041] Herein, a structure-guided design strategy was used to generate MERS-CoV S2-only antigens, with the intention of eliciting cross-reactive antibodies against conserved S2 epitopes. Using the PROSS server (Goldenzweig et al., 2016) to identify candidate stabilizing mutations and biochemical analyses to down-select expressed S2 mutant proteins, two S2 subunit constructs optimized for stability, conformational fidelity, and product yields were identified as immunogens. Intra-protomer disulfide bonds were the most effective means of enhancing protein expression and thermostability. The Cys803-Cys933 pair was introduced to cross-link regions of mobility and immobility during the pre- to post-fusion transition in a manner similar to the Cysl55-Cys290 substitution in RSV F (DS-Cavl) (McLellan et al., 2013). In addition, a covalent linkage was made across the S2' protease cleavage site, via the formation of a Cys838-Cysl089 bridge, akin to the Cys93(HA2)- Cys310(HAl) substitution in the HA stem (Impagliazzo et al., 2015). Finally, Cys898 and Cysl022 substitutions were placed in the fusion peptide and HR1 to prevent the helix-loop region from transitioning to a single, elongated helix. Both Cys898 and Cysl022 substitutions were at regions that move substantially, and a similar approach was employed to increase the trimer fraction of HA stem (Cys68-Cys76) and to keep PIV3 F in a prefusion conformation (Cysl62-Cysl68) (Impagliazzo et al., 2015; Stewart-Jones et al., 2018). Disulfide engineering has also been used to restrict local flexibility of secondary structures in SARS-CoV-2 S (Hsieh et al., 2020) or to trap the RBDs in a closed configuration (Henderson et al., 2020; McCallum et al., 2020; Xiong et al., 2020). Most importantly, MERS SS V2 elicited 10-fold higher neutralizing antibodies against MERS CoV than SS VI in a single prime-boost immunization regimen. Each disulfide substitution significantly improved
13
thermostability of the MERS SS antigens, consistent with disulfide designs in other class I viral fusion proteins.
[0042] The cavity-filling approach proved to be successful in stabilizing loosely packed regions of RSV F in its prefusion conformation (Krarup et al., 2015; McLellan et al., 2013). This tactic was used in the optimization of a stable S2-only MERS immunogen by substituting Ser975 and Val983 with Met and lie, respectively, at the base of MERS-CoV SS. These changes neatly filled a hydrophobic pocket between HR1 and amino acids that remain stationary during the pre- to post-fusion transition. A lone S975M change proved to be the most effective, leading to more than 10-fold increase in protein yields relative to the parental molecule. Similarly, N1132Y substitution seems to pack against Pro937, Vall206, and Proll31 and possibly forms H bonds with Gln800 and Asnl029. Other modifications intended to enhance polar interactions — for instance, V958S, S1091E and L1094Q substitutions — were considered as beneficial additions to the best construct. Alternative strategies, such as stabilizing proline substitutions, reducing hydrophobicity at the S1-S2 interface, and nanoparticle display, are viable options to further improve our MERS SS.V2 antigens in efforts to induce cross-neutralizing antibodies.
[0043] MERS SS -immunization stimulated the production of antibodies that were cross-reactive to multiple CoV S proteins. This disclosure is the first to show protection against lethal CoV challenge with a stem-only immunogen — protection that comes without elicitation of potent neutralizing antibody responses. Previous studies suggest that in vivo activity of influenza virus stem-specific antibodies rely on Fc-mediated functions (DiLillo et al., 2014, 2016). In fact, only a handful of S2-specific neutralizing antibodies against MERS- CoV have been defined (Wang et al., 2015; Widjaja et al., 2019). One of these, murine mAh G4, protects against challenge in a murine lethal model of MERS-CoV infection and binds a hypervariable loop containing a unique N-glycosylation site in the connector domain (Pallesen et al., 2017; Wang et al., 2018). Roughly one third of SS-cross-reactive antibodies compete with G4 Fab for the loop epitope. Deletion of the highly immunogenic loop from an S2 subunit vaccine might be advantageous to prevent natural immunofocusing on an epitope poorly conserved among even closely related lineage C b-HCoVs.
[0044] This disclosure also describes a conserved epitope near the base of S, distinct from the G4-binding site. Two antibodies that recognize this epitope, IgG22 and IgG72, display heterotypic binding to all highly pathogenic b-HCoVs. Both antibodies neutralize
14
authentic MERS-CoV and at low nM concentrations in the case of IgG22. However, IgG72 demonstrated markedly reduced neutralizing activity against MERS-CoV as compared to IgG22 (approximately a 10-fold reduction in inhibitory titer). Sequence alignments of Fab22 and Fab72 reveal only four amino acid differences, one in CDR-L3 and three in CDR-H2, plausibly explaining shared binding profiles for HCoV S proteins. Cryo-EM structures of Fab22 complexed with MERS S-2P and prefusion-stabilized SARS-CoV-2 S (HexaPro) revealed the Fab binding site in proximity to the helical stalk. Although the binding interface was incompletely resolved, the target site was localized to a region upstream of HR2. These residues dramatically refold to form a six-helical bundle with HR1, leading to virus-cell fusion. The faster (nearly 100-fold) dissociation rate of Fab22 for HexaPro (and SARS-CoV S-2P) compared to MERS-CoV S-2P provides an explanation for the undetectable heterotypic neutralizing activity by IgG22 (and IgG72). Similar antibodies have been recently described (Sauer et ak, 2021; Wang et ak, 2020), although in these cases sequential immunization was employed using full-length spikes from divergent b-CoVs to induce a response to the conserved S2.
[0045] In summary, this disclosure provides rationally engineered CoV S stems as stabilized immunogens to elicit antibodies cross-reactive with all three epidemic b-HCoVs and to provide complete protection in animals against a lethal MERS-CoV challenge. Using a stabilized stem construct, the production of antibodies was elicited which enabled the identification of a novel site of vulnerability in the S2 subunit, which will inform development of next-generation CoV vaccines and fortify CoV pandemic preparedness.
II. Definitions
[0046] It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the invention as claimed. In this application, the use of the singular includes the plural unless specifically stated otherwise. In this application, the use of “or” means “and/or” unless stated otherwise. Furthermore, the use of the term “including”, as well as other forms, such as “includes” and “included”, is not limiting. Also, terms such as “element” or “component” encompass both elements and components comprising one unit and elements and components that comprise more than one subunit unless specifically stated otherwise. Also, the use of the term “portion” can include part of a moiety or the entire moiety.
[0047] As used herein, the singular forms “a”, “an” and “the” include plural references unless the context clearly dictates otherwise. As used herein the specification, “a” or “an” may mean one or more. As used herein in the claim(s), when used in conjunction with the word “comprising,” the words “a” or “an” may mean one or more than one.
[0048] The term “about” as used herein when referring to a measurable value such as an amount, a temporal duration, and the like, is meant to encompass variations of up to ±10% from the specified value. Unless otherwise indicated, all numbers expressing quantities of ingredients, properties such as molecular weight, reaction conditions, and so forth used in the specification and claims are to be understood as being modified in all instances by the term “about.” Accordingly, unless indicated to the contrary, the numerical parameters set forth in
17
the following specification and attached claims are approximations that may vary depending upon the desired properties sought to be obtained by the disclosed subject matter. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should at least be construed in light of the number of reported significant digits and by applying ordinary rounding techniques. Notwithstanding that the numerical ranges and parameters setting forth the broad scope of the invention are approximations, the numerical values set forth in the specific examples are reported as precisely as possible. Any numerical value, however, inherently contain certain errors necessarily resulting from the standard deviation found in their respective testing measurements.
[0049] As used herein, “essentially free,” in terms of a specified component, is used herein to mean that none of the specified component has been purposefully formulated into a composition and/or is present only as a contaminant or in trace amounts. The total amount of the specified component resulting from any unintended contamination of a composition is therefore well below 0.05%, preferably below 0.01%. Most preferred is a composition in which no amount of the specified component can be detected with standard analytical methods.
[0050] The term “antibody” refers to an intact immunoglobulin of any isotype, or a fragment thereof that can compete with the intact antibody for specific binding to the target antigen, and includes, for instance, chimeric, humanized, fully human, and bispecific antibodies. An “antibody” is a species of an antigen binding protein. An intact antibody will generally comprise at least two full-length heavy chains and two full-length light chains, but in some instances can include fewer chains such as antibodies naturally occurring in camelids which can comprise only heavy chains. Antibodies can be derived solely from a single source, or can be “chimeric,” that is, different portions of the antibody can be derived from two different antibodies as described further below. The antigen binding proteins, antibodies, or binding fragments can be produced in hybridomas, by recombinant DNA techniques, or by enzymatic or chemical cleavage of intact antibodies. Unless otherwise indicated, the term “antibody” includes, in addition to antibodies comprising two full-length heavy chains and two full-length light chains, derivatives, variants, fragments, and muteins thereof, examples of which are described below. Furthermore, unless explicitly excluded, antibodies include monoclonal antibodies, bispecific antibodies, minibodies, domain antibodies, synthetic
18
antibodies (sometimes referred to herein as “antibody mimetics”), chimeric antibodies, humanized antibodies, human antibodies, antibody fusions (sometimes referred to herein as “antibody conjugates”), and fragments thereof, respectively. In some embodiments, the term also encompasses peptibodies.
[0051] Naturally occurring antibody structural units typically comprise a tetramer. Each such tetramer typically is composed of two identical pairs of polypeptide chains, each pair having one full-length “light” (in certain embodiments, about 25 kDa) and one full- length “heavy” chain (in certain embodiments, about 50-70 kDa). The amino-terminal portion of each chain typically includes a variable region of about 100 to 110 or more amino acids that typically is responsible for antigen recognition. The carboxy-terminal portion of each chain typically defines a constant region that can be responsible for effector function. Human light chains are typically classified as kappa and lambda light chains. Heavy chains are typically classified as mu, delta, gamma, alpha, or epsilon, and define the antibody's isotype as IgM, IgD, IgG, IgA, and IgE, respectively. IgG has several subclasses, including, but not limited to, IgGl, IgG2, IgG3, and IgG4. IgM has subclasses including, but not limited to, IgMl and IgM2. IgA is similarly subdivided into subclasses including, but not limited to, IgAl and IgA2. Within full-length light and heavy chains, typically, the variable and constant regions are joined by a “J” region of about 12 or more amino acids, with the heavy chain also including a “D” region of about 10 more amino acids. See, e.g., Fundamental Immunology, Ch. 7 (Paul, W., ed., 2nd ed. Raven Press, N.Y. (1989)) (incorporated by reference in its entirety for all purposes). The variable regions of each light/heavy chain pair typically form the antigen binding site.
[0052] The term “variable region” or “variable domain” refers to a portion of the light and/or heavy chains of an antibody, typically including approximately the amino-terminal 120 to 130 amino acids in the heavy chain and about 100 to 110 amino terminal amino acids in the light chain. In certain embodiments, variable regions of different antibodies differ extensively in amino acid sequence even among antibodies of the same species. The variable region of an antibody typically determines specificity of a particular antibody for its target.
[0053] The variable regions typically exhibit the same general structure of relatively conserved framework regions (FR) joined by three hyper variable regions, also called complementarity determining regions or CDRs. The CDRs from the two chains of each pair typically are aligned by the framework regions, which can enable binding to a specific
19
epitope. From N-terminal to C-terminal, both light and heavy chain variable regions typically comprise the domains FR1, CDR1, FR2, CDR2, FR3, CDR3 and FR4. The assignment of amino acids to each domain is typically in accordance with the definitions of Rabat Sequences of Proteins of Immunological Interest (National Institutes of Health, Bethesda, Md. (1987 and 1991)), Chothia & Lesk, J. Mol. Biol., 196:901-917 (1987) or Chothia et al, Nature, 342:878-883 (1989).
[0054] In certain embodiments, an antibody heavy chain binds to an antigen in the absence of an antibody light chain. In certain embodiments, an antibody light chain binds to an antigen in the absence of an antibody heavy chain. In certain embodiments, an antibody binding region binds to an antigen in the absence of an antibody light chain. In certain embodiments, an antibody binding region binds to an antigen in the absence of an antibody heavy chain. In certain embodiments, an individual variable region specifically binds to an antigen in the absence of other variable regions.
[0055] In certain embodiments, definitive delineation of a CDR and identification of residues comprising the binding site of an antibody is accomplished by solving the structure of the antibody and/or solving the structure of the antibody-ligand complex. In certain embodiments, that can be accomplished by any of a variety of techniques known to those skilled in the art, such as X-ray crystallography. In certain embodiments, various methods of analysis can be employed to identify or approximate the CDR regions. Examples of such methods include, but are not limited to, the Rabat definition, the Chothia definition, the AbM definition and the contact definition.
[0056] The Rabat definition is a standard for numbering the residues in an antibody and is typically used to identify CDR regions. See, e.g., Johnson & Wu, Nucleic Acids Res., 28: 214-8 (2000). The Chothia definition is similar to the Rabat definition, but the Chothia definition takes into account positions of certain structural loop regions. See, e.g., Chothia et al, J. Mol. Biol., 196: 901-17 (1986); Chothia et al, Nature, 342: 877-83 (1989). The AbM definition uses an integrated suite of computer programs produced by Oxford Molecular Group that model antibody structure. See, e.g., Martin et al, Proc Natl Acad Sci (USA), 86:9268-9272 (1989); “AbM™, A Computer Program for Modeling Variable Regions of Antibodies,” Oxford, UR; Oxford Molecular, Ltd. The AbM definition models the tertiary structure of an antibody from primary sequence using a combination of knowledge databases and ab initio methods, such as those described by Samudrala et ai, “Ab Initio Protein
20
Structure Prediction Using a Combined Hierarchical Approach,” in PROTEINS, Structure, Function and Genetics Suppl., 3:194-198 (1999). The contact definition is based on an analysis of the available complex crystal structures. See, e.g., MacCallum et al., J. Mol. Biol., 5:732-45 (1996).
[0057] By convention, the CDR regions in the heavy chain are typically referred to as HI, H2, and H3 and are numbered sequentially in the direction from the amino terminus to the carboxy terminus. The CDR regions in the light chain are typically referred to as LI, L2, and L3 and are numbered sequentially in the direction from the amino terminus to the carboxy term in us.
[0058] The term “light chain” includes a full-length light chain and fragments thereof having sufficient variable region sequence to confer binding specificity. A full-length light chain includes a variable region domain, VL, and a constant region domain, CL. The variable region domain of the light chain is at the amino-terminus of the polypeptide. Light chains include kappa chains and lambda chains.
[0059] The term “heavy chain” includes a full-length heavy chain and fragments thereof having sufficient variable region sequence to confer binding specificity. A full-length heavy chain includes a variable region domain, VH, and three constant region domains, CHI, CH2, and CH3. The VH domain is at the amino-terminus of the polypeptide, and the CH domains are at the carboxyl-terminus, with the CH3 being closest to the carboxy- terminus of the polypeptide. Heavy chains can be of any isotype, including IgG (including IgGl, IgG2, IgG3 and IgG4 subtypes), IgA (including IgAl and IgA2 subtypes), IgM and IgE.
[0060] A bispecific or bifunctional antibody typically is an artificial hybrid antibody having two different heavy/light chain pairs and two different binding sites. Bispecific antibodies can be produced by a variety of methods including, but not limited to, fusion of hybridomas or linking of Fab' fragments. See, e.g., Songsivilai et al., Clin. Exp. Immunol., 79: 315-321 (1990); Kostelny et al, J. Immunol., 148:1547-1553 (1992).
[0061] The term “antigen” refers to a substance capable of inducing adaptive immune responses. Specifically, an antigen is a substance which serves as a target for the receptors of an adaptive immune response. Typically, an antigen is a molecule that binds to antigen- specific receptors but cannot induce an immune response in the body by itself. Antigens are
21
usually proteins and polysaccharides, less frequently also lipids. As used herein, antigens also include immunogens and haptens.
[0062] An “Fc” region comprises two heavy chain fragments comprising the CHI and CH2 domains of an antibody. The two heavy chain fragments are held together by two or more disulfide bonds and by hydrophobic interactions of the CH3 domains.
[0063] The “Fv region” comprises the variable regions from both the heavy and light chains but lacks the constant regions.
[0064] An antibody that “specifically binds to” or is “specific for” a particular polypeptide or an epitope on a particular polypeptide is one that binds to that particular polypeptide or epitope on a particular polypeptide without substantially binding to any other polypeptide or polypeptide epitope. For example, the Coronavirus S protein specific antibodies of the present invention are specific to Coronavirus S protein. In some embodiments, the antibody that binds to Coronavirus S protein has a dissociation constant (Kd) of £100 nM, £10 nM, £1 nM, £0.1 nM, £0.01 nM, or £0.001 nM (e.g., 10-8M or less, e.g., from 10_8M to 10-13M, e.g., from 10-9M to 10-13 M).
[0065] The term “compete” when used in the context of antigen binding proteins (e.g., atnibody or antigen-binding fragment thereof) that compete for the same epitope means competition between antigen binding proteins as determined by an assay in which the antigen binding protein (e.g., antibody or antigen-binding fragment thereof) being tested prevents or inhibits (e.g., reduces) specific binding of a reference antigen binding protein (e.g., a ligand, or a reference antibody) to a common antigen (e.g., Coronavirus S protein or a fragment thereof). Numerous types of competitive binding assays can be used to determine if one antigen binding protein competes with another, for example: solid phase direct or indirect radioimmunoassay (RIA), solid phase direct or indirect enzyme immunoassay (EIA), sandwich competition assay (see, e.g., Stahli et al., 1983, Methods in Enzymology 9:242- 253); solid phase direct biotin-avidin EIA (see, e.g., Kirkland et al., 1986, J. Immunol. 137:3614-3619) solid phase direct labeled assay, solid phase direct labeled sandwich assay (see, e.g., Harlow and Lane, 1988, Antibodies, A Laboratory Manual, Cold Spring Harbor Press); solid phase direct label RIA using 1-125 label (see, e.g., Morel et al, 1988, Molec. Immunol. 25:7-15); solid phase direct biotin-avidin EIA (see, e.g., Cheung, et al, 1990, Virology 176:546-552); and direct labeled RIA (Moldenhauer et al, 1990,
22
Scand. J. Immunol. 32:77-82). Typically, such an assay involves the use of purified antigen bound to a solid surface or cells bearing either of these, an unlabelled test antigen binding protein and a labeled reference antigen binding protein. Competitive inhibition is measured by determining the amount of label bound to the solid surface or cells in the presence of the test antigen binding protein. Usually the test antigen binding protein is present in excess. Antigen binding proteins identified by competition assay (competing antigen binding proteins) include antigen binding proteins binding to the same epitope as the reference antigen binding proteins and antigen binding proteins binding to an adjacent epitope sufficiently proximal to the epitope bound by the reference antigen binding protein for steric hindrance to occur. Additional details regarding methods for determining competitive binding are provided in the examples herein. Usually, when a competing antigen binding protein is present in excess, it will inhibit (e.g., reduce) specific binding of a reference antigen binding protein to a common antigen by at least 40-45%, 45-50%, 50-55%, 55-60%, 60-65%, 65- 70%, 70-75 % or 75% or more. In some instances, binding is inhibited by at least 80-85%, 85- 90%, 90-95%, 95-97%, or 97% or more.
[0066] The term “epitope” as used herein refers to the specific group of atoms or amino acids on an antigen to which an antibody binds. The epitope can be either linear epitope or a conformational epitope. A linear epitope is formed by a continuous sequence of amino acids from the antigen and interacts with an antibody based on their primary structure. A conformational epitope, on the other hand, is composed of discontinuous sections of the antigen’s amino acid sequence and interacts with the antibody based on the 3D structure of the antigen. In general, an epitope is approximately five or six amino acid in length. Two antibodies may bind the same epitope within an antigen if they exhibit competitive binding for the antigen.
[0067] The term “host cell” means a cell that has been transformed, or is capable of being transformed, with a nucleic acid sequence and thereby expresses a gene of interest. The term includes the progeny of the parent cell, whether or not the progeny is identical in morphology or in genetic make-up to the original parent cell, so long as the gene of interest is present.
[0068] The term “identity” refers to a relationship between the sequences of two or more polypeptide molecules or two or more nucleic acid molecules, as determined by aligning and comparing the sequences. “Percent identity” means the percent of identical
23
residues between the amino acids or nucleotides in the compared molecules and is calculated based on the size of the smallest of the molecules being compared. For these calculations, gaps in alignments (if any) are preferably addressed by a particular mathematical model or computer program (/.<?., an “algorithm”). Methods that can be used to calculate the identity of the aligned nucleic acids or polypeptides include those described in Computational Molecular Biology, (Lesk, A. M., ed.), 1988, New York: Oxford University Press; Biocomputing Informatics and Genome Projects, (Smith, D. W., ed.), 1993, New York: Academic Press; Computer Analysis of Sequence Data, Part I, (Griffin, A. M., and Griffin, H. G., eds.), 1994, New Jersey: Humana Press; von Heinje, G., 1987, Sequence Analysis in Molecular Biology, New York: Academic Press; Sequence Analysis Primer, (Gribskov, M. and Devereux, J., eds.), 1991, New York: M. Stockton Press; and Carillo el al., 1988, SIAM J. Applied Math. 48:1073.
[0069] In calculating percent identity, the sequences being compared are typically aligned in a way that gives the largest match between the sequences. One example of a computer program that can be used to determine percent identity is the GCG program package, which includes GAP (Devereux et al, 1984, Nucl. Acid Res. 12:387; Genetics Computer Group, University of Wisconsin, Madison, Wis.). The computer algorithm GAP is used to align the two polypeptides or polynucleotides for which the percent sequence identity is to be determined. The sequences are aligned for optimal matching of their respective amino acid or nucleotide (the “matched span”, as determined by the algorithm). A gap opening penalty (which is calculated as 3x the average diagonal, wherein the “average diagonal” is the average of the diagonal of the comparison matrix being used; the “diagonal” is the score or number assigned to each perfect amino acid match by the particular comparison matrix) and a gap extension penalty (which is usually 1/10 times the gap opening penalty), as well as a comparison matrix such as PAM 250 or BLOSUM 62 are used in conjunction with the algorithm. In certain embodiments, a standard comparison matrix (see, Dayhoff et al, 1978, Atlas of Protein Sequence and Structure 5:345-352 for the PAM 250 comparison matrix; Henikoff et al, 1992, Proc. Natl. Acad. Sci. U.S.A. 89:10915-10919 for the BLOSUM 62 comparison matrix) is also used by the algorithm.
[0070] Examples of parameters that can be employed in determining percent identity for polypeptides or nucleotide sequences using the GAP program can be found in Needleman et al, 1970, J. Mol. Biol. 48:443-453.
24
[0071] Certain alignment schemes for aligning two amino acid sequences may result in matching of only a short region of the two sequences, and this small aligned region may have very high sequence identity even though there is no significant relationship between the two full-length sequences. Accordingly, the selected alignment method (GAP program) can be adjusted if so desired to result in an alignment that spans at least 50 or other number of contiguous amino acids of the target polypeptide.
[0072] The term “link” as used herein refers to the association via intramolecular interaction, e.g., covalent bonds, metallic bonds, and/or ionic bonding, or inter-molecular interaction, e.g., hydrogen bond or noncovalent bonds.
[0073] The term “operably linked” refers to an arrangement of elements wherein the components so described are configured so as to perform their usual function. Thus, a given signal peptide that is operably linked to a polypeptide directs the secretion of the polypeptide from a cell. In the case of a promoter, a promoter that is operably linked to a coding sequence will direct the expression of the coding sequence. The promoter or other control elements need not be contiguous with the coding sequence, so long as they function to direct the expression thereof. For example, intervening untranslated yet transcribed sequences can be present between the promoter sequence and the coding sequence and the promoter sequence can still be considered “operably linked” to the coding sequence.
[0074] The use of the term “or” in the claims is used to mean “and/or” unless explicitly indicated to refer to alternatives only or the alternatives are mutually exclusive, although the disclosure supports a definition that refers to only alternatives and “and/or.” As used herein “another” may mean at least a second or more.
[0075] The term “polynucleotide” or “nucleic acid” includes both single-stranded and double-stranded nucleotide polymers. The nucleotides comprising the polynucleotide can be ribonucleotides or deoxyribonucleotides or a modified form of either type of nucleotide. Said modifications include base modifications such as bromouridine and inosine derivatives, ribose modifications such as 2',3'-dideoxyribose, and intemucleotide linkage modifications such as phosphorothioate, phosphorodithioate, phosphoroselenoate, phosphorodiselenoate, phosphoroanilothioate, phoshoraniladate and phosphoroamidate.
[0076] The terms “polypeptide” or “protein” means a macromolecule having the amino acid sequence of a native protein, that is, a protein produced by a naturally-occurring
25
and non-recombinant cell; or it is produced by a genetically-engineered or recombinant cell, and comprise molecules having the amino acid sequence of the native protein, or molecules having deletions from, additions to, and/or substitutions of one or more amino acids of the native sequence. The term also includes amino acid polymers in which one or more amino acids are chemical analogs of a corresponding naturally occurring amino acid and polymers. The terms “polypeptide” and “protein” specifically encompass Coronavirus S protein binding proteins, antibodies, or sequences that have deletions from, additions to, and/or substitutions of one or more amino acid of antigen-binding protein. The term “polypeptide fragment” refers to a polypeptide that has an amino-terminal deletion, a carboxyl-terminal deletion, and/or an internal deletion as compared with the full-length native protein. Such fragments can also contain modified amino acids as compared with the native protein. In certain embodiments, fragments are about five to 500 amino acids long. For example, fragments can be at least 5, 6, 8, 10, 14, 20, 50, 70, 100, 110, 150, 200, 250, 300, 350, 400, or 450 amino acids long. Useful polypeptide fragments include immunologically functional fragments of antibodies, including binding domains. In the case of a CORONAVIRUS S PROTEIN- binding antibody, useful fragments include but are not limited to a CDR region, a variable domain of a heavy and/or light chain, a portion of an antibody chain or just its variable region including two CDRs, and the like.
[0077] The pharmaceutically acceptable carriers useful in this invention are conventional. Remington’s Pharmaceutical Sciences, by E. W. Martin, Mack Publishing Co., Easton, PA, 15th Edition (1975), describes compositions and formulations suitable for pharmaceutical delivery of the fusion proteins herein disclosed. In general, the nature of the carrier will depend on the particular mode of administration being employed. For instance, parenteral formulations usually comprise injectable fluids that include pharmaceutically and physiologically acceptable fluids such as water, physiological saline, balanced salt solutions, aqueous dextrose, glycerol or the like as a vehicle. For solid compositions (e.g., powder, pill, tablet, or capsule forms), conventional non-toxic solid carriers can include, for example, pharmaceutical grades of mannitol, lactose, starch or magnesium stearate. In addition to biologically- neutral carriers, pharmaceutical compositions to be administered can contain minor amounts of non-toxic auxiliary substances, such as wetting or emulsifying agents, preservatives, and pH buffering agents and the like, for example sodium acetate or sorbitan monolaurate.
26
[0078] As used herein, the term “subject” refers to a human or any non-human animal (e.g., mouse, rat, rabbit, dog, cat, cattle, swine, sheep, horse or primate). A human includes pre- and post-natal forms. In many embodiments, a subject is a human being. A subject can be a patient, which refers to a human presenting to a medical provider for diagnosis or treatment of a disease. The term “subject” is used herein interchangeably with “individual” or “patient.” A subject can be afflicted with or is susceptible to a disease or disorder but may or may not display symptoms of the disease or disorder.
[0079] The term “therapeutically effective amount” or “effective dosage” as used herein refers to the dosage or concentration of a drug effective to treat a disease or condition. For example, with regard to the use of the monoclonal antibodies or antigen-binding fragments thereof disclosed herein to treat viral infection.
[0080] “Treating” or “treatment” of a condition as used herein includes preventing or alleviating a condition, slowing the onset or rate of development of a condition, reducing the risk of developing a condition, preventing or delaying the development of symptoms associated with a condition, reducing or ending symptoms associated with a condition, generating a complete or partial regression of a condition, curing a condition, or some combination thereof.
[0081] As used herein, a “vector” refers to a nucleic acid molecule as introduced into a host cell, thereby producing a transformed host cell. A vector may include nucleic acid sequences that permit it to replicate in the host cell, such as an origin of replication. A vector may also include one or more therapeutic genes and/or selectable marker genes and other genetic elements known in the art. A vector can transduce, transform or infect a cell, thereby causing the cell to express nucleic acids and/or proteins other than those native to the cell. A vector optionally includes materials to aid in achieving entry of the nucleic acid into the cell, such as a viral particle, liposome, protein coating or the like.
III. Pharmaceutical Formulations
[0082] The present disclosure provides pharmaceutical compositions comprising an engineered, stabilized beta-coronavirus S2 domain-only protein, a nucleic acid molecule encoding an engineered, stabilized beta-coronavirus S2 domain-only protein, and viral vector comprising an engineered, stabilized beta-coronavirus S2 domain-only protein and/or encoding the engineered, stabilized beta-coronavirus S2 domain-only protein in its genomic
27
material. Such compositions can be used for stimulating an immune response, such as part of a vaccine formulation.
[0001] In the case that a nucleic acid molecule encoding an engineered, stabilized beta-coronavirus S2 domain-only protein is used in a pharmaceutical composition, the nucleic acid molecule may comprise or consist of deoxyribonucleotides and/or ribonucleotides, or analogs thereof, covalently linked together. A nucleic acid molecule as described herein generally contains phosphodiester bonds, although in some cases, nucleic acid analogs are included that may have at least one different linkage, e.g., phosphoramidate, phosphorothioate, phosphorodithioate, or O-methylphophoroamidite linkages, and peptide nucleic acid backbones and linkages. Mixtures of naturally occurring polynucleotides and analogs can be made; alternatively, mixtures of different polynucleotide analogs, and mixtures of naturally occurring polynucleotides and analogs may be made. A nucleic acid molecule may comprise modified nucleotides, such as methylated nucleotides and nucleotide analogs. If present, modifications to the nucleotide structure may be imparted before or after assembly of the polymer. The sequence of nucleotides may be interrupted by non-nucleotide components. A polynucleotide may be further modified after polymerization, such as by conjugation with a labeling component. The term also includes both double- and single- stranded molecules. Unless otherwise specified or required, the term polynucleotide encompasses both the double- stranded form and each of two complementary single-stranded forms known or predicted to make up the double- stranded form. A nucleic acid molecule is composed of a specific sequence of four nucleotide bases: adenine (A), cytosine (C), guanine (G), thymine (T), and uracil (U) for thymine when the polynucleotide is RNA. Thus, the term “nucleic acid sequence” is the alphabetical representation of a nucleic acid molecule. Unless otherwise indicated, a particular nucleic acid sequence also implicitly encompasses conservatively modified variants thereof (e.g., degenerate codon substitutions) and complementary sequences as well as the sequence explicitly indicated. Specifically, degenerate codon substitutions may be achieved by generating sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and/or deoxyinosine residues.
[0002] In some embodiments, the nucleic acids of the present disclosure comprise one or more modified nucleosides comprising a modified sugar moiety. Such compounds comprising one or more sugar-modified nucleosides may have desirable properties, such as
28
enhanced nuclease stability or increased binding affinity with a target nucleic acid relative to an oligonucleotide comprising only nucleosides comprising naturally occurring sugar moieties. In some embodiments, modified sugar moieties are substituted sugar moieties. In some embodiments, modified sugar moieties are sugar surrogates. Such sugar surrogates may comprise one or more substitutions corresponding to those of substituted sugar moieties.
[0003] In some embodiments, modified sugar moieties are substituted sugar moieties comprising one or more non-bridging sugar substituent, including but not limited to substituents at the 2' and/or 5' positions. Examples of sugar substituents suitable for the 2'- position, include, but are not limited to: 2'-F, 2'-OCH3 ("OMe" or "O-methyl"), and 2'- 0(CH2)20CH3 ("MOE"). In certain embodiments, sugar substituents at the 2' position is selected from allyl, amino, azido, thio, O-allyl, O-Ci-Cio alkyl, O-Ci-Cio substituted alkyl; OCF3, 0(CH2)2SCH , 0(CH2)2-0— N(Rm)(Rn), and 0-CH2-C(=0)-N(Rm)(Rn), where each Rm and Rn is, independently, H or substituted or unsubstituted Ci-Cio alkyl. Examples of sugar substituents at the 5'-position, include, but are not limited to: 5'-methyl (R or S); 5'- vinyl, and 5'-methoxy. In some embodiments, substituted sugars comprise more than one non-bridging sugar substituent, for example, T-F-5'-methyl sugar moieties (see, e.g., PCT International Application WO 2008/101157, for additional 5',2'-bis substituted sugar moieties and nucleosides).
[0004] Nucleosides comprising 2'-substituted sugar moieties are referred to as 2'- substituted nucleosides. In some embodiments, a 2'-substituted nucleoside comprises a 2'- substituent group selected from halo, allyl, amino, azido, SH, CN, OCN, CF3, OCF3, O, S, or N(Rm)-alkyl; O, S, or N(Rm)-alkenyl; O, S or N(Rm)-alkynyl; O-alkylenyl-O-alkyl, alkynyl, alkaryl, aralkyl, O-alkaryl, O-aralkyl, 0(CH2)2SCH3, 0(CH2)2-0-N(Rm)(Rn) or 0-CH2- C(=0)— N(Rm)(Rn), where each Rm and Rn is, independently, H, an amino protecting group or substituted or unsubstituted C1-C10 alkyl. These 2'-substituent groups can be further substituted with one or more substituent groups independently selected from hydroxyl, amino, alkoxy, carboxy, benzyl, phenyl, nitro (N02), thiol, thioalkoxy (S-alkyl), halogen, alkyl, aryl, alkenyl and alkynyl.
[0005] In some embodiments, a 2'-substituted nucleoside comprises a 2'- substituent group selected from F, NH2, N3, OCF3, O— CH3, 0(CH2)3NH2, CH2 — CH=CH2, 0-CH2— CH=CH2, OCH2CH2OCH3, 0(CH2)2SCH3, O— (CH2)2-0— N(Rm)(Rn),
0(CH2)20(CH2)2N(CH3)2, and N-substituted acetamide (O— CH2-C(=0)— N(Rm)(Rn) where
29
each Rm and Rn is, independently, H, an amino protecting group or substituted or unsubstituted Ci-Cio alkyl.
[0006] In some embodiments, a 2'-substituted nucleoside comprises a sugar moiety comprising a 2'-substituent group selected from F, OCF3, O--CH3, OCH2CH2OCH3, 0(CH2)2SCH3, 0(CH2)2-0-N(CH3)2, -0(CH2)20(CH2)2N(CH3)2, and 0-CH2-C(=0)- N(H)CH3.
[0007] In some embodiments, a 2'-substituted nucleoside comprises a sugar moiety comprising a 2'-substituent group selected from F, O--CH3, and OCH2CH2OCH3.
[0008] In some embodiments, nucleosides of the present disclosure comprise one or more unmodified nucleobases. In certain embodiments, nucleosides of the present disclosure comprise one or more modified nucleobases.
[0009] In some embodiments, modified nucleobases are selected from: universal bases, hydrophobic bases, promiscuous bases, size-expanded bases, and fluorinated bases as defined herein. 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and 0-6 substituted purines, including 2-aminopropyladenine, 5-propynyluracil; 5-propynylcytosine; 5- hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5- propynyl CH3) uracil and cytosine and other alkynyl derivatives of pyrimidine bases, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8- thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo particularly 5- bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 2-F-adenine, 2- amino- adenine, 8-azaguanine and 8-azaadenine, 7- deazaguanine and 7-deazaadenine, 3-deazaguanine and 3-deazaadenine, universal bases, hydrophobic bases, promiscuous bases, size-expanded bases, and fluorinated bases as defined herein. Further modified nucleobases include tricyclic pyrimidines such as phenoxazine cytidine([5,4-b][l,4]benzoxazin-2(3H)-one), phenothiazine cytidine (lH-pyrimido[5,4- b][l,4]benzothiazin-2(3H)-one), G-clamps such as a substituted phenoxazine cytidine (e.g. , 9-(2-aminoethoxy)-H-pyrimido[5,4-13][l,4]benzoxazin-2(3H)-one), carbazole cytidine (2H- pyrimido[4,5-b]indol-2-one), pyridoindole cytidine (H-pyrido[3',2':4,5]pyrrolo[2,3- d]pyrimidin-2-one). Modified nucleobases may also include those in which the purine or
30
pyrimidine base is replaced with other heterocycles, for example 7-deaza-adenine, 7- deazaguanosine, 2-aminopyridine and 2-pyridone. Further nucleobases include those disclosed in U.S. Patent 3,687,808, those disclosed in The Concise Encyclopedia Of Polymer Science And Engineering, Kroschwitz, J. I., Ed., John Wiley & Sons, 1990, 858-859; those disclosed by Englisch et al, 1991; and those disclosed by Sanghvi, Y. S., 1993.
[0010] Representative United States Patents that teach the preparation of certain of the above noted modified nucleobases as well as other modified nucleobases include without limitation, U.S. Patents 3,687,808; 4,845,205; 5,130,302; 5,134,066; 5,175,273; 5,367,066; 5,432,272; 5,457,187; 5,459,255; 5,484,908; 5,502,177; 5,525,711; 5,552,540; 5,587,469; 5,594,121; 5,596,091; 5,614,617; 5,645,985; 5,681,941; 5,750,692; 5,763,588; 5,830,653 and 6,005,096, each of which is herein incorporated by reference in its entirety.
[0011] Additional modifications may also be made at other positions on the oligonucleotide, particularly the 3' position of the sugar on the 3' terminal nucleotide and the 5' position of 5' terminal nucleotide. For example, one additional modification of the ligand conjugated oligonucleotides of the present disclosure involves chemically linking to the oligonucleotide one or more additional non-ligand moieties or conjugates which enhance the activity, cellular distribution or cellular uptake of the oligonucleotide. Such moieties include but are not limited to lipid moieties such as a cholesterol moiety (Letsinger et al, 1989), cholic acid (Manoharan et al, 1994), a thioether, e.g., hexyl-5-tritylthiol (Manoharan et al., 1992; Manoharan et al., 1993), a thiocholesterol (Oberhauser et al., 1992), an aliphatic chain, e.g., dodecandiol or undecyl residues (Saison-Behmoaras et al., 1991; Kabanov et al., 1990; Svinarchuk et al, 1993), a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethylammonium l,2-di-0-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan et al, 1995; Shea et al, 1990), a polyamine or a polyethylene glycol chain (Manoharan et al, 1995), or adamantane acetic acid (Manoharan et al, 1995), a palmityl moiety (Mishra et al, 1995), or an octadecylamine or hexylamino-carbonyl-oxy cholesterol moiety (Crooke et al, 1996). The some aspects, a nucleic acid molecule encoding an engineered Coronavirus S protein is a modified RNA, such as, for example, a modified mRNA. Modified (m)RNA contemplates certain chemical modifications that confer increased stability and low immunogenicity to mRNAs, thereby facilitating expression of therapeutically important proteins. For instance, N1 -methyl-pseudouridine (NIhiY) outperforms several other nucleoside modifications and their combinations in terms of translation capacity. In some embodiments, the (m)RNA
31
molecules used herein may have the uracils replaced with psuedouracils such as 1 -methyl-3 '- pseudouridylyl bases. In some embodiments, some of the uracils are replaced, but in other embodiments, all of the uracils have been replaced. The (m)RNA may comprise a 5’ cap, a 5’ UTR element, an optionally codon optimized open reading frame, a 3’ UTR element, and a poly(A) sequence and/or a polyadenylation signal.
[0012] The nucleic acid molecule, whether native or modified, may be delivered as a naked nucleic acid molecule or in a delivery vehicle, such as a lipid nanoparticle. A lipid nanoparticle may comprise one or more nucleic acids present in a weight ratio to the lipid nanoparticles from about 5:1 to about 1:100. In some embodiments, the weight ratio of nucleic acid to lipid nanoparticles is from about 5:1, 2.5:1, 1:1, 1:5, 1:10, 1:15, 1:20, 1:25, 1:30, 1:35, 1:40, 1:45, 1:50, 1:60, 1:70, 1:80, 1:90, or 1:100, or any value derivable therein.
[0083] In some embodiments, the lipid nanoparticles used herein may contain one, two, three, four, five, six, seven, eight, nine, or ten lipids. These lipids may include triglycerides, phospholipids, steroids or sterols, a PEGylated lipids, or a group with a ionizable group such as an alkyl amine and one or more hydrophobic groups such as C6 or greater alkyl groups.
[0013] In some aspects of the present disclosure, the lipid nanoparticles are mixed with one or more steroid or a steroid derivative. In some embodiments, the steroid or steroid derivative comprises any steroid or steroid derivative. As used herein, in some embodiments, the term “steroid” is a class of compounds with a four ring 17 carbon cyclic structure which can further comprises one or more substitutions including alkyl groups, alkoxy groups, hydroxy groups, oxo groups, acyl groups, or a double bond between two or more carbon atoms.
[0014] In some aspects of the present disclosure, the lipid nanoparticles are mixed with one or more PEGylated lipids (or PEG lipid). In some embodiments, the present disclosure comprises using any lipid to which a PEG group has been attached. In some embodiments, the PEG lipid is a diglyceride which also comprises a PEG chain attached to the glycerol group. In other embodiments, the PEG lipid is a compound which contains one or more C6-C24 long chain alkyl or alkenyl group or a C6-C24 fatty acid group attached to a linker group with a PEG chain. Some non-limiting examples of a PEG lipid includes a PEG modified phosphatidylethanolamine and phosphatidic acid, a PEG ceramide conjugated, PEG
32
modified dialkylamines and PEG modified l,2-diacyloxypropan-3-amines, PEG modified diacylglycerols and dialky lglycerols. In some embodiments, PEG modified diastearoylphosphatidylethanolamine or PEG modified di my ri stoy 1 -.vn-gl ycerol . In some embodiments, the PEG modification is measured by the molecular weight of PEG component of the lipid. In some embodiments, the PEG modification has a molecular weight from about 100 to about 15,000. In some embodiments, the molecular weight is from about 200 to about 500, from about 400 to about 5,000, from about 500 to about 3,000, or from about 1,200 to about 3,000. The molecular weight of the PEG modification is from about 100, 200, 400,
500, 600, 800, 1,000, 1,250, 1,500, 1,750, 2,000, 2,250, 2,500, 2,750, 3,000, 3,500, 4,000,
4,500, 5,000, 6,000, 7,000, 8,000, 9,000, 10,000, 12,500, to about 15,000. Some non-limiting examples of lipids that may be used in the present disclosure are taught by U.S. Patent 5,820,873, WO 2010/141069, or U.S. Patent 8,450,298, which is incorporated herein by reference.
[0015] In some aspects of the present disclosure, the lipid nanoparticles are mixed with one or more phospholipids. In some embodiments, any lipid which also comprises a phosphate group. In some embodiments, the phospholipid is a structure which contains one or two long chain C6-C24 alkyl or alkenyl groups, a glycerol or a sphingosine, one or two phosphate groups, and, optionally, a small organic molecule. In some embodiments, the small organic molecule is an amino acid, a sugar, or an amino substituted alkoxy group, such as choline or ethanolamine. In some embodiments, the phospholipid is a phosphatidylcholine. In some embodiments, the phospholipid is distearoylphosphatidylcholine or dioleoylphosphatidylethanolamine. In some embodiments, other zwitterionic lipids are used, where zwitterionic lipid defines lipid and lipid-like molecules with both a positive charge and a negative charge.
[0016] In some aspects of the present disclosure, lipid nanoparticle containing compounds containing lipophilic and cationic components, wherein the cationic component is ionizable, are provided. In some embodiments, the cationic ionizable lipids contain one or more groups which is protonated at physiological pH but may deprotonated and has no charge at a pH above 8, 9, 10, 11, or 12. The ionizable cationic group may contain one or more protonatable amines which are able to form a cationic group at physiological pH. The cationic ionizable lipid compound may also further comprise one or more lipid components such as two or more fatty acids with C6-C24 alkyl or alkenyl carbon groups. These lipid
33
groups may be attached through an ester linkage or may be further added through a Michael addition to a sulfur atom. In some embodiments, these compounds may be a dendrimer, a dendron, a polymer, or a combination thereof.
[0017] In some aspects of the present disclosure, composition containing compounds containing lipophilic and cationic components, wherein the cationic component is ionizable, are provided. In some embodiments, ionizable cationic lipids refer to lipid and lipid- like molecules with nitrogen atoms that can acquire charge (pKa). These lipids may be known in the literature as cationic lipids. These molecules with amino groups typically have between 2 and 6 hydrophobic chains, often alkyl or alkenyl such as C6-C24 alkyl or alkenyl groups, but may have at least 1 or more that 6 tails.
[0018] In some embodiments, the amount of the lipid nanoparticle with the nucleic acid molecule encapsulated in the pharmaceutical composition is from about 0.1% w/w to about 50% w/w, from about 0.25% w/w to about 25% w/w, from about 0.5% w/w to about 20% w/w, from about 1% w/w to about 15% w/w, from about 2% w/w to about 10% w/w, from about 2% w/w to about 5% w/w, or from about 6% w/w to about 10% w/w. In some embodiments, the amount of the lipid nanoparticle with the nucleic acid molecule encapsulated in the pharmaceutical composition is from about 0.1% w/w, 0.25% w/w, 0.5% w/w, 1% w/w, 2.5% w/w, 5% w/w, 7.5% w/w, 10% w/w, 15% w/w, 20% w/w, 25% w/w, 30% w/w, 35% w/w, 40% w/w, 45% w/w, 50% w/w, 55% w/w, 60% w/w, 65% w/w, 70% w/w, 75% w/w, 80% w/w, 85% w/w, 90% w/w, to about 95% w/w, or any range derivable therein.
[0019] In some aspects, the present disclosure comprises one or more sugars formulated into pharmaceutical compositions. In some embodiments, the sugars used herein are saccharides. These saccharides may be used to act as a lyoprotectant that protects the pharmaceutical composition from destabilization during the drying process. These water- soluble excipients include carbohydrates or saccharides such as disaccharides such as sucrose, trehalose, or lactose, a trisaccharide such as fructose, glucose, galactose comprising raffinose, polysaccharides such as starches or cellulose, or a sugar alcohol such as xylitol, sorbitol, or mannitol. In some embodiments, these excipients are solid at room temperature. Some non-limiting examples of sugar alcohols include erythritol, threitol, arabitol, xylitol, ribitol, mannitol, sorbitol, galactitol, fucitol, iditol, inositol, volemitol, isomalt, maltitol, lactitol, maltotritol, maltotetraitol, or a polyglycitol.
34
[0020] In some embodiments, the amount of the sugar in the pharmaceutical composition is from about 25% w/w to about 98% w/w, 40% w/w to about 95% w/w, 50% w/w to about 90% w/w, 50% w/w to about 70% w/w, or from about 80% w/w to about 90% w/w. In some embodiments, the amount of the sugar in the pharmaceutical composition is from about 10% w/w, 15% w/w, 20% w/w, 25% w/w, 30% w/w, 35% w/w, 40% w/w, 45% w/w, 50% w/w, 52.5% w/w, 55% w/w, 57.5% w/w, 60% w/w, 62.5% w/w, 65% w/w, 67.5 % w/w, 70% w/w, 75% w/w, 80% w/w, 82.5% w/w, 85% w/w, 87.5% w/w, 90% w/w, to about 95% w/w, or any range derivable therein.
[0021] In some embodiments, the pharmaceutically acceptable polymer is a copolymer. The pharmaceutically acceptable polymer may further comprise one, two, three, four, five, or six subunits of discrete different types of polymer subunits. These polymer subunits may include polyoxypropylene, polyoxyethylene, or a similar subunit. In particular, the pharmaceutically acceptable polymer may comprise at least one hydrophobic subunit and at least one hydrophilic subunit. In particular, the copolymer may have hydrophilic subunits on each side of a hydrophobic unit. The copolymer may have a hydrophilic subunit that is polyoxyethylene and a hydrophobic subunit that is polyoxypropylene.
[0084] In some embodiments, expression cassettes are employed to express an engineered, stabilized beta-coronavirus S2 domain-only protein, either for subsequent purification and delivery to a cell/subject, or for use directly in a viral-based delivery approach. Provided herein are expression vectors which contain one or more nucleic acids encoding an engineered, stabilized beta-coronavirus S2 domain-only protein.
[0085] Expression requires that appropriate signals be provided in the vectors and include various regulatory elements such as enhancers/promoters from both viral and mammalian sources that drive expression of the an engineered, stabilized beta-coronavirus S2 domain-only protein in cells. Throughout this application, the term “expression cassette” is meant to include any type of genetic construct containing a nucleic acid coding for a gene product in which part or all of the nucleic acid encoding sequence is capable of being transcribed and translated, /.<?., is under the control of a promoter. A “promoter” refers to a DNA sequence recognized by the synthetic machinery of the cell, or introduced synthetic machinery, required to initiate the specific transcription of a gene. The phrase “under transcriptional control” means that the promoter is in the correct location and orientation in relation to the nucleic acid to control RNA polymerase initiation and expression of the gene.
35
An “expression vector” is meant to include expression cassettes comprised in a genetic construct that is capable of replication, and thus including one or more of origins of replication, transcription termination signals, poly-A regions, selectable markers, and multipurpose cloning sites.
[0086] The term promoter will be used here to refer to a group of transcriptional control modules that are clustered around the initiation site for RNA polymerase II. Much of the thinking about how promoters are organized derives from analyses of several viral promoters, including those for the HSV thymidine kinase (tk) and SV40 early transcription units. These studies, augmented by more recent work, have shown that promoters are composed of discrete functional modules, each consisting of approximately 7-20 bp of DNA, and containing one or more recognition sites for transcriptional activator or repressor proteins.
[0087] At least one module in each promoter functions to position the start site for RNA synthesis. The best known example of this is the TATA box, but in some promoters lacking a TATA box, such as the promoter for the mammalian terminal deoxynucleotidyl transferase gene and the promoter for the SV40 late genes, a discrete element overlying the start site itself helps to fix the place of initiation.
[0088] Additional promoter elements regulate the frequency of transcriptional initiation. Typically, these are located in the region 30-110 bp upstream of the start site, although a number of promoters have recently been shown to contain functional elements downstream of the start site as well. The spacing between promoter elements frequently is flexible, so that promoter function is preserved when elements are inverted or moved relative to one another. In the tk promoter, the spacing between promoter elements can be increased to 50 bp apart before activity begins to decline. Depending on the promoter, it appears that individual elements can function either co-operatively or independently to activate transcription.
[0089] In certain embodiments, viral promotes such as the human cytomegalovirus (CMV) immediate early gene promoter, the SV40 early promoter, the Rous sarcoma vims long terminal repeat, rat insulin promoter and glyceraldehyde-3 -phosphate dehydrogenase can be used to obtain high-level expression of the coding sequence of interest. The use of other viral or mammalian cellular or bacterial phage promoters which are well-known in the
36
art to achieve expression of a coding sequence of interest is contemplated as well, provided that the levels of expression are sufficient for a given purpose. By employing a promoter with well-known properties, the level and pattern of expression of the protein of interest following transfection or transformation can be optimized. Further, selection of a promoter that is regulated in response to specific physiologic signals can permit inducible expression of the gene product.
[0090] Enhancers are genetic elements that increase transcription from a promoter located at a distant position on the same molecule of DNA. Enhancers are organized much like promoters. That is, they are composed of many individual elements, each of which binds to one or more transcriptional proteins. The basic distinction between enhancers and promoters is operational. An enhancer region as a whole must be able to stimulate transcription at a distance; this need not be true of a promoter region or its component elements. On the other hand, a promoter must have one or more elements that direct initiation of RNA synthesis at a particular site and in a particular orientation, whereas enhancers lack these specificities. Promoters and enhancers are often overlapping and contiguous, often seeming to have a very similar modular organization.
[0091] Below is a list of promoters/enhancers and inducible promoters/enhancers that could be used in combination with the nucleic acid encoding a gene of interest in an expression construct. Additionally, any promoter/enhancer combination (as per the Eukaryotic Promoter Data Base EPDB) could also be used to drive expression of the gene. Eukaryotic cells can support cytoplasmic transcription from certain bacterial promoters if the appropriate bacterial polymerase is provided, either as part of the delivery complex or as an additional genetic expression construct.
[0092] The promoter and/or enhancer may be, for example, immunoglobulin light chain, immunoglobulin heavy chain, T-cell receptor, HLA DQ a and/or DQ b, b-interferon, interleukin-2, interleukin-2 receptor, MHC class II 5, MHC class II HLA-Dra, b-Actin, muscle creatine kinase (MCK), prealbumin (transthyretin), elastase I, metallothionein (MTII), collagenase, albumin, a-fetoprotein, t-globin, b-globin, c-fos, c-HA-ra.v, insulin, neural cell adhesion molecule (NCAM), oci-antitrypain, H2B (TH2B) histone, mouse and/or type I collagen, glucose-regulated proteins (GRP94 and GRP78), rat growth hormone, human serum amyloid A (SAA), troponin I (TN I), platelet-derived growth factor (PDGF), SV40, polyoma,
37
retroviruses, papilloma virus, hepatitis B vims, human immunodeficiency vims, cytomegalovirus (CMV), and gibbon ape leukemia virus.
[0093] Where a cDNA insert is employed, one will typically desire to include a polyadenylation signal to effect proper polyadenylation of the gene transcript. Any polyadenylation sequence may be employed such as human growth hormone and SV40 polyadenylation signals. Also contemplated as an element of the expression cassette is a terminator. These elements can serve to enhance message levels and to minimize read through from the cassette into other sequences.
[0094] There are a number of ways in which expression vectors may be introduced into cells. In certain embodiments, the expression construct comprises a virus or engineered constmct derived from a viral genome. The ability of certain viruses to enter cells via receptor-mediated endocytosis, to integrate into host cell genome and express viral genes stably and efficiently have made them attractive candidates for the transfer of foreign genes into mammalian cells. These have a relatively low capacity for foreign DNA sequences and have a restricted host spectrum. Furthermore, their oncogenic potential and cytopathic effects in permissive cells raise safety concerns. They can accommodate only up to 8 kB of foreign genetic material but can be readily introduced in a variety of cell lines and laboratory animals.
[0095] One method for in vivo delivery involves the use of an adenovirus expression vector. “Adenovirus expression vector” is meant to include those constructs containing adenovirus sequences sufficient to (a) support packaging of the constmct and (b) to express engineered, stabilized beta-coronavirus S2 domain-only protein that has been cloned therein. In this context, expression does not require that the gene product be synthesized.
[0096] The expression vector comprises a genetically engineered form of adenovirus. Knowledge of the genetic organization of adenovirus, a 36 kB, linear, double-stranded DNA vims, allows substitution of large pieces of adenoviral DNA with foreign sequences up to 7 kB. In contrast to retrovirus, the adenoviral infection of host cells does not result in chromosomal integration because adenoviral DNA can replicate in an episomal manner without potential genotoxicity. Also, adenoviruses are structurally stable, and no genome rearrangement has been detected after extensive amplification. Adenovims can infect
38
virtually all epithelial cells regardless of their cell cycle stage. So far, adenoviral infection appears to be linked only to mild disease such as acute respiratory disease in humans.
[0097] Adenovirus is particularly suitable for use as a gene transfer vector because of its mid-sized genome, ease of manipulation, high titer, wide target cell range and high infectivity. Both ends of the viral genome contain 100-200 base pair inverted repeats (ITRs), which are cis elements necessary for viral DNA replication and packaging. The early (E) and late (L) regions of the genome contain different transcription units that are divided by the onset of viral DNA replication. The El region (E1A and E1B) encodes proteins responsible for the regulation of transcription of the viral genome and a few cellular genes. The expression of the E2 region (E2A and E2B) results in the synthesis of the proteins for viral DNA replication. These proteins are involved in DNA replication, late gene expression and host cell shut-off. The products of the late genes, including the majority of the viral capsid proteins, are expressed only after significant processing of a single primary transcript issued by the major late promoter (MLP). The MLP, (located at 16.8 m.u.) is particularly efficient during the late phase of infection, and all the mRNAs issued from this promoter possess a 5’- tripartite leader (TPL) sequence which makes them preferred mRNAs for translation. In one system, recombinant adenovirus is generated from homologous recombination between shuttle vector and provirus vector. Due to the possible recombination between two proviral vectors, wild-type adenovirus may be generated from this process. Therefore, it is critical to isolate a single clone of vims from an individual plaque and examine its genomic structure.
[0098] Generation and propagation of the current adenovirus vectors, which are replication deficient, depend on a unique helper cell line, designated 293, which was transformed from human embryonic kidney cells by Ad5 DNA fragments and constitutively expresses El proteins. Since the E3 region is dispensable from the adenovirus genome, the current adenovirus vectors, with the help of 293 cells, carry foreign DNA in either the El, the D3 or both regions. In nature, adenovirus can package approximately 105% of the wild-type genome, providing capacity for about 2 extra kb of DNA. Combined with the approximately 5.5 kb of DNA that is replaceable in the El and E3 regions, the maximum capacity of the current adenovirus vector is under 7.5 kb, or about 15% of the total length of the vector. More than 80% of the adenovirus viral genome remains in the vector backbone and is the source of vector-borne cytotoxicity. Also, the replication deficiency of the El-deleted virus is incomplete.
39
[0099] Helper cell lines may be derived from human cells such as human embryonic kidney cells, muscle cells, hematopoietic cells or other human embryonic mesenchymal or epithelial cells. Alternatively, the helper cells may be derived from the cells of other mammalian species that are permissive for human adenovirus. Such cells include, e.g., Vero cells or other monkey embryonic mesenchymal or epithelial cells. As stated above, the preferred helper cell line is 293.
[00100] The adenoviruses of the disclosure are replication defective, or at least conditionally replication defective. The adenovirus may be of any of the 42 different known serotypes or subgroups A-F. Adenovirus type 5 of subgroup C is one exemplary starting material that may be used to obtain the conditional replication-defective adenovirus vector for use in the present disclosure.
[00101] Other viral vectors may be employed as expression constructs in the present disclosure. Vectors derived from viruses such as vaccinia vims, adeno-associated virus (AAV) and herpesviruses may be employed. They offer several attractive features for various mammalian cells.
[00102] In embodiments, particular embodiments, the vector is an AAV vector. AAV is a small virus that infects humans and some other primate species. AAV is not currently known to cause disease. The vims causes a very mild immune response, lending further support to its apparent lack of pathogenicity. In many cases, AAV vectors integrate into the host cell genome, which can be important for certain applications, but can also have unwanted consequences. Gene therapy vectors using AAV can infect both dividing and quiescent cells and persist in an extrachromosomal state without integrating into the genome of the host cell, although in the native vims some integration of virally carried genes into the host genome does occur. These features make AAV a very attractive candidate for creating viral vectors for gene therapy, and for the creation of isogenic human disease models. Recent human clinical trials using AAV for gene therapy in the retina have shown promise. AAV belongs to the genus Dependoparvovirus , which in turn belongs to the family Parvoviridae. The virus is a small (20 nm) replication-defective, nonenveloped virus.
[00103] Wild-type AAV has attracted considerable interest from gene therapy researchers due to a number of features. Chief amongst these is the vims's apparent lack of pathogenicity. It can also infect non-dividing cells and has the ability to stably integrate into
40
the host cell genome at a specific site (designated AAVS1) in the human chromosome 19. This feature makes it somewhat more predictable than retroviruses, which present the threat of a random insertion and of mutagenesis, which is sometimes followed by development of a cancer. The AAV genome integrates most frequently into the site mentioned, while random incorporations into the genome take place with a negligible frequency. Development of A A Vs as gene therapy vectors, however, has eliminated this integrative capacity by removal of the rep and cap from the DNA of the vector. The desired gene together with a promoter to drive transcription of the gene is inserted between the inverted terminal repeats (ITR) that aid in concatemer formation in the nucleus after the single-stranded vector DNA is converted by host cell DNA polymerase complexes into double-stranded DNA. AAV-based gene therapy vectors form episomal concatemers in the host cell nucleus. In non-dividing cells, these concatemers remain intact for the life of the host cell. In dividing cells, AAV DNA is lost through cell division, since the episomal DNA is not replicated along with the host cell DNA. Random integration of AAV DNA into the host genome is detectable but occurs at very low frequency. AAVs also present very low immunogenicity, seemingly restricted to generation of neutralizing antibodies, while they induce no clearly defined cytotoxic response. This feature, along with the ability to infect quiescent cells present their dominance over adenoviruses as vectors for human gene therapy.
[00104] The AAV genome is built of single- stranded deoxyribonucleic acid (ssDNA), either positive- or negative-sensed, which is about 4.7 kilobase long. The genome comprises inverted terminal repeats (ITRs) at both ends of the DNA strand, and two open reading frames (ORFs): rep and cap. The former is composed of four overlapping genes encoding Rep proteins required for the AAV life cycle, and the latter contains overlapping nucleotide sequences of capsid proteins: VP1, VP2 and VP3, which interact together to form a capsid of an icosahedral symmetry.
[00105] The Inverted Terminal Repeat (ITR) sequences comprise 145 bases each. They were named so because of their symmetry, which was shown to be required for efficient multiplication of the AAV genome. The feature of these sequences that gives them this property is their ability to form a hairpin, which contributes to so-called self-priming that allows primase-independent synthesis of the second DNA strand. The ITRs were also shown to be required for both integration of the AAV DNA into the host cell genome (19th chromosome in humans) and rescue from it, as well as for efficient encapsidation of the AAV
41
DNA combined with generation of a fully assembled, deoxyribonuclease-resistant AAV particles.
[00106] With regard to gene therapy, ITRs seem to be the only sequences required in cis next to the therapeutic gene: structural (cap) and packaging (rep) proteins can be delivered in trans. With this assumption many methods were established for efficient production of recombinant AAV (rAAV) vectors containing a reporter or therapeutic gene. However, it was also published that the ITRs are not the only elements required in cis for the effective replication and encapsidation. A few research groups have identified a sequence designated cis-acting Rep-dependent element (CARE) inside the coding sequence of the rep gene. CARE was shown to augment the replication and encapsidation when present in cis.
[0022] In some aspects, the present disclosure provides pharmaceutical compositions that contain one or more salts. The salts may be an inorganic potassium or sodium salt such as potassium chloride, sodium chloride, potassium phosphate dibasic, potassium phosphate monobasic, sodium phosphate dibasic, or sodium phosphate monobasic. The pharmaceutical composition may comprise one or more phosphate salts such to generate a phosphate buffer solution. The phosphate buffer solution may be comprise each of the phosphates to buffer a solution to a pH from about 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, or 8.0, or any range derivable therein.
[0023] In some aspects, the present disclosure comprises one or more excipients formulated into pharmaceutical compositions. An “excipient” refers to pharmaceutically acceptable carriers that are relatively inert substances used to facilitate administration or delivery of an API into a subject or used to facilitate processing of an API into drug formulations that can be used pharmaceutically for delivery to the site of action in a subject. Furthermore, these compounds may be used as diluents in order to obtain a dosage that can be readily measured or administered to a patient. Non-limiting examples of excipients include polymers, stabilizing agents, surfactants, surface modifiers, solubility enhancers, buffers, encapsulating agents, antioxidants, preservatives, nonionic wetting or clarifying agents, viscosity increasing agents, and absorption-enhancing agents.
[00107] In a specific embodiment, the term “pharmaceutically acceptable” means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more
42
particularly in humans. The term “carrier” refers to a diluent, excipient, or vehicle with which the therapeutic is administered. Such pharmaceutical carriers can be sterile liquids, such as water and can preferably include an adjuvant. Water is a particular carrier when the pharmaceutical composition is administered by injections, such an intramuscular injection. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions. Other suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like.
[00108] The composition, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. These compositions can take the form of solutions, suspensions, emulsion, tablets, pills, capsules, powders, sustained-release formulations and the like. Oral formulations can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc. Examples of suitable pharmaceutical agents are described in “Remington's Pharmaceutical Sciences.” Such compositions will contain a prophylactically or therapeutically effective amount of the antibody or fragment thereof, preferably in purified form, together with a suitable amount of carrier so as to provide the form for proper administration to the patient. The formulation should suit the mode of administration, which can be oral, intravenous, intraarterial, intrabuccal, intranasal, nebulized, bronchial inhalation, or delivered by mechanical ventilation.
[00109] Engineered proteins or nucleic acids encoding engineered proteins of the present disclosure, as described herein, can be formulated for parenteral administration, e.g., formulated for injection via the intradermal, intravenous, intramuscular, subcutaneous, intra- tumoral or even intraperitoneal routes. The formulation could alternatively be administered by a topical route directly to the mucosa, for example by nasal drops, inhalation, or by nebulizer. Pharmaceutically acceptable salts include the acid salts and those which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like. Salts formed with the free carboxyl groups may also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine, procaine, and the like.
43
[00110] Generally, the ingredients of compositions of the disclosure are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water-free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent. Where the composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the composition is administered by injection, an ampoule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration·
[00111] The compositions of the disclosure can be formulated as neutral or salt forms. Pharmaceutically acceptable salts include those formed with anions such as those derived from hydrochloric, phosphoric, acetic, oxalic, tartaric acids, etc. , and those formed with cations such as those derived from sodium, potassium, ammonium, calcium, ferric hydroxides, isopropylamine, triethylamine, 2-ethylamino ethanol, histidine, procaine, etc.
[00112] Dosage can be by a single dose schedule or a multiple dose schedule. Multiple doses may be used in a primary immunization schedule and/or in a booster immunization schedule. In a multiple dose schedule the various doses may be given by the same or different routes. Multiple doses will typically be administered at least 1 week apart (e.g., about 2 weeks, about 3 weeks, about 4 weeks, about 6 weeks, about 8 weeks, about 10 weeks, about 12 weeks, about 16 weeks, etc.).
[00113] The compositions disclosed herein may be used to treat both children and adults. Thus a human subject may be less than 1 year old, 1-5 years old, 5-16 years old, 16-55 years old, 55-65 years old, or at least 65 years old.
[00114] Preferred routes of administration include, but are not limited to, intramuscular, intraperitoneal, intradermal, subcutaneous, intravenous, intraarterial, and intraoccular injection. Particularly preferred routes of administration include intramuscular, intradermal and subcutaneous injection.
IV. Immunodetection Methods
[00115] In still further embodiments, the present disclosure concerns immunodetection methods for binding, purifying, removing, quantifying and otherwise generally detecting Coronavirus S protein. While such methods can be applied in a traditional
44
sense, another use will be in quality control and monitoring of vaccine stocks, where antibodies according to the present disclosure can be used to assess the amount or integrity (/.<?., long term stability) of antigens. Alternatively, the methods may be used to screen various antibodies for appropriate/desired reactivity profiles.
[00116] Some immunodetection methods include enzyme linked immunosorbent assay (ELISA), radioimmunoassay (RIA), immunoradiometric assay, fluoroimmunoassay, chemiluminescent assay, bioluminescent assay, and Western blot to mention a few. In particular, a competitive assay for the detection and quantitation of Coronavirus S protein also is provided. The steps of various useful immunodetection methods have been described in the scientific literature, such as, e.g., Doolittle and Ben-Zeev (1999), Gulbis and Galand (1993), De Jager et al. (1993), and Nakamura et al. (1987). In general, the immunobinding methods include obtaining a sample suspected of containing Coronavirus S protein, and contacting the sample with a first antibody in accordance with the present disclosure, as the case may be, under conditions effective to allow the formation of immunocomplexes.
[00117] These methods include methods for detecting or purifying Coronavirus S protein or Coronavirus S protein from a sample. The antibody will preferably be linked to a solid support, such as in the form of a column matrix, and the sample suspected of containing the Coronavirus S protein will be applied to the immobilized antibody. The unwanted components will be washed from the column, leaving the Coronavirus S protein-expressing cells immunocomplexed to the immobilized antibody, which is then collected by removing the organism or antigen from the column.
[00118] The immunobinding methods also include methods for detecting and quantifying the amount of Coronavirus S protein or related components in a sample and the detection and quantification of any immune complexes formed during the binding process. Here, one would obtain a sample suspected of containing Coronavirus S protein and contact the sample with an antibody that binds Coronavirus S protein or components thereof, followed by detecting and quantifying the amount of immune complexes formed under the specific conditions. In terms of antigen detection, the biological sample analyzed may be any sample that is suspected of containing Coronavirus S protein, such as a tissue section or specimen, a homogenized tissue extract, a biological fluid (e.g., a nasal swab), including blood and serum, or a secretion, such as feces or urine.
45
[00119] Contacting the chosen biological sample with the antibody under effective conditions and for a period of time sufficient to allow the formation of immune complexes (primary immune complexes) is generally a matter of simply adding the antibody composition to the sample and incubating the mixture for a period of time long enough for the antibodies to form immune complexes with, i.e., to bind to Coronavirus S protein. After this time, the sample-antibody composition, such as a tissue section, ELISA plate, dot blot or Western blot, will generally be washed to remove any non-specifically bound antibody species, allowing only those antibodies specifically bound within the primary immune complexes to be detected.
[00120] In general, the detection of immunocomplex formation is well known in the art and may be achieved through the application of numerous approaches. These methods are generally based upon the detection of a label or marker, such as any of those radioactive, fluorescent, biological and enzymatic tags. Patents concerning the use of such labels include U.S. Patents 3,817,837, 3,850,752, 3,939,350, 3,996,345, 4,277,437, 4,275,149 and 4,366,241. Of course, one may find additional advantages through the use of a secondary binding ligand such as a second antibody and/or a biotin/avidin ligand binding arrangement, as is known in the art.
[00121] The antibody employed in the detection may itself be linked to a detectable label, wherein one would then simply detect this label, thereby allowing the amount of the primary immune complexes in the composition to be determined. Alternatively, the first antibody that becomes bound within the primary immune complexes may be detected by means of a second binding ligand that has binding affinity for the antibody. In these cases, the second binding ligand may be linked to a detectable label. The second binding ligand is itself often an antibody, which may thus be termed a “secondary” antibody. The primary immune complexes are contacted with the labeled, secondary binding ligand, or antibody, under effective conditions and for a period of time sufficient to allow the formation of secondary immune complexes. The secondary immune complexes are then generally washed to remove any non-specifically bound labeled secondary antibodies or ligands, and the remaining label in the secondary immune complexes is then detected.
[00122] Further methods include the detection of primary immune complexes by a two-step approach. A second binding ligand, such as an antibody that has binding affinity for the antibody, is used to form secondary immune complexes, as described above.
46
After washing, the secondary immune complexes are contacted with a third binding ligand or antibody that has binding affinity for the second antibody, again under effective conditions and for a period of time sufficient to allow the formation of immune complexes (tertiary immune complexes). The third ligand or antibody is linked to a detectable label, allowing detection of the tertiary immune complexes thus formed. This system may provide for signal amplification if this is desired.
[00123] One method of immunodetection uses two different antibodies. A first biotinylated antibody is used to detect the target antigen, and a second antibody is then used to detect the biotin attached to the complexed biotin. In that method, the sample to be tested is first incubated in a solution containing the first step antibody. If the target antigen is present, some of the antibody binds to the antigen to form a biotinylated antibody/antigen complex. The antibody/antigen complex is then amplified by incubation in successive solutions of streptavidin (or avidin), biotinylated DNA, and/or complementary biotinylated DNA, with each step adding additional biotin sites to the antibody/antigen complex. The amplification steps are repeated until a suitable level of amplification is achieved, at which point the sample is incubated in a solution containing the second step antibody against biotin. This second step antibody is labeled, as for example with an enzyme that can be used to detect the presence of the antibody/antigen complex by histoenzymology using a chromogen substrate. With suitable amplification, a conjugate can be produced which is macroscopically visible.
[00124] Another known method of immunodetection takes advantage of the immuno-PCR (Polymerase Chain Reaction) methodology. The PCR method is similar to the Cantor method up to the incubation with biotinylated DNA, however, instead of using multiple rounds of strep tavidin and biotinylated DNA incubation, the DNA/biotin/streptavidin/antibody complex is washed out with a low pH or high salt buffer that releases the antibody. The resulting wash solution is then used to carry out a PCR reaction with suitable primers with appropriate controls. At least in theory, the enormous amplification capability and specificity of PCR can be utilized to detect a single antigen molecule.
A. ELISAs
[00125] Immunoassays, in their most simple and direct sense, are binding assays. Certain preferred immunoassays are the various types of enzyme linked
47
immunosorbent assays (ELISAs) and radioimmunoassays (RIA) known in the art. Immunohistochemical detection using tissue sections is also particularly useful. However, it will be readily appreciated that detection is not limited to such techniques, and western blotting, dot blotting, FACS analyses, and the like may also be used.
[00126] In one exemplary ELISA, the antibodies of the disclosure are immobilized onto a selected surface exhibiting protein affinity, such as a well in a polystyrene microtiter plate. Then, a test composition suspected of containing the Coronavirus S protein is added to the wells. After binding and washing to remove non- specifically bound immune complexes, the bound antigen may be detected. Detection may be achieved by the addition of another anti-Coronavirus S protein antibody that is linked to a detectable label. This type of ELISA is a simple “sandwich ELISA.” Detection may also be achieved by the addition of a second anti-Coronavirus S protein antibody, followed by the addition of a third antibody that has binding affinity for the second antibody, with the third antibody being linked to a detectable label.
[00127] In another exemplary ELISA, the samples suspected of containing the Coronavirus S protein (e.g., potentially infected cells) are immobilized onto the well surface and then contacted with the anti- Coronavirus S protein antibodies of the disclosure. After binding and washing to remove non-specifically bound immune complexes, the bound anti- Coronavirus S protein antibodies are detected. Where the initial anti-Coronavirus S protein antibodies are linked to a detectable label, the immune complexes may be detected directly. Again, the immune complexes may be detected using a second antibody that has binding affinity for the first anti-Coronavirus S protein antibody, with the second antibody being linked to a detectable label.
[00128] Irrespective of the format employed, ELISAs have certain features in common, such as coating, incubating and binding, washing to remove non-specifically bound species, and detecting the bound immune complexes. These are described below.
[00129] In coating a plate with either antigen or antibody, one will generally incubate the wells of the plate with a solution of the antigen or antibody, either overnight or for a specified period of hours. The wells of the plate will then be washed to remove incompletely adsorbed material. Any remaining available surfaces of the wells are then “coated” with a nonspecific protein that is antigenically neutral with regard to the test
48
antisera. These include bovine serum albumin (BSA), casein or solutions of milk powder. The coating allows for blocking of nonspecific adsorption sites on the immobilizing surface and thus reduces the background caused by nonspecific binding of antisera onto the surface.
[00130] In ELISAs, it is probably more customary to use a secondary or tertiary detection means rather than a direct procedure. Thus, after binding of a protein or antibody to the well, coating with a non-reactive material to reduce background, and washing to remove unbound material, the immobilizing surface is contacted with the biological sample to be tested under conditions effective to allow immune complex (antigen/antibody) formation. Detection of the immune complex then requires a labeled secondary binding ligand or antibody, and a secondary binding ligand or antibody in conjunction with a labeled tertiary antibody or a third binding ligand.
[00131] “Under conditions effective to allow immune complex (antigen/antibody) formation” means that the conditions preferably include diluting the antigens and/or antibodies with solutions such as BSA, bovine gamma globulin (BGG) or phosphate buffered saline (PBS)/Tween. These added agents also tend to assist in the reduction of nonspecific background.
[00132] The “suitable” conditions also mean that the incubation is at a temperature or for a period of time sufficient to allow effective binding. Incubation steps are typically from about 1 to 2 to 4 hours or so, at temperatures preferably on the order of 25 °C to 27°C, or may be overnight at about 4°C or so.
[00133] Following all incubation steps in an ELISA, the contacted surface is washed so as to remove non-complexed material. A preferred washing procedure includes washing with a solution such as PBS/Tween, or borate buffer. Following the formation of specific immune complexes between the test sample and the originally bound material, and subsequent washing, the occurrence of even minute amounts of immune complexes may be determined.
[00134] To provide a detecting means, the second or third antibody will have an associated label to allow detection. Preferably, this will be an enzyme that will generate color development upon incubating with an appropriate chromogenic substrate. Thus, for example, one will desire to contact or incubate the first and second immune complex with a urease, glucose oxidase, alkaline phosphatase or hydrogen peroxidase-conjugated antibody
49
for a period of time and under conditions that favor the development of further immune complex formation (e.g., incubation for 2 hours at room temperature in a PBS -containing solution such as PBS-Tween).
[00135] After incubation with the labeled antibody, and subsequent to washing to remove unbound material, the amount of label is quantified, e.g., by incubation with a chromogenic substrate such as urea, or bromocresol purple, or 2,2'-azino-di-(3-ethyl- benzthiazoline-6-sulfonic acid (ABTS), or ¾(¾, in the case of peroxidase as the enzyme label. Quantification is then achieved by measuring the degree of color generated, e.g., using a visible spectra spectrophotometer.
B. Western Blot
[00136] The Western blot (alternatively, protein immunoblot) is an analytical technique used to detect specific proteins in a given sample of tissue homogenate or extract. It uses gel electrophoresis to separate native or denatured proteins by the length of the polypeptide (denaturing conditions) or by the 3-D structure of the protein (native/ non denaturing conditions). The proteins are then transferred to a membrane (typically nitrocellulose or PVDF), where they are probed (detected) using antibodies specific to the target protein.
[00137] Samples may be taken from whole tissue or from cell culture. In most cases, solid tissues are first broken down mechanically using a blender (for larger sample volumes), using a homogenizer (smaller volumes), or by sonication. Cells may also be broken open by one of the above mechanical methods. Assorted detergents, salts, and buffers may be employed to encourage lysis of cells and to solubilize proteins. Protease and phosphatase inhibitors are often added to prevent the digestion of the sample by its own enzymes. Tissue preparation is often done at cold temperatures to avoid protein denaturing.
[00138] The proteins of the sample are separated using gel electrophoresis. Separation of proteins may be by isoelectric point (pi), molecular weight, electric charge, or a combination of these factors. The nature of the separation depends on the treatment of the sample and the nature of the gel. This is a very useful way to determine a protein. It is also possible to use a two-dimensional (2-D) gel which spreads the proteins from a single sample out in two dimensions. Proteins are separated according to isoelectric point (pH at which they
50
have neutral net charge) in the first dimension, and according to their molecular weight in the second dimension.
[00139] In order to make the proteins accessible to antibody detection, they are moved from within the gel onto a membrane made of nitrocellulose or polyvinylidene difluoride (PVDF). The membrane is placed on top of the gel, and a stack of filter papers placed on top of that. The entire stack is placed in a buffer solution which moves up the paper by capillary action, bringing the proteins with it. Another method for transferring the proteins is called electroblotting and uses an electric current to pull proteins from the gel into the PVDF or nitrocellulose membrane. The proteins move from within the gel onto the membrane while maintaining the organization they had within the gel. As a result of this blotting process, the proteins are exposed on a thin surface layer for detection (see below). Both varieties of membrane are chosen for their non-specific protein binding properties (/.<?., binds all proteins equally well). Protein binding is based upon hydrophobic interactions, as well as charged interactions between the membrane and protein. Nitrocellulose membranes are cheaper than PVDF, but are far more fragile and do not stand up well to repeated probings. The uniformity and overall effectiveness of transfer of protein from the gel to the membrane can be checked by staining the membrane with Coomassie Brilliant Blue or Ponceau S dyes. Once transferred, proteins are detected using labeled primary antibodies, or unlabeled primary antibodies followed by indirect detection using labeled protein A or secondary labeled antibodies binding to the Fc region of the primary antibodies.
C. Immunohistochemistry
[00140] The antibodies of the present disclosure may also be used in conjunction with both fresh-frozen and/or formalin-fixed, paraffin-embedded tissue blocks prepared for study by immunohistochemistry (IHC). The method of preparing tissue blocks from these particulate specimens has been successfully used in previous IHC studies of various prognostic factors, and is well known to those of skill in the art (Brown et al, 1990; Abbondanzo et al, 1990; Allred el al. , 1990).
[00141] Briefly, frozen- sections may be prepared by rehydrating 50 ng of frozen “pulverized” tissue at room temperature in phosphate buffered saline (PBS) in small plastic capsules; pelleting the particles by centrifugation; resuspending them in a viscous embedding medium (OCT); inverting the capsule and/or pelleting again by centrifugation; snap-freezing in -70°C isopentane; cutting the plastic capsule and/or removing the frozen
51
cylinder of tissue; securing the tissue cylinder on a cryostat microtome chuck; and/or cutting 25-50 serial sections from the capsule. Alternatively, whole frozen tissue samples may be used for serial section cuttings.
[00142] Permanent- sections may be prepared by a similar method involving rehydration of the 50 mg sample in a plastic microfuge tube; pelleting; resuspending in 10% formalin for 4 hours fixation; washing/pelleting; resuspending in warm 2.5% agar; pelleting; cooling in ice water to harden the agar; removing the tissue/agar block from the tube; infiltrating and/or embedding the block in paraffin; and/or cutting up to 50 serial permanent sections. Again, whole tissue samples may be substituted.
D. Immunodetection Kits
[00143] In still further embodiments, the present disclosure concerns immunodetection kits for use with the immunodetection methods described above. As the antibodies may be used to detect Coronavirus S protein, the antibodies may be included in the kit. The immunodetection kits will thus comprise, in suitable container means, a first antibody that binds to an Coronavirus S protein, and optionally an immunodetection reagent.
[00144] In certain embodiments, the antibody may be pre-bound to a solid support, such as a column matrix and/or well of a microtitre plate. The immunodetection reagents of the kit may take any one of a variety of forms, including those detectable labels that are associated with or linked to the given antibody. Detectable labels that are associated with or attached to a secondary binding ligand are also contemplated. Exemplary secondary ligands are those secondary antibodies that have binding affinity for the first antibody.
[00145] Further suitable immunodetection reagents for use in the present kits include the two-component reagent that comprises a secondary antibody that has binding affinity for the first antibody, along with a third antibody that has binding affinity for the second antibody, the third antibody being linked to a detectable label. As noted above, a number of exemplary labels are known in the art and all such labels may be employed in connection with the present disclosure.
[00146] The kits may further comprise a suitably aliquoted composition of Coronavirus S protein, whether labeled or unlabeled, as may be used to prepare a standard curve for a detection assay. The kits may contain antibody-label conjugates either in fully
52
conjugated form, in the form of intermediates, or as separate moieties to be conjugated by the user of the kit. The components of the kits may be packaged either in aqueous media or in lyophilized form.
[00147] The container means of the kits will generally include at least one vial, test tube, flask, bottle, syringe or other container means, into which the antibody may be placed, or preferably, suitably aliquoted. The kits of the present disclosure will also typically include a means for containing the antibody, antigen, and any other reagent containers in close confinement for commercial sale. Such containers may include injection or blow- molded plastic containers into which the desired vials are retained.
E. Flow Cytometry and FACS
[00148] The antibodies of the present disclosure may also be used in flow cytometry or FACS. Flow cytometry is a laser- or impedance-based technology employed in many detection assays, including cell counting, cell sorting, biomarker detection and protein engineering. The technology suspends cells in a stream of fluid and passing them through an electronic detection apparatus, which allows simultaneous multiparametric analysis of the physical and chemical characteristics of up to thousands of particles per second. Flow cytometry is routinely used in the diagnosis disorders, especially blood cancers, but has many other applications in basic research, clinical practice and clinical trials.
[00149] Fluorescence-activated cell sorting (FACS) is a specialized type of cytometry. It provides a method for sorting a heterogenous mixture of biological cells into two or more containers, one cell at a time, based on the specific light scattering and fluorescent characteristics of each cell. In general, the technology involves a cell suspension entrained in the center of a narrow, rapidly flowing stream of liquid. The flow is arranged so that there is a large separation between cells relative to their diameter. A vibrating mechanism causes the stream of cells to break into individual droplets. Just before the stream breaks into droplets, the flow passes through a fluorescence measuring station where the fluorescence of each cell is measured. An electrical charging ring is placed just at the point where the stream breaks into droplets. A charge is placed on the ring based immediately prior to fluorescence intensity being measured, and the opposite charge is trapped on the droplet as it breaks form the stream. The charged droplets then fall through an electrostatic deflection system that diverts droplets into containers based upon their charge.
53
[00150] In certain embodiments, to be used in flow cytometry or FACS, the antibodies of the present disclosure are labeled with fluorophores and then allowed to bind to the cells of interest, which are analyzed in a flow cytometer or sorted by a FACS machine.
V. Examples
[00151] The following examples are included to demonstrate preferred embodiments of the invention. It should be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques discovered by the inventor to function well in the practice of the invention, and thus can be considered to constitute preferred modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention.
Materials & Methods
[00152] Design scheme for MERS stem stabilized spike variants. The base construct used for the S2 subunit of MERS-CoV S-2P variant contained residues 762-1291 of MERS-CoV S (GenBank ID: AFY13307) with proline substituted at residues 1060 and 1061, the foldon dimerization motif of T4 fibritin, an HRV3C protease recognition site, an octa- histidine tag, and a tandem Twin-Strep-tag, cloned into the mammalian expression plasmid paH. All mutations in subsequent designs were introduced into this base construct. The initial design was conducted via the PROSS server (Goldenzweig et ah, 2016), and a total of 11 substitutions were picked (yielding the ‘mutll’ construct) from 53 computational designs based on the biochemical property of the residues and steric effect on the prefusion-stabilized MERS S-2P structure (PDB ID: 5W9I). Using structure-based design, additional substitutions that were aimed at favoring the stability of the prefusion structure were introduced into the mutll backbone. Pairs of core-facing residues less than 5 A apart were replaced with aromatic sidechains or pairs of aromatic and positively charged sidechains to favor pi-pi or pi-cation interactions, respectively. Alternatively, residues were replaced with extended or bulkier hydrophobic sidechains in efforts to fill pre-existing internal cavities. Disulfide bonds were designed to increase overall stability or prevent formation of the postfusion conformation. The charged or polar substitutions were aimed to establish hydrogen bonds or salt bridges with the native residues that were predicted to be within 4.0 A. To examine the
54
effect of the substitutions in the mutll backbone, the mutations were individually or combinatorially reverted back to the wild-type sequence. Three designs, each containing 5-7 of the beneficial substitutions from the PROSS server (mut5, mut6 and mut7) were chosen to serve as backgrounds for subsequent rounds of design. These were then combined with individual substitutions or combinations of substitutions from the structure-based designs that were shown to be beneficial, for subsequent assessment of improved monodispersity and thermostability. Substitutions predicted to potentially interfere with one another or clash with native residues were avoided.
[00153] Protein expression and purification for MERS SS variants. Plasmids encoding MERS SS variants were transiently transfected into FreeStyle293F cells (Thermo Fisher) using polyethyleneimine, with 5 mM kifunensine being added 3h post-transfection. Cultures were grown for 6 days, and culture supernatant was separated via centrifugation and passage through a 0.22 pm filter. Protein was purified from supernatants using StrepTactin resin (IB A). MERS SS variants were further purified by size-exclusion chromatography (SEC) using a Superose 6 10/300 column (GE Healthcare) in a buffer composed of 2 mM Tris pH 8.0, 200 mM NaCl and 0.02% NaN3. For initial purification and characterization, single-substitution and combinatorial variants were purified from 40 mL cultures. The SS.V1 and SS.V2 variants were further tested in large-scale expression and purification from 1 L cultures. The protein purity, monodispersity and expression level were determined by SDS- PAGE and SEC.
[00154] Differential scanning fluorimetry . MERS SS variants were prepared at a concentration of 1.5 pM with a final concentration 5X SYPRO Orange Protein Gel Stain (ThermoFisher) in a white, opaque 96-wellplate. Continuous fluorescence measurements (/.ex=465 nm, /.em=580 nm) were performed using a Roche LightCycler 480 II, with a temperature ramp rate of 4.4 °C/minute, and a temperature range of 25 °C to 95 °C. Data were plotted as the derivative of the melting curve.
[00155] Mouse experiments. Mouse experiments were carried out in compliance with all pertinent US National Institutes of Health regulations and approval from the Animal Care and Use Committee (ACUC) of the Vaccine Research Center, University of North Carolina at Chapel Hill, or Abcellera Biologies. For immunogenicity studies, female BALB/cJ mice aged 6- to 8-weeks (Jackson Laboratory) were used. Per the experimental design schema outlined in figure 3A, mice were inoculated intramuscularly with protein
55
immunogens adjuvanted with SAS as previously described (Pallesen et al., 2017) and bled for serological assays. For challenge studies to evaluate MERS-CoV vaccines, 16- to 20-week- old male and female 288/330+/+mice (Cockrell et ah, 2016) were immunized, bled, and challenged, as detailed in figure 4 A. Mice were challenged with 5 x 105 PFU of a mouse- adapted MERS-CoV EMC derivative, m35c4 (Douglas et ak, 2018). On days 3 and 5 post challenge, lungs were collected from selected mice to assess viral titers and hemorrhage, using previously published methods. For S -reactive monoclonal antibody isolation, female C57BL/6J mice aged 4- to 8-weeks (Jackson Laboratory) were used. Mice were immunized intramuscularly with 10 pg MERS SS.V1 + SAS at weeks 0, 3, and 9. At week 13, mice were euthanized and spleens, thymuses, and lymph nodes were harvested for single B cell technology for mAh isolation. Sample size for animal experiments was determined on the basis of criteria set by institutional ACUC. Experiments were neither randomized nor blinded.
[00156] Serum IgG measurement. HCoV S-2P-specific IgG in immunized mouse sera were quantified via enzyme-linked immunosorbent assay (ELISA). Briefly, Nunc MaxiSorp 96-well plates (ThermoFisher) were coated with either MERS S2P, SARS S-2P, SARS-CoV-2 S-2P, or HKU1 S-2P at 1 pg/mL in IX PBS 400 at 4°C for 16h. Sera dilutions were prepared in blocking buffer, which consisted of PBS-Tween 20 + 5% non-fat dairy milk, and diluted serially at 1:100, four- fold, 8x. To eliminate foldon- specific binding, 50 pg/mL of foldon was added to the dilutions and incubated for an hour at room temperature. After standard washes and blocks, goat anti-mouse IgG-horseradish peroxidase (HRP) conjugate (SigmaAldrich) was used as secondary antibody. Plates were reacted with 3,5,3’5’- tetramethylbenzidine (TMB) (KPL) to detect binding responses. Plates were read at OD450/650 using SpectraMax Paradigm (Molecular Devices). Endpoint titers were calculated as the reciprocal serum dilution that yielded a signal 4x greater than that of the background signal (secondary antibody alone).
[00157] Pseudovirus neutralization assay. Neutralization activity was assessed as previously described (Pallesen et ak, 2017). Briefly, Huh7.5 cells were seeded at 10,000 cells/well in 96-well black/white Isoplates (PerkinElmer) 24-h prior to infection. Sera were serially diluted (1:40, 4-fold dilutions, 8x) in DMEM (Gibco) + 1% penicillin/streptomycin, and mixed with a pseudotyped MERS-CoV Englandl lentivirus reporter that was previously titrated to 104 RLU, and incubated for 30 minutes at room temperature. Thr sera +
56
pseudovirus mixture was then added to Huh7.5 cells in duplicate, and incubated at 37°C and 5% C02 for 2h. Then, 100 pL of DMEM supplemented with 10% FBS, 2 mM glutamine, and 1% penicillin/streptomycin was added to each well, and incubated for 72h. Cells were then lysed, and luciferase substrate (Promega) was added. Luciferase activity was measured as relative luciferase units (RLU) at 570 nm, using a SpectraMaxL (Molecular Devices). Sigmoidal curves, taking averages of triplicates at each dilution, were generated from RLU readings; 50% neutralization (ID50) titers were calculated considering uninfected cells as 100% neutralization and cells transduced with only vims as 0% neutralization, by fitting RLU readings to a log(agonist) vs. normalized-response (variable slope) nonlinear regression model in Prism v8 (GraphPad).
[00158] Single-cell screening and recovery. Immunized mice exhibiting elevated serum titers were sacrificed and plasma cells from lymph node, spleen, and bone marrow tissues were isolated using standard protocols. Samples were screened with AbCellera’ s high-throughput single-cell microfluidic platform using a multiplexed microbead assay on devices containing individual nanoliter-volume reaction chambers (Lecault et al., 2011). The multiplexed assay employed multiple optically-encoded beads, each conjugated to one of the following unique antigens: full-length pre- fusion stabilized spike proteins of MERS-CoV, SARS-CoV, or HKUl-CoV, or the S2 subunit of MERS-CoV spike. Bead- conjugated bovine serum albumin (BSA) His-tag and T4 foldon trimerization domain were used as negative controls. Beads were flowed into microfluidic screening devices and incubated with single antibody- secreting cells, and monoclonal antibody binding to cognate antigens was detected via a fluorescently labeled anti-human IgG secondary antibody. Positive hits were identified using machine vision and recovered using automated robotics- based protocols.
[00159] Single-cell sequencing, bioinformatic analysis, and cloning. For recovery of paired heavy and light chain sequences, single-cell polymerase chain reaction (PCR) and next-generation sequencing (MiSeq, Illumina) were performed using automated workstations (Bravo, Agilent) and custom molecular biology protocols. Sequences were analyzed using a custom bioinformatics pipeline to yield paired heavy and light chain sequences for each recovered antibody secreting cell. Each sequence was assigned the closest germline (V(D)J) genes, degree of somatic hypermutation, and potential sequence liabilities.
57
[00160] Expression and purification of IgGs and Fab. Twenty monoclonal antibodies discovered by single B cell technology were selected for characterization based on their binding specifies to HKU1-S, MERS-S and SARS-l-S (monospecific, bi-specific or tri specific), diversity of heavy and light chain CDR3s, and high frequency rates in the B cell repertoire (independently isolated by the probes more than 2 times). The individual VH sequence of selected IgGs was cloned into a mammalian expression plasmid pVRC8400 containing HRV 3C cleavage site in the hinge, and human IgGl Fc domain. VL sequences were also cloned into pVRC8400 with human CL. Paired VH and VL in a 1 : 1 ratio were co transfected transiently into FreeStyle293F cells as previously described. The supernatant was harvested six days post-transfection and IgGs were purified with Protein A agarose (ThermoFisher). IgGs were eluted with 100 mM glycine, pH 3 into 1/lOth volume 1 M Tris- HC1 pH 8.0. IgGs were then buffer exchanged into PBS pH 7.4. Fab fragments were generated by digesting the IgGs with HRV 3C protease at 4 °C. Fc was removed by passing digests over a fresh Protein A agarose, leaving the Fab in the flowthrough, which was further purified by SEC using a Superdex 200 increase 10/300 column (GE Healthcare) in PBS buffer, pH 7.4.
[00161] Spike binding analysis by Biolayer interferometry. The binding affinity of purified IgGs to HKUl-CoV S, MERS-CoV S or SARS-CoV S was characterized by BLI using an Octet RED96e (ForteBio). Briefly, anti-human Fc (AHC) sensors (ForteBio) with captured IgG were dipped into the wells containing 100 nM of CoV spikes in a BLI buffer composed of 10 mM HEPES pH 7.4, 150 mM NaCl, 0.005% v/v Tween 20 and 1 mg/mL BSA. After 600s association step, the dissociation step was carried out in the wells containing only BLI buffer for 600s. RSV F-foldon was also included in the experiments as negative control. The binding affinity of purified mAh G4 to MERS-CoV S and MERS SS was also characterized by BLI using similar approach. AHC sensors with captured mAh G4 were dipped into the wells containing serial dilutions of MERS-CoV S or MERS SS at concentration ranging from 100 to 1.56 nM in a BLI buffer. The data were aligned to a baseline prior to association step and fit to a 1:1 binding model to calculate rate and dissociation constants using Octet Data Analysis software vll.l. The IgGs exhibiting binding to MERS-CoV S was further examined for the ability to compete with mAh G4, the only S2- targed antibody MERS-S antibody with a defined epitope (Pallesen et al., 2017). Four-fold molar excess of G4 Fab was preincubated with 100 nM MERS-S at room temperature for 10 min. The IgG being tested was loaded on AHC sensors and then dipped into either 100 nM
58
apo MERS-S or 100 nM G4-presaturated MERS-S. G4 IgG was also included in one set of the experiments as a control. The data were plotted as the difference between the binding level of G4-saturated and apo MERS-S, normalized to the binding level of apo MERS-S to the IgG of interest.
[00162] Surface plasmon resonance. To accurately determine the binding kinetics, His-tagged spike variants (MERS-CoV S-2P, SARS-CoV S-2P and SARS-CoV-2 S- HexaPro) were immobilized to a Ni-NTA sensorchip (GE Healthcare) to a level of -600 response units (RUs) using a Biacore X100 (GE Healthcare) and running buffer composed of 10 mM HEPES pH 8.0, 150 mM NaCl and 0.05% Tween 20. Serial dilutions of purified Fab22 were injected at concentrations ranging from 400 to 6.25 nM over immobilized MERS-CoV S-2P. For the SARS-CoV S-2P and SARS-CoV-2 S-HexaPro binding experiments, Fab22 concentrations ranging from 100 to 3.13 nM were used instead. The Ni- NTA sensorchip was regenerated between each cycle with 0.35 M EDTA, 50 mM NaOH and followed by 0.5 mM NiC12. Response curves were double-reference subtracted and fit to a 1:1 binding model using Biacore X100 Evaluation Software (GE Healthcare).
[00163] Plaque reduction neutralization test (PRNT). Four-fold serial dilutions of mAbs were combined with an average of 124 plaque-forming units of MERS-CoV (HCo V -EMC/2012) or SARS-CoV-2 (SARS-CoV-2/human/USA/USA-WAl/2020) in 200 pL gelatin saline (0.3% [wt/vol] gelatin in phosphate-buffered saline supplemented with CaCh and MgCh) for 20 min at 37°C, and 100 pL of vims-mAb mixture was applied to each of two confluent Vero 81 or Vero E6 cell monolayers, respectively, in 6-well (10-cm2) plates. Monolayers were overlaid with Dulbecco’s modified Eagle’s medium (DMEM) containing 1% agar following vims adsorption for 30 min at 37°C, and plaques were enumerated at 72 h or 96 h post-infection. Percent plaque reduction resulting from mAh treatment (relative to untreated vims control) was plotted as a function of logio mAh concentration. Neutralization data were subjected to five-parameter logistic regression modeling using GraphPad PRISM 9.0.0. Minimum mAh concentrations resulting in 50% and 80% virus neutralization were interpolated from fitted dose-response curves.
[00164] Negative stain EM for spike-Fab complexes. Purified MERS-CoV S- 2P or SARS-CoV-2 S-HexaPro were incubated with 2-fold molar excess of Fab22 or Fab72 in 2 mM Tris pH 8.0, 200 mM NaCl and 0.02% NaN3 at room temperature for 30 min. The spike-Fab complexes were diluted to a concentration of 0.06 mg/mL in 2 mM Tris pH 8.0,
59
200 mM NaCl and 0.02% NaN3. Each protein complex was deposited on a CF-400-CU grid (Electron Microscopy Sciences) that had been plasma cleaned for 30 seconds in a Solarus 950 plasma cleaner (Gatan) with a 4:1 ratio of O2/H2 and stained using methylamine tungstate (Nanoprobes). Grids were imaged at a magnification of 92,000X (corresponding to a calibrated pixel size of 1.63 A/pix) in a Talos F200C TEM microscope equipped with a Ceta 16M detector (Thermo Fisher Scientific). The CTF-estimation and particle picking were performed in cisTEM (Grant et al., 2018). Particles were then imported into cryoSPARC v2.15.0 for 2D classification (Punjani et al., 2017).
[00165] Cryo-EM sample preparation, data collection and processing. Purified MERS-CoV S-2P at 1 mg/mL was incubated with 2-fold molar excess of Fab22 in 2 mM Tris pH 8.0, 200 mM NaCl and 0.02% NaN3 at room temperature for 30 min. Sample was then deposited on a plasma-cleaned CF-400 1.2/1.3 grid before being blotted for 5 seconds with +1 force in a Vitrobot Mark IV (ThermoFisher) and plunge-frozen into liquid ethane. Similarly, purified SARS-CoV-2 S (HexaPro variant) complexed with 2-fold molar excess of Fab22 was diluted to a concentration of 0.37 mg/mL in 2 mM Tris pH 8.0, 200 mM NaCl, 0.02% NaN3 and applied to plasma-cleaned CF-400 1.2/1.3 grids before being blotted for 3.5 seconds with -4 force in a Vitrobot Mark IV and plunge-frozen into liquid ethane. For the Fab22-MERS S-2P sample, 4,330 micrographs were collected from a single grid. For the Fab22-HexaPro sample, 2,013 micrographs were collected from a single grid. FEI Titan Krios (ThermoFisher) equipped with a K3 direct electron detector (Gatan) was used for imaging. Data were collected at a magnification of 22,500x, corresponding to a calibrated pixel size of 1.07 A/pix. A full description of the data collection parameters can be found in Table 4. Warp was used for motion correction, CTF estimation, and particle picking (Tegunov and Cramer, 2019). The particle stack was then imported into cryoSPARC v2.15.0, which was used to curate the particles via iterative rounds of 2D classification (Punjani et al., 2017). The final reconstructions were then arrived at via ab initio reconstruction, heterogeneous refinement, and subsequently non-uniform homogeneous refinement of final classes. The structure validation can be found in FIGS. 12A-C.
Example 1 - Structure-based vaccine design of MERS-CoV stabilized stem (SS) antigens
[00166] To stabilize the stem region (S2 subunit) of the spike, the Protein Repair One-Stop Shop (PROSS) was first used to computationally design stabilizing mutations based on a prefusion-stabilized structure of the MERS-CoV spike ectodomain (PDB ID: 5W9I) (Goldenzweig et ah, 2016; Pallesen et ak, 2017). Among 53 designs, 11 substitutions were selected and introduced in varying combinations into the S2 subunit of MERS-CoV S. The protein expression level of the mutant containing all 11 substitutions (mutll) was substantially higher than MERS S2-2P (base construct) (FIG. 2A). To further improve the protein expression and thermostability of S2, a variety of stabilization strategies were employed to design 12 different substitutions, which were added onto the mutll background. The strategies employed include using hydrophobic residues to fill loosely packed internal cavities (FIG. 2B), disulfide bonds to lock the regions that move substantially during the pre-to-postfusion transition (FIG. 2C), polar residues to counter internal charge imbalance (FIG. 2D), and aromatic side chains to favor pi-pi or cation-pi interactions with positively charged residues (FIG. 2B). Except for the S858C/G953C variant, all other single substitutions increased the protein expression to various extents compared to mutll. Particularly, S975M, F923W/F1033F, Q796C/S858C, T803C/K933C, S845E, A1094S and A1093R substitutions exhibited more than 10-fold higher expression than their parental
61
construct mutll (FIGS. 2A-D). The size-exclusion chromatography (SEC) traces of all variants showed a major trimeric peak with some minor shoulder peaks, with the retention volumes of the trimeric variants being similar to the base construct and mutl 1.
[00167] Next, whether the contribution of the individual substitutions comprising mutll to protein expression and thermostability was examined by reverting each of the substitutions back to the wildtype residue. Reverting K816R, H1020Q, H1146Y or V1150T increased the protein expression relative to mutll, meaning these four substitutions in mutl 1 are dispensable. Thus, a new base construct containing 7 substitutions (mut7) was used for subsequent designs (FIG. 2E). To test whether the structure-based designs (previously tested individually on the mutll background) have additive effects, a disulfide design (T803C/K933C), a cavity filling design (S975M), or a combination of both designs (S975M, T803C/K933C) was added on top of mut7. However, unlike the increase in expression for mutll, T803C/K933C decreased the protein expression relative to mut7, but increased the Tm by 1.7 °C (FIG. 7A). S975M substitution not only boosted the protein expression relative to mut7, but also enhanced the thermostability. Combining both T803C/K933C and S975M on the mut7 backbone restored the expression to a level similar to mut7 and increased Tm by 4.0°C. After iterative screening of WT reversions in mut7 S975M/T803C/K933C, A918P and V1139F were found to have adverse effects on protein expression and thermostability (FIGS. 2E and 7). Removal of A918P and V1193F resulted in the first stabilized stem antigen, MERS SS.V1, containing 7 substitutions in addition to the original 2P mutations (S975M, T803C/K933C, V958S, V983I, S1091E, L1094Q, N1132Y, V1060P, L1061P).
[00168] To evaluate the viability of MERS SS.V1 as an immunogen, large- scale production in FreeStyle 293 -F cells, thermostability, and epitope integrity were investigated. After two consecutive runs of SEC, MERS SS.V1 exhibited a monodispersed trimeric peak, with a yield of 2.2 mg from 1 L of cell culture (FIG. 2H). The Tm of MERS SS.V1 is 59.9 °C, which is a 6.3 °C increase relative to mutll. mAh G4 is one of very few S2-directed antibodies showing neutralizing activity to MERS-CoV (Wang et ah, 2015). The binding kinetics of MERS SS.V1 to G4 IgG were comparable to those of MERS S-2P ectodomain, with apparent affinities of 8.5 nM and 13.2 nM, respectively (FIG. 8). Taken together, these results suggest that MERS SS.V1 retains the integrity of the known neutralization epitope and should be amenable to large-scale production.
62
[00169] Introducing disulfide linkages to lock viral glycoproteins in the prefusion conformation has proven effective in class I viral fusion proteins such as RSV F, HIV-1 Env and Ebola GP (McLellan et ak, 2013; Rutten et ak, 2020; Sanders et ak, 2013). Although it was not successfully applied to the SARS CoV-2 spike (Hsieh et ak, 2020), its feasibility on MERS SS.V1 was explored. Three disulfide designs, A838C/S1089C, S845C/A1096C and V898C/V1022C, were introduced individually or in combination to stabilize the region proximal to the fusion peptide and central helix. With the addition of V898C/V1022C, the protein expression level increased 1.3-fold relative to MERS SS.V1 and the Tm increased by 4.0 °C (FIGS. 2F-G). Upon combination with either A838C/S1089C or S845C/A1096C substitutions, the protein expression levels increased 1.7-fold relative to MERS SS.V1 and the Tm increased by 6.3 °C. Notably, both constructs exhibited a sharp monodisperse trim eric peak on SEC without any prominent shoulder peaks. This led to the MERS SS.V2 construct, which contains A838C/S1089C and V898C/V1022C added onto the MERS SS.V1 background. The large-scale expression of MERS SS.V2 outperformed MERS SS.V1, yielding 9.5 mg from 1L of FreeStyle 293-F cells (FIG. 2H).
Example 2 - MERS SS immunization elicits cross-reactive b-CoV antibodies
[00170] To evaluate the cross-reactive immunogenicity of MERS SS immunogens, BALB/cJ mice were immunized with 0.4, 2, or 10 pg of MERS SS.V1 or SS.V2 or the maximally effective dose of 1 pg stabilized MERS spike ectodomain (MERS S- 2P) (Pallesen et ak, 2017). The immunogens were administered at weeks 0 and 3 with Sigma Adjuvant System (SAS). Mice were bled 2 weeks post-boost to assess binding IgG and pseudovirus neutralizing antibody responses (FIG. 3A). All doses of both immunogens elicited robust ~105 MERS S-2P-specific reciprocal endpoint binding titers (FIG. 3B). Both MERS SS.V1 and SS.V2 elicited HKU1, SARS, and SARS-2 S-2P-specific IgG that trended toward dose-dependency; most notably at the 0.4 pg dose, heterotypic SARS and SARS-2 S- 2P-specific binding IgG responses were more significant in mice immunized with SS.V1 compared to mice immunized with SS.V2 (FIGS. 3C-E). Conversely, neutralizing antibody responses against a pseudotyped lentivirus reporter expressing MERS-CoV S was not dose- dependent. As expected, both SS immunogens elicited significantly fewer neutralizing antibodies than MERS S-2P given the lack of the SI subunit in the SS immunogens. While MERS SS.V1 elicited only modest baseline neutralizing antibody responses (up to a geometric mean ID50 titer, GMT = 1/156), SS.V2 induced stronger neutralization responses
63
with GMT of 1/550 (FIG. 3F). Altogether, these data corroborate that the introduction of stabilizing disulfide bonds into the SS.V1 backbone promotes the production of more potently neutralizing MERS-CoV S2-specific antibodies. Additionally, they underscore the importance of targeting conserved epitopes to induce broadly specific antibody responses.
Example 3 - MERS SS protects humanized-DPP4 mice against lethal MERS-CoV challenge
[00171] In order to assess the ability of MERS stabilized stems to protect against lethal MERS-CoV challenge, 288/330+/+ mice (Cockrell et ak, 2016) were immunized with 10 pg of MERS SS.V1 or S-2P, adjuvanted with SAS. Mock-immunized mice received PBS. 288/330+/+ mice express human DPP4 and harbor localized lung viral replication and succumb to lethal doses of mouse-adapted (MA) MERS-CoV maM35c4 (Douglas et ak, 2018). Giving three immunogen doses at weeks 0, 3, and 9, the antibody responses were then assessed two weeks post-boost and challenged at week 13 (FIG. 4A). Firstly, ELISA revealed MERS SS.V1 elicits similar levels of robust ~105 homotypic binding IgG as MERS S-2P (FIG. 4B). However, stem-specific binding antibodies were sub neutralizing as MERS SS. VI -immunized mice had significantly reduced homotypic pseudo virus neutralizing antibody responses (GMT = 1/185) as compared to mice receiving MERS S-2P (GMT = 1/5758), similar to BALB/cJ mice in FIG. 3F. In fact, only 5 out of 20 MERS SS.V 1 -immunized 288/330+/+ mice had detectable neutralizing antibody responses (FIG. 4C).
[00172] Following challenge, mice immunized with either MERS S-2P or MERS SS.V1 demonstrated no weight loss throughout the course of infection. Conversely, mice in the PBS control group demonstrated severe clinical presentations and succumbed to death one week post-challenge (FIG. 4D). At day 3 post-challenge, the day of peak lung viral titers in this model, MERS S-2P-immunized mice had no detectable lung viral load, and MERS SS.V1 -immunized mice hovered about the viral detection limit (geometric mean PFU per lung lobe = 167) (FIG. 4E). At day 4 post-challenge, MERS SS.V1 and S-2P-immunized mice alike had cleared viral replication, contrasting against PBS-immunized mice, which presented 2xl06 geometric mean PFU per lung lobe (FIG. 4F). In line with trends of viral replication among SS.V1 and S-2P-immunized mice, at both days 3 and 5 post-challenge there was little to no distinguishable pulmonary hemorrhage; indicating that both vaccines effectively impeded infection and further prevented substantial lung disease (FIG. 4G-H).
64
These findings emphasize the utility of eliciting protective immunity by targeting epitopes outside of immunodominant and neutralization sensitive SI sites.
Example 4 - Discovery of pan-CoV antibodies from MERS SS-immunized mice
[00173] Next, AbCellera’s single B cell technology was used to isolate cross reactive monoclonal antibodies from the spleen, thymus and lymph nodes of mice immunized with MERS SS.V1 antigen. Using HCoV HKU1 S-2P, SARS-CoV S-2P, MERS-CoV S-2P, and MERS SS.V1 as probes, 146 antibodies with a diverse spectrum of specificities to the b- CoV spikes were discovered. Antibodies exhibiting broader spike reactivities, higher frequencies, and unique CDR3s in both heavy and light chains were selected for in order to cover a wide distribution of the germline family. The selected IgGs were then expressed recombinantly in vitro and characterized by binding specificities to b-CoV prefusion- stabilized S, namely HCoV-HKUl S-2P, MERS-CoV S-2P, and SARS-CoV S-2P. IgG20, IgG23 and IgG62 demonstrated cross-reactive binding to MERS- and SARS-CoV S with higher apparent affinity to the former (FIG. 9A). Intriguingly, IgG21, IgG22 and IgG72 were also MERS- and SARS-specific, but the association rates of these mAbs to SARS-CoV S were nearly 5-fold higher than to MERS-CoV S (FIG. 9B). In contrast, IgG12, IgG19 and IgG42 only bound to MERS-CoV S (FIG. 9C). Competitive binding experiments with G4, the only MERS S2-targeted antibody with a structurally defined epitope, were also performed (Pallesen et ak, 2017). One third of selected mAbs (IgG20, IgG23 and IgG62) competed with G4 binding to MERS-CoV S (FIG. 10). By contrast, IgG12, IgG19, IgG21, IgG22, IgG42, and IgG72 appeared to bind to regions outside of the G4 epitope.
Example 5 - IgG22 binds to multiple CoV spikes and neutralizes authentic MERS-CoV
[00174] IgG22 and the clonally related IgG72 are two of the cross-reactive antibodies that exhibited faster association to SARS-CoV S than MERS-CoV S (FIG. 9B). To determine the kinetics of their interactions, surface plasmon resonance experiments were performed where Fab was flowed over spike ectodomain immobilized to a sensor chip. The binding affinity of Fab22 to MERS-CoV S was comparable to those of SARS-CoV S and SARS-CoV-2 S, with KD values of 2.9 nM, 7.2 nM, and 6.7 nM, respectively (FIGS. 5A-C). However, Fab22 exhibited distinct binding kinetics to MERS-CoV S, featuring a much slower on-rate and off-rate than SARS-CoV or SARS-CoV-2 S. The neutralization activities of selected mAbs were examined against authentic MERS-CoV. IgG22 and IgG72 exhibited
65
potent neutralizing activity, with IC50 values of 0.12 pg/rnL and 2.45 pg/mL, respectively (FIG. 5D). On the other hand, IgG20, IgG21 and IgG42 showed no neutralization activity against MERS-CoV. Interestingly, IgG22 and IgG72 failed to neutralize authentic SARS- CoV-2 (FIG. 5E), which may be due to the faster off-rate of IgG22 to SARS-CoV-2.
Example 6 - Cryo-EM structure of Fab22 bound to the MERS-CoV spike
[00175] To investigate Fab22 and Fab72 binding sites on the spikes, negative stain electron microscopy (nsEM) analysis were performed for the Fab-spike complexes. 2D classification showed three distinct densities for Fab22 attached to the S2 stalk region of MERS-CoV S-2P, a region that undergoes substantial conformation changes during the pre- to-postfusion transition (FIG. 11 A). Interestingly, Fab72 also binds to a similar region of S2 in proximity to HR2 (FIG. 1 IB). Given that binding of HR2 could potentially prevent virus cell membrane fusion, a cryo-EM structure of Fab22 bound to MERS S-2P was determined. Resembling the nsEM analysis, three distinct Fab9 densities were seen from multiple 2D classes (FIG. 5F). The initial 3D reconstruction exhibited a single conformation of the spike, with all three RBDs in the down conformation. A total of 183,556 particles led to a 3.3 A reconstruction with well-defined side chain densities at the core of S2. Three Fab densities could be visualized at the bottom stalk of S2, although one of the Fabs displayed a broader than usual Fab density. It is possible that the highly flexible nature of the stalk-HR2 region could lead to broadened Fab density. Therefore, the initial set of particles was subjected to two additional rounds of heterogeneous refinement to sort out 3D classes with diverse Fab orientations. A 3D reconstruction (3.3 A) from about half of the total particles (48.7%) was obtained, which demonstrated three distinct Fab densities bound to the spike. Interestingly, both reconstructions displayed three-RBD-down conformations. Focused refinement on the Fab22 densities was attempted, but the Fab-spike interface could not be resolved.
Example 7 - CryoEM structure of Fab22 bound to the SARS-CoV-2 spike
[00176] Resembling the Fab22-MERS-CoV S complex, nsEM analysis showed that Fab22 binds to the stalk region of SARS-CoV-2 S (FIG. 11C). To ascertain the discrepancy between the MERS-CoV and SARS-CoV-2 neutralization by IgG22, a high- resolution structure of Fab22 bound to SARS-CoV-2 S HexaPro, a prefusion-stabilized spike (Hsieh et ak, 2020), was attempted to be determined. The initial 3D reconstruction exhibited a disc-shaped Fab density beneath the helical stalk of the globular ectodomain. After two
66
additional rounds of heterogeneous refinement, two different conformations of the spikes were identified: one-RBD-up at 4.0 A (53% of the total particles) and three-RBD-down at 4.4 A (31% of the total particles) (FIGS. 6A-B). Although Fab22 density was not well defined, the Fab binding site on the spike could be located to the helical stalk, which is only resolved in the full-length spike model (PDB: 6XR8) (FIG. 6C). Sequence alignments of the helical stalk show that, among the b-CoVs, HCoV-HKUl is the least conserved in this region. This could explain why IgG22 has the weakest affinity to the HCoV-HKUl S. To further narrow down the binding site, two C-terminal truncations of the spike variants were constructed: AHR2 (1-1160) and Astalk (1-1142). In line with the cryo-EM map, Fab22 retained the affinity to HexaPro-AHR2 but completely lost the binding to HexaPro-Astalk (FIG. 6D). Collectively, these data demonstrate that the conserved helical stalk region between residues 1142 and 1160 is a novel epitope with the potential to elicit cross-reactive S2-targeted antibodies.
* * * [00177] All of the methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the methods and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the invention. More specifically, it will be apparent that certain agents which are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention as defined by the appended claims.
67
REFERENCES
The following references, to the extent that they provide exemplary procedural or other details supplementary to those set forth herein, are specifically incorporated herein by reference.
Baden, L.R., el Sahly, H.M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S.A., Rouphael, N., Creech, C.B., et al. (2020). Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. The New England Journal of Medicine.
Boyoglu-Bamum, S., Hutchinson, G.B., Boyington, J.C., Moin, S.M., Gillespie, R.A., Tsybovsky, Y., Stephens, T., Vaile, J.R., Lederhofer, J., Corbett, K.S., et al. (2020). Glycan repositioning of influenza hemagglutinin stem facilitates the elicitation of protective cross-group antibody responses. Nature Communications 11, 791.
Chi, X., Yan, R., Zhang, J., Zhang, G., Zhang, Y., Hao, M., Zhang, Z., Fan, P., Dong, Y., Yang, Y., et al. (2020). A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS CoV-2. Science (New York, N.Y.) 369, 650- 655.
Choi, B., Choudhary, M.C., Regan, J., Sparks, J.A., Padera, R.F., Qiu, X., Solomon, I.H., Kuo, H.-H., Boucau, J., Bowman, K., et al. (2020). Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host. The New England Journal of Medicine 383, 2291-2293.
Cockrell, A.S., Yount, B.L., Scobey, T., Jensen, K., Douglas, M., Beall, A., Tang, X.-C., Marasco, W.A., Heise, M.T., and Baric, R.S. (2016). A mouse model for MERS coronavirus-induced acute respiratory distress syndrome. Nature Microbiology 2, 16226.
Corbett, K.S., Moin, S.M., Yassine, H.M., Cagigi, A., Kanekiyo, M., Boyoglu-Bamum, S., Myers, S.I., Tsybovsky, Y., Wheatley, A.K., Schramm, C.A., et al. (2019). Design of Nanoparticulate Group 2 Influenza Virus Hemagglutinin Stem Antigens That Activate Unmutated Ancestor B Cell Receptors of Broadly Neutralizing Antibody Lineages. MBio 10.
Corbett, K.S., Edwards, D.K., Leist, S.R., Abiona, O.M., Boyoglu-Bamum, S., Gillespie, R.A., Himansu, S., Schafer, A., Ziwawo, C.T., DiPiazza, A.T., et al. (2020a). SARS- CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature 586, 567-571.
68
Corbett, K.S., Flynn, B., Foulds, K.E., Francica, J.R., Boyoglu-Bamum, S., Werner, A.P., Flach, B., O’Connell, S., Bock, K.W., Minai, M., et al. (2020b). Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. The New England Journal of Medicine 383, 1544-1555.
Douglas, M.G., Kocher, J.F., Scobey, T., Baric, R.S., and Cockrell, A.S. (2018). Adaptive evolution influences the infectious dose of MERS-CoV necessary to achieve severe respiratory disease. Virology 517, 98-107.
Goldenzweig, A., Goldsmith, M., Hill, S.E., Gertman, O., Laurino, P., Ashani, Y., Dym, O., Unger, T., Albeck, S., Prilusky, J., et al. (2016). Automated Structure- and Sequence- Based Design of Proteins for High Bacterial Expression and Stability. Molecular Cell 63, 337-346.
Grant, T., Rohou, A., and Grigorieff, N. (2018). cisTEM, user-friendly software for single particle image processing. ELife 7.
Grubaugh, N.D., Hodcroft, E.B., Fauver, J.R., Phelan, A.L., and Cevik, M. (2021). Public health actions to control new SARS-CoV-2 variants. Cell.
Gu, H., Chen, Q., Yang, G., He, L., Fan, H., Deng, Y.-Q., Wang, Y., Teng, Y., Zhao, Z., Cui, Y., et al. (2020). Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy. Science 369, 1603 LP - 1607.
Hsieh, C.-L., Goldsmith, J.A., Schaub, J.M., DiVenere, A.M., Kuo, H.-C., Javanmardi, K., Le, K.C., Wrapp, D., Lee, A.G., Liu, Y., et al. (2020). Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. Science 369, 1501 LP - 1505.
Impagliazzo, A., Milder, F., Kuipers, H., Wagner, M. v, Zhu, X., Hoffman, R.M.B., van Meersbergen, R., Huizingh, J., Wanningen, P., Verspuij, J., et al. (2015). A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen. Science (New York, N.Y.) 349, 1301-1306.
Jackson, L.A., Anderson, E.J., Rouphael, N.G., Roberts, P.C., Makhene, M., Coler, R.N., McCullough, M.P., Chappell, J.D., Denison, M.R., Stevens, L.J., et al. (2020). An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. The New England Journal of Medicine 383, 1920-1931.
Ke, Z., Oton, J., Qu, K., Cortese, M., Zila, V., McKeane, L., Nakane, T., Zivanov, J., Neufeldt, C.J., Cerikan, B., et al. (2020). Structures and distributions of SARS-CoV-2 spike proteins on intact virions. Nature 588, 498-502.
Kirchdoerfer, R.N., Wang, N., Pallesen, J., Wrapp, D., Turner, H.L., Cottrell, C.A., Corbett, K.S., Graham, B.S., McLellan, J.S., and Ward, A.B. (2018). Stabilized coronavirus
69
spikes are resistant to conformational changes induced by receptor recognition or proteolysis. Scientific Reports 8, 15701.
Krarup, A., Truan, D., Furmanova-Hollenstein, P., Bogaert, L., Bouchier, P., Bisschop, I.J.M., Widjojoatmodjo, M.N., Zahn, R., Schuitemaker, H., McLellan, J.S., et al. (2015). A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism. Nature Communications 6, 8143.
Ku, Z., Xie, X., Davidson, E., Ye, X., Su, H., Menachery, V.D., Li, Y., Yuan, Z., Zhang, X., Muruato, A.E., et al. (2021). Molecular determinants and mechanism for antibody cocktail preventing SARS-CoV-2 escape. Nature Communications 12, 469.
Kupferschmidt, K. (2021). Fast-spreading U.K. vims variant raises alarms· Science 371, 9 LP - 10.
Li, F. (2016). Structure, Function, and Evolution of Coronavirus Spike Proteins. Annual Review of Virology 3, 237-261.
Liu, L., Wang, P., Nair, M.S., Yu, L, Rapp, M., Wang, Q., Luo, Y., Chan, J.F.-W., Sahi, V., Figueroa, A., et al. (2020). Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584, 450-456.
McLellan, J.S., Chen, M., Joyce, M.G., Sastry, M., Stewart-Jones, G.B.E., Yang, Y., Zhang,
B., Chen, L., Srivatsan, S., Zheng, A., et al. (2013). Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science (New York, N.Y.) 342, 592-598.
Ng, K.W., Faulkner, N., Cornish, G.H., Rosa, A., Harvey, R., Hussain, S., Ulferts, R., Earl,
C., Wrobel, A.G., Benton, D.J., et al. (2020). Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. Science 370, 1339 LP - 1343.
Pallesen, J., Wang, N., Corbett, K.S., Wrapp, D., Kirchdoerfer, R.N., Turner, H.L., Cottrell, C.A., Becker, M.M., Wang, L., Shi, W., et al. (2017). Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. Proceedings of the National Academy of Sciences of the United States of America 114, E7348-E7357.
Polack, F.P., Thomas, S.J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J.L., Perez Marc, G., Moreira, E.D., Zerbini, C., et al. (2020). Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. The New England Journal of Medicine 383, 2603-2615.
Punjani, A., Rubinstein, J.L., Fleet, D.J., and Brubaker, M.A. (2017). cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nature Methods 14, 290-296.
70
Rutten, L., Gilman, M.S.A., Blokland, S., Juraszek, J., McLellan, J.S., and Langedijk, J.P.M. (2020). Structure-Based Design of Prefusion-Stabilized Filovirus Glycoprotein Trimers. Cell Reports 30, 4540-4550.e3.
Sanders, R.W., Derking, R., Cupo, A., Julien, J.-P., Yasmeen, A., de Val, N., Kim, H.J., Blattner, C., de la Pena, A.T., Korzun, J., et al. (2013). A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gpl40, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathogens 9, el003618.
Siebert, D.N., Bosch, B.J., van der Zee, R., de Haan, C.A.M., and Rottier, P.J.M. (2003). The Coronavirus Spike Protein Is a Class I Vims Fusion Protein: Structural and Functional Characterization of the Fusion Core Complex. Journal of Virology 77, 8801-8811.
Starr, T.N., Greaney, A.J., Hilton, S.K., Ellis, D., Crawford, K.H.D., Dingens, A.S., Navarro, M.J., Bowen, J.E., Tortorici, M.A., Walls, A.C., et al. (2020). Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding. Cell 182, 1295-1310.e20.
Stewart-Jones, G.B.E., Chuang, G.-Y., Xu, K., Zhou, T., Acharya, P., Tsybovsky, Y., Ou, L., Zhang, B., Fernandez-Rodriguez, B., Gilardi, V., et al. (2018). Structure-based design of a quadrivalent fusion glycoprotein vaccine for human parainfluenza virus types 1- 4. Proceedings of the National Academy of Sciences of the United States of America 115, 12265-12270.
Tang, J.W., Toovey, O.T.R., Harvey, K.N., and Hui, D.D.S. (2021). Introduction of the South African SARS-CoV-2 variant 501Y.V2 into the UK. The Journal of Infection.
Tegunov, D., and Cramer, P. (2019). Real-time cryo-electron microscopy data preprocessing with Warp. Nature Methods 16, 1146-1152.
Turonova, B., Sikora, M., Schiirmann, C., Hagen, W.J.H., Welsch, S., Blanc, F.E.C., von Billow, S., Gecht, M., Bagola, K., Horner, C., et al. (2020). In situ structural analysis of SARS-CoV-2 spike reveals flexibility mediated by three hinges. Science 370, 203 LP - 208.
Walls, A.C., Park, Y.J., Tortorici, M.A., Wall, A., McGuire, A.T., and Veesler, D. (2020). Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell 181, 281-292.e6.
Wang, L., Shi, W., Chappell, J.D., Joyce, M.G., Zhang, Y., Kanekiyo, M., Becker, M.M., van Doremalen, N., Fischer, R., Wang, N., et al. (2018). Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East
71
Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape. Journal of Virology 92, e02002-17.
Wang, Z., Schmidt, F., Weisblum, Y., Muecksch, F., Barnes, C.O., Finkin, S., Schaefer- Babajew, D., Cipolla, M., Gaebler, C., Fieberman, J.A., et al. (2021). mRNA vaccine- elicited antibodies to SAR-CoV-2 and circulating variants. BioRxiv : The Preprint Server for Biology.
Weisblum, Y., Schmidt, F., Zhang, F., DaSilva, J., Poston, D., Forenzi, J.C.C., Muecksch, F., Rutkowska, M., Hoffmann, H.-H., Michailidis, E., et al. (2020). Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. EFife 9, e61312.
Widjaja, I., Wang, C., van Haperen, R., Gutierrez-Alvarez, J., van Dieren, B., Okba, N.M.A., Raj, V.S., Fi, W., Femandez-Delgado, R., Grosveld, F., et al. (2019). Towards a solution to MERS: protective human monoclonal antibodies targeting different domains and functions of the MERS -coronavirus spike glycoprotein. Emerging Microbes & Infections 8, 516-530.
Wrapp, D., Wang, N., Corbett, K.S., Goldsmith, J.A., Hsieh, C.-F., Abiona, O., Graham, B.S., and McFellan, J.S. (2020). Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367, 1260 FP - 1263.
Wu, K., Werner, A.P., Moliva, J.I., Koch, M., Choi, A., Stewart-Jones, G.B.E., Bennett, H., Boyoglu-Bamum, S., Shi, W., Graham, B.S., et al. (2021). mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants. BioRxiv : The Preprint Server for Biology.
Yassine, H.M., Boyington, J.C., McTamney, P.M., Wei, C.-J., Kanekiyo, M., Kong, W.-P., Gallagher, J.R., Wang, F., Zhang, Y., Joyce, M.G., et al. (2015). Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection. Nature Medicine 21, 1065-1070.
Zhang, J., Wu, Q., Fiu, Z., Wang, Q., Wu, J., Hu, Y., Bai, T., Xie, T., Huang, M., Wu, T., et al. (2021). Spike- specific circulating T follicular helper cell and cross-neutralizing antibody responses in CO VID- 19-convalescent individuals. Nature Microbiology 6, 51-58.
Zhao, S., Fou, J., Cao, F., Zheng, H., Chong, M.K.C., Chen, Z., Chan, R.W.Y., Zee, B.C.Y., Chan, P.K.S., and Wang, M.H. (2021). Quantifying the transmission advantage associated with N501Y substitution of SARS-CoV-2 in the United Kingdom: An early data-driven analysis. Journal of Travel Medicine.
72
Claims
1. An engineered protein comprising an engineered beta-coronavirus S2 domain that comprises a sequence at least 90% identical to: (a) positions 762-1291 of SEQ ID NO: 1; (b) positions 687-1208 of SEQ ID NO: 2; or (c) positions 668-1190 of SEQ ID NO: 3; wherein the engineered protein comprises the following substitutions relative to the sequence of SEQ ID NO: 1: S975M, T803C, K933C, V958S, V983I, S1091E, L1094Q, N1132Y, V1060P, L1061P, V898C, V1022C, A838C, and S0189C, wherein the engineered protein does not comprise a beta-coronavirus S 1 domain.
2. An engineered protein comprising an engineered beta-coronavirus S2 domain that comprises a sequence at least 90% identical to: (a) positions 762-1291 of SEQ ID NO: 1; (b) positions 687-1208 of SEQ ID NO: 2; or (c) positions 668-1190 of SEQ ID NO: 3; wherein the engineered protein does not comprise a beta-coronavirus SI domain, and wherein the engineered protein comprises at least one substitution relative to the sequence of SEQ ID NO: 1, 2, or 3, said at least one substitution being at a position corresponding to: V958, V983, A918, V1139, L1094, S1091, N1132, K816, H1020, H1146, V1150, S845, T803, K933, S858, G953, S975, L923, L1033, P937, M939, A1049, L923, L1033, S787, Q1003, L840, Q769, S858, A1093, V1060, L1061, V898, V1022, S845, A1096, A838, or S1089 relative to SEQ ID NO: 1.
3. The engineered protein of any one of claims 1-2, comprising at least one engineered disulfide bond comprising paired cysteine substitutions at positions corresponding to: T803C and K933C; S858C and G953C; and/or Q769C and S858C relative to SEQ ID NO: 1.
4. The engineered protein of claim 3, further comprising at least one additional engineered disulfide bond.
5. The engineered protein of any one of claims 1-2, comprising at least one cavity filling substitution at a position corresponding to: S975, P937, M939, L923, and/or L1033 relative to SEQ ID NO: 1.
6. The engineered protein of claim 5, comprising at least one cavity filling substitution selected from: S975M, P937F, M939K, L923W, and L1033F relative to SEQ ID NO: 1.
73
7. The engineered protein of any one of claims 1-2, comprising at least one substitution that provides an electrostatic interaction substitution at a position corresponding to: S845, L923, L1033, A1049, S787, Q1003, L840, and/or A1093 relative to SEQ ID NO: 1.
8. The engineered protein of claim 7, comprising at least one electrostatic interaction substitution selected from S845E, L923K, L1033E, A1049S, S787D, Q1003K, L840E, and A1093R relative to SEQ ID NO: 1.
9. The engineered protein of any one of claims 1-8, comprising V1060P and L1061P substitutions relative to SEQ ID NO: 1.
10. The engineered protein of any one of claims 1-9, comprising a combination of at least one engineered disulfide bond, at least one cavity filling substitution, at least one proline substitution, and at least one electrostatic interaction substitution.
11. The engineered protein of any one of claims 1-10, comprising the following substitutions relative to SEQ ID NO: 1: V983I/, V958S, L1094Q, S1091E, N1132Y, V1060P, and L1061P.
12. The engineered protein of any one of claims 1-10, comprising the following substitutions relative to SEQ ID NO: 1: V983I, A918P, V1139F, V958S, L1094Q, S1091E, N1132Y, V1060P, and L1061P.
13. The engineered protein of any one of claims 1-10, comprising the following substitutions relative to SEQ ID NO: 1: V983I, A918P, V1139F, V958S, L1094Q, S1091E, N1132Y, K816R, H1020Q, H1146Y, V1150T, V1060P, and L1061P.
14. The engineered protein of any one of claims 1-10, comprising the following substitutions relative to SEQ ID NO: 1: S975M, T803C, K933C, V958S, V983I, S1091E, L1094Q, N1132Y, V1060P, and L1061P.
15. The engineered protein of any one of claims 1-10, comprising the following substitutions relative to SEQ ID NO: 1: S975M, T803C, K933C, V958S, V983I, S1091E, L1094Q, N1132Y, V1060P, L1061P, V898C, V1022C, A838C, and S0189C.
16. The engineered protein of any one of claims 1-15, having at least 95% identity to positions 762-1291 of SEQ ID NO: 1.
74
17. The engineered protein of any one of claims 1-16, wherein the protein is fused or conjugated to a trimerization domain.
18. The engineered protein of claim 17, wherein the protein is fused to a trimerization domain.
19. The engineered protein of claim 17, wherein the trimerization domain is positioned C- terminally relative to S protein ectodomain.
20. The engineered protein of claim 18, wherein the trimerization domain comprises a T4 fibritin trimerization domain.
21. The engineered protein of any one of claims 1-20, wherein the protein is fused or conjugated to a transmembrane domain.
22. The engineered protein of claim 21, wherein the protein is fused to a transmembrane domain.
23. The engineered protein of claim 21, wherein the transmembrane domain comprises a beta-coronavirus spike protein transmembrane domain.
24. The engineered protein of claim 23, wherein the transmembrane domain comprises a homologous beta-coronavirus spike protein transmembrane domain.
25. An engineered beta-coronavirus S2 trimer comprising at least one subunit according to any one of claims 1-24.
26. The engineered trimer of claim 25, wherein the S2 trimer is stabilized in a prefusion conformation relative to a S2 trimer of wildtype S protein subunits.
27. The engineered trimer of claim 25, wherein the S2 trimer comprises at least one engineered disulfide bond between subunits.
28. The engineered trimer of claim 27, wherein the at least one engineered disulfide bond between subunits is selected from: T803C and K933C; S858C and G953C; and/or Q769C and S858C relative to SEQ ID NO: 1.
75
29. A pharmaceutical composition comprising a pharmaceutically acceptable carrier; and (i) an engineered protein of any one of claims 1-24, or (ii) an engineered trimer of any one of claims 25-28.
30. The composition of claim 29, further comprising an adjuvant.
31. A nucleic acid molecule comprising a nucleotide sequence that encodes an amino acid sequence of an engineered protein of any one of claims 1-24.
32. The nucleic acid of claim 31, wherein the nucleic acid comprises a DNA expression vector.
33. The nucleic acid of claim 31, wherein the nucleic acid comprises a mRNA.
34. A method of preventing coronavirus infection or a disease associate with coronavirus infection in a subject, comprising administering to the subject an effective amount of the pharmaceutical composition according to any one of claims 29-30 or a nucleic acid molecule according to any one of claims 31-33.
35. The method of claim 34, wherein the method elicits a beta-coronavirus cross-reactive immune response.
36. The method of claim 34, wherein the method elicits the production of pan-coronavirus antibodies in the subject.
37. A composition comprising an engineered protein of any one of claims 1-24 bound to an antibody.
76
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163188813P | 2021-05-14 | 2021-05-14 | |
US63/188,813 | 2021-05-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022241229A1 true WO2022241229A1 (en) | 2022-11-17 |
Family
ID=84029832
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2022/029216 WO2022241229A1 (en) | 2021-05-14 | 2022-05-13 | Stabilized s2 beta-coronavirus antigens |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2022241229A1 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018081318A1 (en) * | 2016-10-25 | 2018-05-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Prefusion coronavirus spike proteins and their use |
WO2018115527A2 (en) * | 2016-12-23 | 2018-06-28 | Curevac Ag | Mers coronavirus vaccine |
-
2022
- 2022-05-13 WO PCT/US2022/029216 patent/WO2022241229A1/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018081318A1 (en) * | 2016-10-25 | 2018-05-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Prefusion coronavirus spike proteins and their use |
WO2018115527A2 (en) * | 2016-12-23 | 2018-06-28 | Curevac Ag | Mers coronavirus vaccine |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230242594A1 (en) | Engineered coronavirus spike (s) protein and methods of use thereof | |
Hsieh et al. | Stabilized coronavirus spike stem elicits a broadly protective antibody | |
US20230285539A1 (en) | Vaccines against sars-cov-2 and other coronaviruses | |
US10858400B2 (en) | Prefusion RSV F proteins and their use | |
Du et al. | The spike protein of SARS-CoV—a target for vaccine and therapeutic development | |
CN111671890B (en) | Novel coronavirus vaccine and application thereof | |
US11919927B2 (en) | Prefusion-stabilized hMPV F proteins | |
Coughlin et al. | Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: target, mechanism of action, and therapeutic potential | |
AU2018282476A1 (en) | Prefusion rsv f proteins and their use | |
Verma et al. | A comparative study of human betacoronavirus spike proteins: structure, function and therapeutics | |
Guo et al. | Targetable elements in SARS-CoV-2 S2 subunit for the design of pan-coronavirus fusion inhibitors and vaccines | |
Malonis et al. | A Powassan virus domain III nanoparticle immunogen elicits neutralizing and protective antibodies in mice | |
Yeung et al. | Severe acute respiratory syndrome coronavirus entry into host cells: Opportunities for therapeutic intervention | |
Coughlin et al. | Human monoclonal antibodies to SARS-coronavirus inhibit infection by different mechanisms | |
WO2023288296A1 (en) | Prefusion-stabilized chimeric hmpv-rsv f proteins | |
US20230277653A1 (en) | Stabilized beta-coronavirus antigens | |
WO2022241229A1 (en) | Stabilized s2 beta-coronavirus antigens | |
US20240140994A1 (en) | Prefusion-stabilized hmpv f proteins | |
Thavorasak et al. | Enhancing epitope of PEDV spike protein | |
Fenwick et al. | Broadly potent anti-SARS-CoV-2 antibody shares 93% of epitope with ACE2 and provides full protection in monkeys | |
Duan et al. | Negative effects of a disulfide bond mismatch in anti-rabies G protein single-chain antibody variable fragment FV57 | |
WO2024050549A2 (en) | Prefusion-stabilized cmv gb proteins | |
Li et al. | Interactions between SARS coronavirus and its receptor | |
Wang | Structure-Guided Vaccine, Antibody and Drug Discovery | |
WO2023023520A1 (en) | Membrane fusion and immune evasion by the spike protein of sars-cov-2 delta variant |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22808415 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |